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Treatment Improvement Protocols (TIPs) are developed by the Center for Substance Abuse 
Treatment (CSAT), part of the Substance Abuse and Mental Health Services Administration 
(SAMHSA) within the U.S. Department of Health and Human Services (HHS). Each TIP 
involves the development of topic-specific best-practice guidelines for the prevention and treat-
ment of substance use and mental disorders. TIPs draw on the experience and knowledge of 
clinical, research, and administrative experts of various forms of treatment and prevention. TIPs 
are distributed to facilities and individuals across the country. Published TIPs can be accessed via 
the Internet at http://www.kap.samhsa.gov.
Although each consensus-based TIP strives to include an evidence base for the practices it 
recommends, SAMHSA recognizes that behavioral health is continually evolving, and research 
frequently lags behind the innovations pioneered in the field. A major goal of each TIP is 
to convey “front-line” information quickly but responsibly. If research supports a particular 
approach, citations are provided.
TIp Format
Most of the research that forms the evidence basis for a particular TIP is not provided in the 
TIP itself. Rather, those who wish to review the supporting research can access a bibliography 
and literature review via the Internet at http://www.kap.samhsa.gov. These online resources 
include links to abstracts; the online bibliography and literature review are updated every 6 
months for 5 years after publication of the TIP.
TIPs focus on how-to information. Coverage of topics is limited to what the audience needs to 
understand and use to improve treatment outcomes. TIPs increasingly use quick-reference tools 
such as tables and lists in lieu of extensive text discussion, making the information more readily 
accessible and useful for treatment providers.
TIp Development process
TIP topics are based on the current needs of behavioral healthcare professionals and other  
medical care practitioners for information and guidance. After selecting a topic, SAMHSA 
invites staff members from Federal agencies and national organizations to be members of a 
resource panel that reviews an initial draft prospectus and outline and recommends specific 
areas of focus as well as resources that should be considered in developing the content for the 
TIP. These recommendations are communicated to a consensus panel composed of experts on 
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the topic who have been nominated by their peers. In partnership with Knowledge Application 
Program writers, consensus panel members participate in creating a draft document and then 
meet to review and discuss the draft. The information and recommendations on which they 
reach consensus form the foundation of the TIP. The panel Chair ensures that the guidelines 
mirror the results of the group’s collaboration.
A diverse group of experts closely reviews the draft document. Once the changes recommended 
by these field reviewers have been incorporated, the TIP is prepared for publication, in print and 
online.
xi
The Treatment Improvement Protocol (TIP) series fulfills the Substance Abuse and Mental 
Health Services Administration’s (SAMHSA’s) mission to improve prevention and treatment  
of substance use and mental disorders by providing best practices guidance to clinicians, program 
administrators, and payers. TIPs are the result of careful consideration of all relevant clinical and 
health services research findings, demonstration experience, and implementation requirements. 
A panel of non-Federal clinical researchers, clinicians, program administrators, and patient advo-
cates debates and discusses their particular area of expertise until they reach a consensus on best 
practices. This panel’s work is then reviewed and critiqued by field reviewers.
The talent, dedication, and hard work that TIPs panelists and reviewers bring to this highly 
participatory process have helped bridge the gap between the promise of research and the needs 
of practicing clinicians and administrators to serve, in the most scientifically sound and effective 
ways, people in need of behavioral health services. We are grateful to all who have joined with us 
to contribute to advances in the behavioral health field.
Pamela S. Hyde, J.D.
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Foreword
Dr. H. Westley Clark, M.D., 
J.D., M.P.H., CAS, FASAM
Director
Center for Substance Abuse 
Treatment 
Substance Abuse and 
Mental Health Services 
Administration
Francis M. Harding
Director
Center for Substance Abuse 
Prevention 
Substance Abuse and 
Mental Health Services 
Administration
A. Kathryn Power, M.Ed.
Director
Center for Mental Health 
Services 
Substance Abuse and 
Mental Health Services 
Administration

In ThIs ChapTer
1
c A
•	Chronic Pain Impact
•	Audience
•	Purpose
•	Definitions
•	Pain and Addiction 
Basics
•	Summary of TIP
•	Key Points
Introduction
chronic pain Impact
Chronic noncancer pain (CNCP) is common in the general population 
as well as in people who have a substance use disorder (SUD) (Exhibit 
1-1). Chronic pain is not harmless; it has physiological, social, and 
psychological dimensions that can seriously harm health, functioning, 
and well-being. As a multidimensional condition with both objective  
and subjective aspects, CNCP is difficult to assess and treat. Although 
CNCP can be managed, it usually cannot be completely eliminated. 
When patients with CNCP have comorbid SUD or are recovering  
from SUD, a complex condition becomes even more difficult to 
manage. 
1
exhibit 1-1 statistics on substance Use and chronic 
 pain in the United states
category statistic
Chronic pain patients who may 
have addictive disorders
32% (Chelminski et al., 2005)
People ages 20 and older who 
report pain that lasted more than 
3 months
56% (National Center for Health 
Statistics, 2006)
People experiencing disabling 
pain in the previous year
36% (Portenoy, Ugarte, Fuller, & 
Haas, 2004)
People ages 65 and older who 
experience pain that has lasted 
more than 12 months
57% (National Center for Health 
Statistics, 2006)
Civilian, noninstitutionalized U.S. 
residents ages 12 and older who 
report nonmedical use* of pain 
relievers in past year
5% (Substance Abuse and 
Mental Health Services 
Administration [SAMHSA], 2007)
People ages 12 and older who 
report that they initiated illegal 
drug use with pain relievers
19% (SAMHSA, 2008)
People with opioid addiction who 
report chronic pain
29–60% (Peles, Schreiber, 
Gordon, & Adelson, 2005; 
Potter, Shiffman, & Weiss, 2008; 
Rosenblum et al., 2003; Sheu et 
al., 2008)
*Nonmedical use is use for purposes other than that for which the medication was 
prescribed.
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Audience
This Treatment Improvement Protocol (TIP) 
is for primary care providers who treat or are 
likely to treat adult patients with or in recovery 
from SUDs who present with CNCP. Given 
the prevalence of CNCP in the population, 
this audience includes virtually all primary care 
providers. Addiction specialists, psychiatrists, 
nurses, and other clinicians may find infor-
mation here that will help them ensure that 
their patients with CNCP receive adequate 
pain treatment. By providing a shared basic 
understanding of and a common language for 
these two chronic conditions, this TIP facili-
tates cooperation and communication between 
healthcare professionals treating pain and 
those treating addiction.
purpose
This TIP equips clinicians with practical  
guidance and tools for treating CNCP in 
adults with histories of SUDs. It does not 
describe how to treat SUDs or other behav-
ioral health disorders in patients with CNCP; 
however, it provides readers with information 
about SUD assessments and referrals for fur-
ther evaluation. For patients with histories  
of SUDs, the most controversial and possibly 
hazardous pain treatment in widespread use 
is opioid treatment. For this reason, this topic 
receives significant attention in Chapters 3 
and 4. 
Definitions 
Many terms important to the treatment of 
CNCP in people with SUDs are used incon-
sistently. Clinicians should not assume that 
their definitions of addiction, CNCP, physical 
dependence, recovery, tolerance, or other terms 
are shared by others, especially by patients  
and their families. 
It is especially important that clinicians clarify 
with their patients terms related to substance 
use. For example, patients with histories of 
SUDs who are no longer using substances 
may or may not consider themselves to be in 
recovery. Likewise, some mutual-help groups 
may not regard patients as abstinent if they 
are treated for SUDs with medications such 
as naltrexone, buprenorphine, or methadone. 
Many people equate physical dependence or 
tolerance with addiction. However, if clinicians 
prescribing opioids for CNCP equate these 
terms, they may misdiagnose their patients on 
opioids as having an addiction, when in fact 
they do not. 
In 2001, the American Academy of Pain 
Medicine, the American Pain Society, and 
the American Society of Addiction Medicine 
formed a Liaison Committee on Pain and 
Addiction to standardize the use of the terms 
addiction, physical dependence, and tolerance 
among pain professionals. Shared under-
standings of these and other terms facilitate 
research, advance dialog among professionals 
in the fields of addiction and pain, and help 
patients make informed decisions about their 
treatment. 
Definitions used in this TIP are presented 
below.
•	 addiction. A primary, chronic, neurobio-
logic disease, with genetic, psychosocial, 
and environmental factors influencing 
its development and manifestations. It is 
characterized by behaviors that include 
one or more of the following: impaired 
control over drug use or compulsive use, 
continued use despite harm, and craving 
(Savage et al., 2003); clinicians commonly 
refer to these behaviors as the “3Cs.” 
•	 addictive substance. The phrase addictive 
substance is controversial. The phrase draws  
attention to the properties of the sub-
stance; however, some experts prefer to 
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emphasize the importance of individual 
variability, environment, and situational 
factors in addiction. Evidence suggests 
that animals will self-administer all drugs 
commonly sought by humans (with the 
exception of hallucinogens). Evidence also 
suggests that, if animals are exposed to a 
sufficient dose for a sufficient time, a sub-
stantial percentage will develop behaviors 
remarkably similar to those that suggest 
addiction in humans (e.g., “drug seeking” 
despite electrical shocks). Nonrewarding 
drugs (see Neurobiology of Addiction, 
below) do not elicit these behaviors in 
animals or humans. In this TIP, drugs 
or medications that elicit “drug seeking” 
behaviors are referred to as addictive. 
•	 behavioral health. The term comprises 
substance use issues, mental health issues, 
and the prevention of both.
•	 chronic noncancer pain (CNCP). 
Pain that is (1) unassociated with an 
imminently terminal condition, and (2) 
unlikely to abate as a result of tissue 
healing, thus requiring long-term man-
agement. The term often refers to pain 
not caused by ongoing tissue pathology 
(e.g., backache, fibromyalgia). The term is 
problematic because it includes pain asso-
ciated with sickle cell disease or recurrent 
pancreatitis, in which both neurological 
sensitization and tissue damage, at least 
in part, are likely. Inflammatory arthritis, 
connective tissue diseases, ischemia, and 
other conditions cause pain that persists 
for years yet are not, at least initially, life 
threatening. 
•	 chronic pain syndrome. Intractable pain 
of 6 months or longer, with marked alter-
ation of behavior; depression or anxiety; 
marked restriction in daily activities; 
frequent use of medication and medical 
services; no clear relationship to organic 
disorder; and a history of multiple, non- 
productive tests, treatment, and surgeries 
(U.S. Commission on the Evaluation of 
Pain, 1987). This term is used casually and 
imprecisely to refer to pain, distress, and 
dysfunction that are not fully attributable 
to an identifiable medical condition. 
•	 hyperalgesia. An abnormally intense 
response to a normally noxious stimulus. 
•	 narcotic. Substance used to induce narco-
sis or stupor. Narcotic is not a synonym for 
the opioid class of medications. 
•	 opioid-induced hyperalgesia. 
Hyperalgesia that results from the effects 
of opioids on the central nervous system 
(CNS). 
•	 pain. An unpleasant sensory or emotional 
experience associated with actual or poten-
tial tissue damage or described in terms  
of such damage (International Association  
for the Study of Pain, 1986). Pain is subjec-
tive and may not always be corroborated 
by objective data. 
•	 physical dependence. A state of adaptation 
that is manifested by a drug-class-specific  
withdrawal syndrome that can be pro-
duced by abrupt cessation, rapid dose 
reduction, decreasing the level of the  
drug in the blood, or administration of  
an antagonist (a substance that opposes 
the action of the drug) (Savage et al., 
2003). 
•	 pseudoaddiction. A controversial term 
coined to describe aberrant drug-related 
behaviors (e.g., clock watching, drug seek-
ing), that resemble those of patients with 
addiction but that actually result from 
inadequate treatment of pain (Weissman 
& Haddox, 1989). 
•	 recovery. A process of change through 
which an individual with an SUD achieves  
abstinence, wellness, and improved health 
and quality of life (Center for Substance 
Abuse Treatment [CSAT], 2007).
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•	 relapse. A return to substance abuse after 
a period of abstinence.
•	 substance use disorder (SUD). A condition 
that includes alcohol and drug problems. 
SAMHSA recognizes that several term- 
inologies (e.g., substance abuse and addic-
tion) can be applied and respects that 
some individuals and communities may 
choose to use different terminologies 
(CSAT, 2007).
•	 tolerance. A state of adaptation in which 
exposure to a substance induces changes 
that result in a diminution of one or 
more of the substance’s effects over time 
(Savage et al., 2003). 
pain and Addiction Basics
Studies indicate that CNCP and addiction 
frequently co-occur (Chelminski et al., 2005; 
Rosenblum et al., 2003; Savage, Kirsh, & 
Passik, 2008). Chronic pain and addiction 
have many shared neurophysiological patterns. 
Most chronic pain involves abnormal neural 
processing, which can occur at various levels 
of the peripheral and CNS. Similarly, the dis-
ease of addiction results when normal neural 
processes, primarily in the brain’s memory, 
reward, and stress systems, are altered into 
dysfunctional patterns. A full understanding 
of each condition is still emerging, and there 
is much to be learned regarding neurobiologic 
interactions between the conditions when they 
co-exist. 
Chronic pain and addiction are not static 
conditions. Both fluctuate in intensity over 
time and under different circumstances and 
require ongoing management. Treatment for 
one condition can support or conflict with 
treatment for the other; a medication that may 
be appropriately prescribed for a particular 
chronic pain condition may be inappropriate 
given the patient’s substance use history. Other 
commonalities include the following: 
•	 Both are neurobiological conditions with 
evidence of disordered CNS function. 
•	 Both are mediated by genetics and 
environment.
•	 Both may have significant behavioral 
components.
•	 Both may have serious harmful conse-
quences if untreated.
•	 Both often require multifaceted 
treatment. 
Chronic pain and SUDs have similar physical,  
social, emotional, and economic effects on 
health and well-being (Green, Baker, Smith,  
& Sato, 2003). Patients with one or both 
of these conditions may report insomnia, 
depression, impaired functioning, and other 
symptoms. Effective CNCP management 
in patients with or in recovery from SUDs 
must address both conditions simultaneously 
(Trafton, Oliva, Horst, Minkel, & Humphreys, 
2004). 
neurobiology of pain
Both pain and responses to pain are shaped 
by culture, temperament, psychological state, 
memory, cognition, beliefs and expectations, 
co-occurring health conditions, gender, age, 
and other biopsychosocial factors. Because pain 
is both a sensory and an emotional experience, 
it is by nature subjective. 
When nociceptors are excited, the stimulus 
is converted through transduction into action 
potentials that travel to the dorsal horn of the 
spinal cord. Signals then continue from the 
dorsal horn to the brain along multiple path-
ways in the cord: to the somatosensory cortex, 
where pain is evaluated; to the limbic system, 
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where emotional reactions are mediated; to 
the autonomic centers that control such auto-
matic functions as breathing, perspiration, 
and heart rate; and to other parts of the brain, 
where a behavioral response to the stimuli 
is determined. Nociceptive impulses are also 
transmitted to nearby terminals of the same 
nerve, where they may lead to diffuse pain and 
release of inflammatory substances that pro-
duce the flare and swelling that is a protective 
response to tissue injury (Exhibit 1-2). 
Nociceptive input triggers a pain-inhibiting 
response. Signals traveling the ascending 
pathways are met by descending signals that 
emerge at various points along the spinal 
cord and brain. This antinociceptive response 
involves a panoply of chemicals, including 
endorphins, enkephalins, gamma-aminobutyric 
acid, norepinephrine, serotonin, oxytocin, and 
relaxin. Inhibitory signaling serves to attenuate 
nociceptive input, dampening the formation 
of pain sensation and providing pain relief 
(Brookoff, 2005). 
Pain may be acute (e.g., postoperative pain), 
acute intermittent (e.g., migraine headache, 
pain caused by sickle cell disease), or chronic 
(persistent pain that may or may not have 
a known etiology). These categories are not 
mutually exclusive; for example, acute pain 
may be superimposed on chronic pain. Acute 
nociceptive or neuropathic pain can transform 
into chronic neuropathic pain in which the 
original sensations are extended and amplified.
exhibit 1-2 The pain pathways
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chronic pain
Chronic pain can be nociceptive, neuropathic, 
or a mixture of both (Exhibit 1-3). Pains such 
as migraine and fibromyalgia, in which there 
is no noxious stimulus and no apparent neuro-
logical lesion, are attributed to dysfunction of 
a structurally intact CNS.
Chronic pain often results from a process of 
neural sensitization following injury or illness 
in which thresholds are lowered, responses are 
amplified (hyperalgesia), normally non-nox-
ious stimulation becomes painful (allodynia), 
and spontaneous neural discharges occur. 
Increased signaling disconnected from noci-
ceptive input can become autonomous, self-
sustaining, and progressive, leading to the con-
tinuous perception of pain even in the absence 
of ongoing tissue damage. Thus, chronic pain 
is not equivalent to prolonged acute pain and 
for clinical purposes is best considered a dis-
tinct disorder (Brookoff, 2005). 
The etiology of the abnormal processing in 
chronic pain is not fully understood. However, 
there are two main, nonexclusive causes. First, 
tissue damage can trigger the release of chem-
icals that sensitize the nerve fibers and alter 
gene expression, causing changes in signaling 
through many different mechanisms. Some 
of these changes enable non-pain-conducting 
fibers to trigger pain in the CNS. Second, 
pain can result from injured nerve fibers that 
regenerate in a neuroma, which generates pain 
signals with little or no stimulation. 
When injury occurs to key pain-processing 
sectors of the CNS (e.g., the dorsal horn,  
thalamus), neural signals that pass through 
them may be interpreted as pain. Injury may 
also lead to degeneration of pain inhibitory 
cells. Modulation of nociceptive stimuli and 
inhibitory responses can occur at one or more 
locations in the CNS: the peripheral nerves, 
spinal cord neurons and tracts, thalamus, and 
cortex (Compton & Gebhart, 2003). Accurate 
identification of the source of the chronic 
pain, and of the neurological processes that 
modulate it, can lead to rational therapeutic 
approaches that target the source of aberrant 
signaling on the CNS pathway. 
exhibit 1-3 pain Types
Type Description
Nociceptive Pain Pain that results from suprathreshold stimulation of nociceptors, which 
are neural receptors specialized for the detection of potentially harm-
ful situations. This is an adaptive function of the nervous system. 
Nociceptors can be excited by mechanical, thermal, or chemical stimu-
lation. The immediate physical response is reflexive and protective, 
causing a person to pull a hand away from a hot surface, for example. 
Nociceptive pain persists while the injurious agent remains or until heal-
ing occurs. Prolonged nociceptive input can cause central hypersensitiza-
tion and the experience of spontaneous or amplified pain.
Neuropathic Pain Pain that results from lesion or dysfunction of the sensory nervous sys-
tem. A compressed, injured, or severed nerve can trigger neuropathic 
pain, as can disorders that affect the neural axis (e.g., metabolic diseases, 
infections, autoimmune disorders, vascular diseases, neoplasia [Campbell 
& Meyer, 2006]).
Mixed Nociceptive/ 
Neuropathic Pain
A combination of the two types of pain. For example, patients with 
degenerative disc disease may suffer from mechanical (nociceptive) back 
pain and radicular (neuropathic) pain.
71—Introduction
pain’s effect on health 
Persistent pain can have significant adverse 
effects on health. When pain stimuli continu-
ously trigger the stress response, the acute 
signs of sympathetic activation (e.g., rapid 
heart rate, sweating) may cease or appear 
intermittently, yet the body continues to be 
stressed. This situation contributes to a sense 
of exhaustion. 
Continued pain can trigger emotional responses, 
including sleeplessness, anxiety, and depressive 
symptoms, which in turn produce more pain. 
Such feedback cycles may continue to cause 
pain after the physiological causes have been 
addressed. Several studies show that the out-
come of pain treatment is worse in the pres-
ence of depression, or when depression does 
not respond to treatment, and that the future 
course of pain syndromes can be, in part, pre-
dicted by emotional status. The physiological 
and psychological sequelae of CNCP can be 
exacerbated by such factors as inactivity and 
overuse of sedating drugs. Physical inactivity 
and a lack of engagement with life may also 
lead to increased levels of anxiety, depression, 
and an increased risk for suicidal ideation; 
these increases may lead a person to use sub-
stances in an attempt to treat these sequelae 
of CNCP and the losses that occur due to its 
presence. 
neurobiology of Addiction 
A person may use substances initially for 
several reasons, such as to experience the 
euphoric effects, to relieve stress, to overcome 
anxiety or depression (or both), or to blunt 
the pain (National Institute on Drug Abuse 
[NIDA], 2007). With repeated exposure, how-
ever, substance use in some people can become 
uncontrollable. The defining characteristics of 
the disease of addiction have been summarized 
as the “3Cs”  (see the definition of addiction). 
Changes to the brain occur in a process that is 
mediated by both genetic and environmental 
factors, which result in an overvaluation of the 
substance, a devaluation of other things, and 
impaired control of substance-related behavior. 
Evidence indicates that addiction is a chronic 
disease. 
The primary rewarding effects of addictive 
substances occur in the cortico-mesolimbic 
dopamine systems, where several structures 
link to control the basic emotions and con-
nect them to memories, which drive behavior. 
These systems produce sensations of pleasure 
in response to actions that support survival 
(e.g., eating, sex) and sensations of fear in 
response to potential dangers. In a cascading 
effect, these sensations trigger the endocrine 
and autonomic nervous systems, stimulating 
bodily responses. The prefrontal cortex also 
plays a role in the formation of addictions, 
modifying pleasure and pain signals based on 
other considerations. Thus, the brain’s reward 
and stress systems reinforce life-sustaining 
behaviors. 
Reward Response
Feelings of reward emerge from the core of 
the limbic system after neurons in the ventral 
tegmental area (VTA) release the neurotrans-
mitter dopamine into the nucleus accumbens 
(NAc). Neural activity within this VTA–NAc 
circuit is necessary to experience reward, but 
other areas within the broader brain reward 
circuit also exert a strong influence. For exam-
ple, the hippocampus contributes information 
from the past that may be relevant to the 
current experience. The amygdala adds critical 
information about the emotional valence of 
the stimulus that activated the reward circuit, 
thus contributing to the overall motivational 
power of the experience. In addition, parts of 
the prefrontal cortex (i.e., anterior cingulate 
and orbitofrontal cortices) help integrate all 
the information, a vital function that allows 
the individual to decide whether to initiate  
or suppress a particular behavior in response  
to the stimulus. 
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Most addictive substances increase the levels 
of dopamine in limbic targets well beyond 
what occurs in naturally rewarding situations 
(e.g., sex, food). Some drugs (e.g., marijuana, 
heroin) produce dopaminergic effects indi-
rectly. Amphetamines cause the release of 
dopamine, and cocaine prevents its reuptake; 
both effects result in amplified messaging that 
eventually disrupts normal neuronal signaling. 
It appears that the brain adjusts to excess 
dopamine levels by producing less dopamine 
and by reducing the number of receptors that 
respond to it in the receiving (postsynaptic) 
neuron. As a result, the pleasurable effects of  
a drug become diminished with continued use. 
The pleasurable effects of normal activities also 
are blunted, creating a state called anhedonia 
(an inability to experience pleasure).
It is commonly believed that continued  
substance use is driven by the need to prevent 
symptoms of withdrawal; however, this idea  
is misleading. Withdrawal, as commonly 
conceptualized, involves rebound symptoms 
resulting from the drug’s absence. In the  
case of opioids, these symptoms include,  
but are not limited to, anxiety, sweating,  
tachycardia, diarrhea, piloerection, and chills.  
Although unpleasant, these symptoms are  
typically absent after a relatively brief period  
of detoxification or weaning and do not 
explain phenomena such as addiction relapse 
and prolonged craving. Even though detoxi-
fication is quick and technically easy, the 
prevention of relapse is extremely difficult 
and, in fact, the majority of those who attain 
abstinence experience at least one relapse 
(Dennis, Foss, & Scott, 2007). These more 
difficult problems are thought to result from 
the prolonged impairment of hedonic tone 
and conditioned responses that lead to intense 
craving. 
Stress Response
The dysregulation of the brain’s reward system 
that occurs through substance use is paralleled 
by similar dysregulating effects in the stress 
system. Use of an addictive substance increases 
the flow of neurochemicals (e.g., corticotropin- 
releasing factor, norepinephrine, dynorphin). 
These chemicals can produce a negative 
emotional state that manifests as chronic irri-
tability, emotional pain, lethargy, disinterest in 
natural rewards, and other dysphoric condi-
tions. The stress response becomes more sensi-
tive with repeated withdrawal and can persist 
into abstinence (Koob, 2009). 
An individual may seek to avert the stress 
response by again using the substance. This 
negative reinforcement combines with the 
positive reinforcement of the substance’s 
euphoric effects in an operant process that 
creates a compulsion for substance use. 
Thus, addiction is reflected in compulsive 
use combined with loss of control mediated 
by memory (cue-induced triggers for reuse), 
substance-induced reductions in executive 
functioning that hamper rational decisionmak-
ing, and habit formation (Koob, 2009). 
risk Factors for Addiction 
People who use substances with addictive 
potential may develop tolerance to some of 
their effects and develop some degree of physi-
cal dependence. However, only a minority 
develops the disease of addiction. Important 
risk factors for addiction include genetics,  
psychological factors, and environmental 
factors. 
Genetics plays a substantial role in risk factors  
for addiction: NIDA (2007) estimates that 
between 40 and 60 percent of a person’s vul-
nerability to addiction may be genetic. The 
91—Introduction
disease of addiction may be more heritable 
than type 2 diabetes, hypertension, and breast 
cancer (Nestler, 2005). Genes also underlie 
human variability in drug metabolism, suscep-
tibility to psychiatric disorders that commonly 
co-occur with addiction, and response to envi-
ronmental risk factors (e.g., drug availability, 
peer group pressure [Vaillant, 2003]). 
Mental illness is another major risk factor for 
addiction (Volkow & Li, 2009), and the two 
conditions have high comorbidity (NIDA, 
2009). One condition can follow the other 
(NIDA, 2007). For example, a person may 
attempt to relieve depression or anxiety with 
substances, and this behavior may lead to 
addiction. Conversely, chronic substance use 
may lead to mental disorders, such as psy-
chosis, or make existing mental illness worse 
(NIDA, 2007). Environmental influences on 
addiction include, but are not limited to, pov-
erty, poor parental support, living in a com-
munity with high drug availability, and using 
substances at an early age (NIDA, 2007, 2009; 
Volkow & Li, 2009). 
cross-Addiction
Addiction to one substance can be linked with 
addiction to other substances in a pattern 
termed cross-addiction. An individual who vol-
untarily or involuntarily decreases use of one 
substance may increase use of another sub-
stance with similar effects on the brain (e.g., 
the person with an alcohol use disorder may 
use barbiturates for the sedative effects). The 
term cross-addiction is also used to describe 
simultaneous addiction (e.g., co-occurring 
addictions to nicotine, alcohol, and marijuana). 
Cross-addiction is not official diagnostic 
nomenclature; rather, it refers to the observa-
tion that a person with an addiction to one 
substance may develop addiction to a sub-
sequent substance, especially if the original 
drug of choice becomes inaccessible or is 
relinquished for other reasons. For example,  
a study of patients hospitalized for controlled-
release oxycodone addiction found that the 
majority (77 percent) had previously had a 
non-opioid SUD (Potter, Hennessey, Borrow, 
Greenfield, & Weiss, 2004). 
Individuals with chronic pain and histories 
of SUDs may be at increased risk of cross-
addiction to any medication that acts on the 
brain as a reinforcing agent (Edlund, Sullivan, 
Steffick, Harris, & Wells, 2007). Because of 
cross-addiction, persons who abuse marijuana 
may be at increased risk for opioid addiction. 
People with alcohol use disorders have been 
found to be more than 18 times as likely to 
report nonmedical use of prescription medica-
tions as people who do not drink (McCabe, 
Cranford, & Boyd, 2006). 
The cycle of chronic pain and 
Addiction 
Although multiple factors influence the course 
of addiction, CNCP provides both positive 
and negative reinforcement of substance use. 
Positive reinforcement occurs when a behavior 
is followed by a consequence that is desirable— 
a donkey’s walking may be rewarded by a 
carrot. Negative reinforcement occurs when 
a behavior is followed by the elimination of 
a negative consequence—a donkey’s walking 
may eliminate the blows from a stick. For 
example, euphoria is a positive reinforcer for 
taking heroin, and pain reduction is a nega-
tive reinforcer for taking heroin. Prescribed 
opioids, benzodiazepines, or other medications 
may dramatically relieve pain or distress (e.g., 
depression, anxiety). Unprescribed substances 
may be used for similar reasons; for example, 
alcohol may promote relaxation or sleep. Such 
relief is a strong reinforcement for repeated 
consumption of the substance. 
Unfortunately, analgesic and anxiolytic efficacy 
may diminish over the course of weeks, months, 
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or years as tolerance develops. This loss of effi-
cacy often elicits dose escalation to recapture 
efficacy. This escalation is rewarded, as the 
increased dose is initially more effective than 
the lower dose. 
If the drug produces physical dependence, the 
person may have not only increased pain when 
the substance is absent, but also withdrawal 
symptoms (e.g., anxiety, nausea, cramps, 
insomnia). Withdrawal symptoms may lead to 
an increase in symptoms of depression and an 
increase in the potential risk for suicide. All 
these symptoms are relieved by ingesting more 
of the drug that caused the dependence. A 
similar situation may occur if the drug is one 
that elicits rebound symptoms. For example, 
ergot relieves migraine, but excessive use leads 
to rebound headaches that are more persistent 
and treatment resistant than were the original 
headaches. 
An illusion of benefit produced by reinforcing  
drugs can create a paradoxical situation in 
which long-term use of the substance creates 
the very symptoms the person hopes to  
alleviate. People commonly drink to relax or 
“cheer up,” yet chronic alcohol abuse leads to 
depression and anxiety.
In some people, a cycle develops in which  
pain or distress elicits severe preoccupation 
with the substance that previously provided 
relief. This cycle—seeking pain relief, experi-
encing relief, and then having pain recur—can 
be very difficult to break, even in the person 
without an addiction, and the development of 
addiction markedly exacerbates the difficulty. 
The propensity to develop this cycle is influ-
enced by genetic and environmental factors; 
some people will experience greater degrees  
of analgesia than others, and some will have 
more severe or prolonged abstinence symp-
toms. Genetic variability in susceptibility to 
these experiences may explain some cases  
of iatrogenic addiction.
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summary of TIp
The management of CNCP in patients with a comorbid SUD is challenging for both 
patients and clinicians; however, it can be done successfully. This TIP advises clinicians 
to conduct a careful assessment; develop a treatment plan that addresses pain, functional 
impairment, and psychological symptoms; and closely monitor patients for relapse. Even 
the best treatment is unlikely to completely eliminate chronic pain, and efforts to achieve 
total pain relief can be self-defeating. Patients may benefit when clinicians team with other 
professionals ( e.g., psychologists, addiction counselors, pharmacists, holistic care providers). 
Patients must also assume a significant amount of responsibility for optimal management of 
their pain. Educating patients, family members, and caregivers in this process, and helping 
patients improve their quality of life, can be gratifying for everyone involved. 
Key points
•	 CNCP and the disease of addiction involve neurophysiological processes.
•	 Both genetic and environmental factors contribute to and influence the development 
and course of CNCP and addiction.
•	 Clinicians must understand CNCP, addiction, and other behavioral health issues to best 
serve the chronic pain patient with or in recovery from an SUD. 
•	 Despite the complexities of CNCP and SUDs, patients with these co-occurring, 
chronic conditions can be treated effectively.

In ThIs ChapTer
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patient Assessment
elements of Assessment
Researchers and clinicians agree that, because chronic noncancer 
pain (CNCP) is a multifaceted condition, assessment must include 
more than measures of pain intensity (Brunton, 2004; Haefeli & 
Elfering, 2006; Karoly, Ruehlman, Aiken, Todd, & Newton, 2006; 
Sullivan & Ferrell, 2005). Some elements are essential to assess; 
others, ideal. In many cases, even after a thorough assessment, the 
clinician may not detect the nociceptive source of a patient’s chronic 
pain. 
Collateral information is an important part of the assessment. 
Clinicians need to communicate with families, pharmacists, and 
other clinicians after the patient has given full consent for these  
discussions. If the patient declines to give consent, prolonged treat- 
ment with controlled substances may be contraindicated. Furthermore, 
a clinician who prescribes controlled substances to a patient who 
refuses to permit access to outside information could be considered 
to be ignoring evidence of addiction or substance misuse and, there-
fore, to be trafficking. Collateral information also helps protect the 
patient from misusing medications. Exhibit 2-1 presents elements of 
a comprehensive assessment.
Assessment Tools
Standardized instruments provide ways to assess and track patient 
pain levels, function, substance use, and other factors important to 
managing CNCP. Standardized tools provide supplemental informa-
tion for treatment planning and assessment of risk and outcomes. If 
used well, tools can reduce clinician bias during patient assessment. 
The sensitivity and specificity of screening instruments vary, and 
all can yield false-positive or false-negative results. In addition, no 
single instrument has been shown to be appropriate for use with  
all patient populations (Bird, 2003; Brunton, 2004). Because of their 
limitations, standardized tools should not be the absolute determinants 
of treatments offered or withheld.
2
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exhibit 2-1 elements of a comprehensive patient Assessment
element Assessment Factor
Pain and Coping •	Location, character (e.g., shooting or stinging, continuous or 
intermittent) 
•	Pain types (i.e., nociceptive, neuropathic, mixed)
•	Lowest and highest extent of pain in a typical day, on a 0-to-10 
scale 
•	Usual pain in a typical day, on a 0-to-10 scale 
•	When and how the pain started 
•	Exacerbating factors (e.g., exertion/activity, food consumption, 
elimination, stress, medical issues)
•	Palliating factors (e.g., heat, cold, stretching, rest, medications, 
complementary and alternative treatments)
•	Prior evaluations to determine the source of pain
•	Response to previous pain treatments, including complementary 
and alternative treatments and interventional treatments
•	Goals and expectations for pain relief
Collateral Information It is crucial to obtain such information as:
•	Findings of other clinicians, prior and current
•	Family concerns, beliefs, and observations
•	Pharmacist concerns, where relevant
•	Data from State electronic prescription monitoring programs,  
if available
•	Medical records, including psychiatric and substance use disorders 
(SUDs) treatment records
Function Effect of pain on:
•	Activities of daily living/ability to care for oneself
•	Sleep
•	Mood
•	Work/household responsibilities
•	Sex
•	Socialization and support systems
•	Recreation
•	Goals and expectations for restored function
Contingencies •	Family support of wellness versus illness behavior
•	Vocational incentives and disincentives
•	Financial incentives and disincentives
•	 Insurance/legal incentives and disincentives
•	Environmental and social resources for wellness
15
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exhibit 2-1 elements of a comprehensive patient Assessment (continued)
element Assessment Factor
Substance Use History 
and Risk for Addiction
•	Current use of substances, including tobacco, alcohol, over-the-
counter medications, prescription medications, and illicit drugs 
(confirmed by toxicology)
•	Focus on opioids to the exclusion of other treatments
•	Adverse consequences of use (e.g., functional impairment; legal, 
social, financial, family, work, medical problems)
•	Age at first use 
•	Treatment history, including attendance at mutual-help groups
•	Periods of abstinence
•	Strength of recovery support network (e.g., sponsor, sober 
support network, mutual-help meetings)
•	Family history of SUD
•	History of physical, sexual, or emotional abuse or trauma 
Co-Occurring Conditions 
and Disorders
•	Psychological conditions (e.g., depression, anxiety, post-traumatic 
stress disorder [PTSD], somatoform disorders)
•	Medical conditions (e.g., hepatic, renal, cardiovascular, metabolic)
•	Cognitive impairments (e.g., dementia, delirium, intoxication, 
traumatic brain injury)
Physical Exam •	Relevant associated signs of pain disorder
•	Signs of substance abuse (e.g., track marks, hepatomegaly, 
residua of skin infections, nasal and oropharyngeal pathology)
Mental Status •	Medication focused
•	Somatic preoccupation
•	Mood
•	Suicidal ideation and behavior
•	Cognition (e.g., attentional capacity, memory)
When using standardized tools, clinicians 
should (Bird, 2003):
•	 Understand the strengths and weaknesses 
of each tool.
•	 Select a tool appropriate for the patient, 
considering memory problems, cognitive 
impairments, eyesight, literacy level, cul-
tural background, gender, ethnicity, and  
other factors. 
•	 Teach patients how to use self-adminis-
tered tools, even “self-explanatory” tools; 
otherwise, the information they provide 
may be invalid.
Instruments are available to assist with assess-
ment of pain and functioning, SUDs, psychi-
atric comorbidities, coping skills, and potential 
problems with opioid use. 
Assessing pain and Function 
The assessment of CNCP should include 
documentation of the following:
•	 Pain onset, quality, and severity; mitigating  
and exacerbating factors; and the results 
of investigations into etiology
•	 Pain-related functional impairment 
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•	 Emotional changes (e.g., anxiety, depres-
sion, anger) and sleep disturbances
•	 Cognitive changes (e.g., attentional 
capacity, memory)
•	 Family response to pain (i.e., supportive, 
enabling, rejecting)
•	 Environmental consequences (e.g., dis-
ability income, loss of desired activities, 
absence from desirable or feared work)
•	 Physical examination
•	 Partial mental status examination (e.g., 
affect [how pain is experienced], somatic 
preoccupation, cognition, moans, gasps, 
lying down during the interview)
Several factors may complicate an assessment 
of pain levels in any pain patient:
•	 Some patients may report not only their 
level of pain intensity, but their suffering, 
which may be greater than their pain 
intensity. 
•	 Clinicians tend to believe that a patient’s 
pain level is actually lower than the patient 
reports, except when the patient reports 
low pain (Sloman, Rosen, Rom, & Shir, 
2005; Stalnikowicz, Mahamid, Kaspi, & 
Brezis, 2005). 
•	 Clinicians are especially likely to under-
estimate—and, therefore, to undertreat—
pain and disability in women, the elderly, 
minorities, people of low economic status, 
and people with SUDs (Green, Baker, 
Smith, & Sato, 2003; Rupp & Delaney, 
2004).
An assessment of pain and function in 
patients with SUD histories may be further 
complicated by the following factors:
•	 Some patients with histories of SUDs 
may overreport their pain experience if 
they are afraid that they will be under-
medicated or that their symptoms will 
not be taken seriously.
•	 Others may underreport their pain  
experience if they are afraid they will  
be prescribed medications that will cause 
them to relapse. 
•	 Some patients may exaggerate pain and 
disability levels to get opioids for reasons 
other than pain control. 
The level of functional impairment in patients 
with CNCP is markedly modified by envi-
ronmental contingencies (e.g., the incentives 
and disincentives for healthful versus so-called 
“sick role” behaviors). For instance, evidence 
shows that pain-related behaviors increase 
in the presence of a solicitous spouse, mean-
ing one who is attentive to and reinforcing 
of such behaviors (Pence, Thorn, Jensen, & 
Romano, 2008). It is also demonstrated that 
work-related functional impairment varies 
with the strengths of reinforcement contin-
gencies for function versus absenteeism. The 
workers’ compensation system may provide a 
special example of this. Studies typically find 
that patients receiving income from this source 
respond less well to rehabilitation efforts 
than do those not receiving disability income 
from this or other sources. The explanation 
is thought to reside in such factors as the 
need to “prove” one is ill to obtain tests and 
specialty consultation and the fear of loss of 
income if one is witnessed engaging in normal 
activities. The relative magnitude of rewards 
and punishments for function may thus play 
a determining role in disability. A thorough 
assessment of a patient with CNCP, therefore, 
requires a review of the overall consequences 
of resuming healthy function.
When assessing pain and function in patients 
with histories of SUDs, clinicians should keep 
in mind the following: 
•	 Individuals with similar complaints (e.g., 
low back pain) usually describe and rate 
their pain differently.
•	 Functional impairments affect patients 
differently.
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•	 Pain scores do not reflect tissue pathology, 
disability, or treatment response.
•	 Pain reduction is insufficient to judge 
treatment success, which also requires 
optimization of function and normaliza-
tion of mood.
Exhibits 2-2 and 2-3 list the strengths and 
weaknesses of common one-dimensional and 
multidimensional pain tools, respectively. 
Exhibit 2-4 presents tools for assessing the 
extent to which pain interferes with usual 
functions and activities. Information on how 
to obtain the tools is located in Appendix B.
Studies show that patients who have chronic 
pain may develop cognitive impairments (e.g., 
changes in attentional capacity, memory, pro-
cessing speed) that appear to be independent 
of other variables (e.g., age, educational level, 
pain intensity, pain relief ) (Dick & Rashtiq, 
2007; Hart, Martelli, & Zasler, 2000; Hart, 
Wade, & Martelli, 2003). Therefore, clinicians  
need to be alert to the possibility of these 
changes and include an evaluation of mental  
status as part of the patient’s ongoing 
assessment (e.g., the Mini-Mental State 
Examination, [Folstein & Folstein, 2010]) or 
refer the patient to a neurologist as necessary. 
exhibit 2-2 Tools To Assess pain level
Tool strength Weakness
Faces Pain Scale •	Easy to use
•	Usable with people who have 
mild to moderate cognitive 
impairment 
•	Translates across cultures and 
languages
•	Visual impairment 
may affect accuracy or 
completion 
•	May measure pain affect, 
not only pain intensity
Numeric Rating Scale (NRS) •	Easy to use if patient can trans-
late pain into numbers
•	Easy to administer and score
•	Can measure small changes in 
pain intensity
•	Oral or written administration
•	Sensitive to changes in chronic 
pain
•	Translates across cultures and 
languages
•	Difficult to administer to 
patients with cognitive 
impairments because of 
difficulty translating pain 
into numbers
Verbal Rating Scale/Graphic 
Rating Scale
•	Easy to use 
•	Oral or written administration
•	High completion rate with 
patients with cognitive 
impairments
•	Sensitive to change and vali-
dated for use with chronic pain
•	Correlates strongly with other 
tools
•	Not as sensitive as NRS or 
Visual Analog Scale
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exhibit 2-3 Tools To Assess several Dimensions of pain
Tool strength Weakness
Brief Pain Inventory •	Short form better for clinical 
practice
•	Fairly easy to use
•	Useful in different cultures
•	Translated into and validated 
in several languages
•	Not easily used with patients 
with cognitive impairments
McGill Pain Questionnaire •	Short form easier to 
administer
•	Extensively studied
•	Measures pain affect 
•	Not appropriate for patients 
with cognitive impairments 
•	Translation complicated
•	Meaning of pain descriptors 
may vary across racial and 
ethnic groups
Department of Veterans Affairs & Department of Defense, 2003.
Assessing Substance Use and 
Addiction 
As with assessing pain and function, assessing 
patient self-reports of substance use, whether 
via interviews or structured self-report 
questionnaires, should be corroborated by 
other sources of information (e.g., medical 
records, interviews with family, urine toxicol-
ogy, information from State prescription mon-
itoring programs) (Katz & Fanciullo, 2002). 
exhibit 2-2 Tools To Assess pain level (continued)
Tool strength Weakness
Visual Analog Scale (VAS) •	Easy to use, but must be pre-
sented carefully 
•	Precise 
•	Sensitive to ethnic differences 
•	Easily translated across cul-
tures and languages
•	Some evidence that a hori-
zontal line may be better than 
a vertical (“thermometer”) 
orientation
•	Visual impairment may affect 
accuracy 
•	Can be time consuming to 
score, unless mechanical or 
computerized VAS tools are 
used 
•	Low completion rate in 
patients with cognitive 
impairments 
•	Difficult to administer to 
patients with cognitive 
impairments
•	Cannot be administered by 
phone or email
•	Subject to measurement error
Bird, 2003; Brunton, 2004.
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exhibit 2-4 Tools To Assess pain Interference With life Activities and Functional 
capacities
Tool purpose
Katz Basic Activities of Daily Living Scale Rates independence by assessing six areas of daily 
activities
Pain Disability Index Measures chronic pain and chronic pain interference 
in daily life
Roland-Morris Disability Questionnaire Measures perceived disability from low back pain
WOMAC Index Assesses pain, stiffness, and physical function in 
patients with osteoarthritis
When initiating a conversation about alcohol 
and drug use, clinicians should:
•	 Approach the topic matter-of-factly, 
handling it as part of the overall medical 
history.
•	 Incorporate questions about drug and 
alcohol use into a general behavioral 
health inventory including discussion 
of other lifestyle behaviors (e.g., diet, 
exercise).
•	 Ask about nicotine and caffeine use; 
questions about use of these substances 
provide opportunities to move to assess-
ment of other substances, beginning with  
alcohol, the most commonly abused 
substance. 
•	 Assure patients that honest answers to 
questions of substance use are necessary 
to developing a treatment plan and that 
their responses will remain confidential.
A good prescreening question is, “When did 
you last have a drink of beer, wine, or liquor?” 
If the patient reports drinking within the past 
year, the clinician should ask questions to 
determine:
•	 Frequency (“How many days per week do 
you typically drink alcohol?”) 
•	 Quantity (“How much alcohol do you 
drink on a typical drinking occasion?”) 
•	 Evidence of binge drinking (for men:  
“On any day in the past year, have you 
ever had five or more drinks?”; for 
women: “On any day in the past year, 
have you ever had four or more drinks?”) 
The clinician should ask the patient to define 
what the patient means by “a drink” (e.g., 
an 8-ounce glass, half a glass). The National 
Institute on Alcohol Abuse and Alcoholism 
(NIAAA) defines one drink as one 12-ounce 
bottle of beer or wine cooler, one 5-ounce 
glass of wine, or 1.5 ounces of 80-proof dis-
tilled spirits. According to NIAAA (2005), if 
the male patient drinks more than 4 standard 
drinks in a day (or more than 14 drinks per 
week), or more than 3 drinks in a day (or more 
than 7 drinks per week) for the female patient, 
the person is at increased risk for developing 
alcohol-related problems. 
Whether or not the patient reports drinking, 
the clinician should probe for the use of licit 
and illicit drugs, starting with the most com-
monly used illicit drug in the United States: 
marijuana. Questions can continue to address 
other major classes of drugs with abuse poten-
tial (e.g.,  depressants, stimulants,  opioids), 
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with particular attention to use related to 
controlling pain or the patient’s anxiety and 
fear of pain (Passik & Kirsch, 2004). Exhibit 
2-5 summarizes the substances that patients 
should be asked about using.
NIDA provides a Web-based tool that helps 
clinicians screen for tobacco, alcohol, and illicit 
and nonmedical prescription drug use, and 
suggests levels of intervention. The tool is at 
http://ww1.drugabuse.gov/nmassist.
screening for substance Use 
Disorders 
Although the amount of substance used is 
significant, it is more important to evaluate 
the consequences of the drug and alcohol 
use on life domains, such as family, work or 
school, and involvement with the criminal 
justice system (e.g., arrests for driving under 
the influence). When drug or alcohol use 
interferes with normal function, addiction is 
likely. Furthermore, addiction is characterized 
by impaired ability to control use of the sub-
stance. Asking whether the patient has ever 
attempted to decrease the amount consumed 
is an approach to determining his or her abil-
ity to modulate use. In the case of prescription 
medication, a patient’s loss of control may 
manifest as the inability to ration pills until 
the next prescription, so the patient’s partner 
may oversee the dispensing of the medications. 
The Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR; American Psychiatric 
Association [APA], 2000) provides criteria for 
determining substance dependence that enable 
the clinician to distinguish between patients 
with at-risk substance use and those whose 
use is consistent with an SUD (Exhibit 2-6). 
It is important to remember that, essentially, 
all patients taking prescribed opioids or seda-
tives on a long-term basis will have a degree 
of tolerance and withdrawal and that these 
criteria are not indicative of addiction absent 
the “maladaptive pattern of substance use.”
exhibit 2-5 Items To Include in substance Use Assessment
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exhibit 2-6 Dsm-Iv-Tr criteria for substance Abuse and substance 
Dependence
category criteria
Substance 
Abuse
A maladaptive pattern of substance use leading to clinically significant  
impairment or distress, as manifested by one (or more) of the following,  
occurring within a 12-month period:
•	Recurrent substance use resulting in a failure to fulfill major role obligations 
at work, school, or home (e.g., repeated absences or poor work performance 
related to substance use; substance-related absences, suspensions, or expul-
sions from school; neglect of children or household)
•	Recurrent substance use in situations in which it is physically hazardous (e.g., 
driving an automobile or operating machinery when impaired by substance 
use) 
•	Recurrent substance-related legal problems (e.g., arrests for substance-
related disorderly conduct) 
•	Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance 
(e.g., arguments with spouse about consequences of intoxication, physical 
fights)
Substance 
Dependence
A maladaptive pattern of substance use, leading to clinically significant  
impairment or distress, as manifested by three (or more) of the following, 
occurring any time in a 12-month period:
•	Tolerance, as defined by either of the following: (a) a need for markedly 
increased amounts of the substance to achieve intoxication or desired effect, 
or (b) markedly diminished effect with continued use of the same amount of 
the substance 
•	Withdrawal, as manifested by either of the following: (a) the characteristic 
withdrawal syndrome for the substance, or (b) the same (or closely related) 
substance is taken to relieve or avoid withdrawal symptoms 
•	The substance is often taken in larger amounts or over a longer period than 
intended 
•	There is a persistent desire or unsuccessful efforts to cut down or control 
substance use 
•	A great deal of time is spent in activities necessary to obtain the substance, 
use the substance, or recover from its effects 
•	 Important social, occupational, or recreational activities are given up or 
reduced because of substance use 
•	The substance use is continued despite knowledge of having a persistent 
physical or psychological problem that is likely to have been caused or exac-
erbated by the substance (e.g., current cocaine use despite recognition of 
cocaine-induced depression, continued drinking despite recognition that an 
ulcer was made worse by alcohol consumption)
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(Copyright 2000). American Psychiatric Association.
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Although a patient’s former drug of choice is 
the one that is most likely to lead to cravings  
and relapse (Daley, Marlatt, & Spotts, 2003; 
Gardner, 2000), clinical experience suggests  
that a person with a history of an SUD involv-
ing any drug is susceptible to developing a 
cross-addiction with opioids (Covington, 
2008; Savage, 2002). 
Clinicians should try to determine patients’ 
recovery status, which is crucial in developing 
a treatment plan (Exhibit 2-7). Many patients 
will be forthcoming about past or recent sub-
stance abuse during a comprehensive assess-
ment. Some patients who have an SUD lack 
a full appreciation of the effects of substances, 
prescribed or otherwise, on their function; 
however, family members can usually provide 
this information.
Several standardized tools for SUD screening 
are listed in Exhibit 2-8. Information on how 
to obtain the tools is in Appendix B. Most 
tools are short, can be self-administered, and 
can be integrated into the health-screening 
forms the patient completes prior to seeing  
the clinician. Although no tool is a substitute 
for a good clinical interview, screening is 
essential to case finding and a useful comple-
ment to the patient interview, the physical 
exam, and ongoing observation (Fishman, 
2007).
exhibit 2-7 steps Following substance Abuse Assessment
If Then
Abuse is remote and patient is in long-term 
recovery
Verify and support recovery efforts
Patient is on buprenorphine or methadone 
maintenance therapy (MMT)
Verify and continue buprenorphine or MMT
Abuse appears active Refer patient to substance abuse specialist for 
further evaluation
Adapted from Passik & Kirsh, 2004.
exhibit 2-8 Tools To screen for substance Use Disorders
Tool Format Administration/ 
scoring Time
Training 
required
Alcohol, Smoking, and 
Substance Involvement 
Screening Test
1 item for lifetime use, 6 
items for each of 10 sub-
stances used, and 1 item 
on injection use
Depends on number of 
substances used
Yes
Alcohol Use Disorders 
Identification Test (AUDIT)
10-item screening 
questionnaire
2 minutes to administer/ 
1 minute to score
Yes
AUDIT-C 3-item screening 
questionnaire
Less than 1 minute to 
administer and score
Yes
CAGE Adapted To Include 
Drugs
4 yes/no questions Less than 1 minute/ 
not scored
No
Drug Abuse Screening 
Test
20 yes/no questions about 
current and past use
1–2 minutes to administer/
not scored
No
Michigan Alcoholism 
Screening Test (MAST) 
(MAST-G for older adults)
24 yes/no questions 10 minutes to administer/ 
5 minutes to score
No
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The Substance Abuse and Mental Health 
Services Administration’s Screening, Brief 
Intervention, and Referral to Treatment 
(SBIRT) initiative may be helpful in the  
primary care context (Exhibit 2-9). More 
information can be obtained from the Center 
for Substance Abuse Treatment (CSAT, 
1999a). Research findings on SBIRT are 
available from National Association of State 
Alcohol and Drug Abuse Directors (2006).
referring for Further Assessment 
If the clinical interview, collateral interview, 
medical records, and screening suggest an 
unacknowledged SUD in a patient seeking 
treatment for CNCP, the clinician should  
refer the patient to an SUD specialist, if pos-
sible. Ideally, clinicians should develop a strong 
referral network of substance abuse treatment 
clinicians who can collaborate in the care of 
these high-risk patients, but specialists may 
not always be available or accessible. Referral 
for an SUD does not obviate the need for pain 
treatment because addiction treatment facili-
ties rarely have the resources or expertise to 
treat pain. 
Patients may react negatively to a referral to an 
SUD specialist. To avoid surprising the patient 
and putting the specialist in an awkward situ-
ation, the clinician should clearly explain the 
purpose of the referral. When referring the 
patient, clinicians should:
•	 Present the referral to the SUD specialist 
as they would a referral to any specialist, 
using a matter-of-fact and unapologetic 
tone. 
•	 Explain to the patient the importance of 
assessing factors that may be contributing 
to chronic pain, including substance use, 
and the problems SUDs or substance use 
may present for optimal treatment of  
chronic pain.
•	 Avoid getting distracted by the patient’s 
explanation of his or her substance use.
•	 Assure the patient that the referral does 
not mean transfer of care. The patient 
needs to know that care will be coordi-
nated among all professionals involved,  
if indicated, and that discussions of short- 
and long-term treatment will involve 
everyone, including the patient.
exhibit 2-9 elements of screening, Brief Intervention, and referral to 
Treatment
category Description
Screening Identifies individuals with problems related to substance use. Screening 
can be through interview and self-report.
Brief Intervention Follows a screening result indicating a moderate risk. A successful 
brief intervention encompasses support of the patient’s ability to make 
behavioral change.
Brief Treatment Follows a screening result of moderate to high risk. Brief treatment 
includes assessment, education, solving problems, introducing coping 
mechanisms, and building a supportive social environment.
Referral to Treatment Follows a screening result indicating severe abuse or dependence. This 
process facilitates access to care for individuals requiring more exten-
sive treatment than SBIRT provides and ensures access to the appropri-
ate level of care for all who are screened.
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•	 Help the patient make the appointment 
or make the appointment for the patient. 
The clinician–patient relationship is especially 
critical for patients who have comorbid pain 
and an SUD. They may anticipate that clini-
cians will criticize their substance use and 
discount their pain, and they may misinterpret 
a concern about an SUD as a lack of concern 
for their pain. They may blame themselves 
for having developed an SUD and expect 
the clinician to do the same. Therefore, the 
clinician must maintain an attitude of respect 
and concern. The clinician should assure the 
patient that both pain and the SUD are unin-
vited chronic illnesses and that both need to 
be treated concurrently. 
Federal regulations hold clinicians to a high 
standard of confidentiality regarding patient drug 
and alcohol treatment information (Exhibit 
2-10). Appendix C provides elements of a 
written consent and a sample consent form 
from 42 Code of Federal Regulations (CFR).
psychiatric comorbidities 
Both CNCP and SUDs are associated with 
high rates of psychiatric comorbidities, such as 
anxiety, depression, PTSD, and somatoform 
disorders (Chelminski et al., 2005; Dersh, 
Polatin, & Gatchel, 2002; Lebovits, 2000; 
Manchikanti et al., 2007; Saffier, Colombo, 
Brown, Mundt, & Fleming, 2007). Psychiatric 
comorbidity can be preexisting, or it can 
exhibit 2-10 Federal protection of patient health Information
regulation Description
42 CFR Applies to substance abuse treatment programs.
Protects the identities and records of patients in federally assisted 
drug and alcohol treatment programs. With few exceptions, clini-
cians must obtain written consent from a patient before disclosing 
any information regarding his or her identity or the specific type 
and extent of the patient’s health information, including that the 
patient is in an SUD treatment program. 
45 CFR and Health 
Insurance Portability and 
Accountability Act (HIPAA) 
Privacy Rule
Applies to all clinicians. 
Regulates patient privacy in regard to public health. HIPAA Privacy 
Rule requires clinicians (or their hospitals and clinics) to safeguard 
information regarding patient identification and to: 
•	Notify individuals regarding their privacy rights and how their 
protected health information is used or disclosed.
•	Adopt and implement internal privacy policies and procedures.
•	Train employees to understand these privacy policies and proce-
dures as appropriate for their functions within the covered entity.
•	Designate individuals who are responsible for implementing pri-
vacy policies and procedures and who will receive privacy-related 
complaints.
•	Establish privacy requirements in contracts with business associ-
ates that perform covered functions.
•	Have in place appropriate administrative, technical, and physical 
safeguards to protect the privacy of health information.
•	Meet obligations with respect to health consumers exercising 
their rights under the Privacy Rule. 
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develop or worsen with chronic pain or SUDs. 
Therefore, the presence of comorbid psychiat-
ric conditions should be assessed regularly in 
every patient with CNCP (see CSAT [2005b], 
for information on treating SUDs in people 
with co-occurring disorders). 
Adults with chronic pain often exhibit fear 
about the loss of control over routine aspects 
of daily life; apprehension that clinicians 
will view their pain reports as exaggerated, 
imaginary, or contrived; and catastrophic 
thinking (hopelessness based on a convic-
tion that things are worse than they really 
are). However, the distress that frequently 
accompanies CNCP may or may not signal 
a psychiatric disorder, so the clinician should 
try to make the distinction. Nevertheless, the 
decision to treat is based on the patient’s level 
of suffering and not on whether the symp-
toms reach the threshold for a DSM-IV-TR 
diagnosis. It is often difficult to differentiate 
a substance-induced condition from a pri-
mary psychiatric disorder, and evaluation of 
symptoms over time may be necessary. Where 
indicated, refer patients to a mental health 
provider. Exhibit 2-11 identifies instruments 
to assess distress, anxiety, fear, and depression. 
Information on obtaining these instruments is 
in Appendix B.
Anxiety 
Anxiety is common among people with CNCP 
and a current SUD, and it may persist in some 
people recovering from SUD. It is frequently 
associated with depression but can be present  
without it. Patients who have CNCP, espe-
cially those with a history of trauma, have 
increased rates of both anxiety symptoms and 
anxiety disorders (Dersh et al., 2002). 
The presence of an anxiety disorder has a  
negative effect on treatment of CNCP. Anxiety 
contributes to patient suffering and can make 
patients less able to participate in their pain 
management. Treating anxiety lowers pain 
scores, reduces the need for analgesics, and 
improves quality of life. 
Depression 
Patients who have CNCP and comorbid 
depression tend to: 
•	 Have high pain scores. 
•	 Feel less in control of their lives.
•	 Use passive–avoidant coping strategies.
•	 Adhere less to treatment plans than 
patients who are not depressed.
•	 Have greater interference from pain, 
including more pain behaviors observed 
by others. 
•	 Respond less well to pain treatment, 
unless depression is addressed.
Clinical depression has been shown to worsen 
other medical illnesses, interfere with their 
ongoing management, and amplify their det-
rimental effects on health-related quality of 
life (Cassano & Fava, 2002; Gaynes, Burns, 
Tweed, & Erickson, 2002). For these reasons, 
depression should be treated. It may be diffi-
cult to determine whether a patient’s negative 
affect represents clinical depression or the psy-
chological distress of chronic pain, an SUD, or 
other medical conditions. Sleep apnea, hypo-
thyroidism, and hypogonadism can present 
as depression. Hypogonadism is particularly 
relevant because it can result from prolonged 
exposure to opioids. 
Post-Traumatic Stress Disorder
CNCP and PTSD frequently co-occur; 
Asmundson and colleagues (2002) report that 
PTSD symptoms are especially common in 
patients who have CNCP who have high pain 
scores, high pain affect, and high pain interfer-
ence. Otis and colleagues (2003) recommend 
that patients presenting with either condition 
be assessed for both.
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exhibit 2-11 Tools To Assess emotional Distress, Anxiety, pain-related Fear, 
and Depression
Tool purpose Format Administration 
Time
Beck Depression 
Inventory
Measures depression 21 items 10 minutes
Brief Patient Health 
Questionnaire
Measures depression, panic, 
stress, and women’s health 
issues
9 items on depression, 
1–5 items on panic, 13 
items on stress, and 
6 items on women’s 
health
Varies
Center for 
Epidemiologic 
Studies Depression 
Scale
Measures how a patient has 
felt and behaved in past week
20 items 5–10 minutes
Geriatric 
Depression Scale
Seeks yes/no responses to 
measure depression in older 
adults
Short form: 15 items 
Long form: 30 items
5–10 minutes
Profile of Chronic 
Pain: Screen
Measures pain severity, inter-
ference, and emotional burden
15 items 5 minutes
Clinician 
Administered PTSD 
Scale
Assesses for PTSD symptoms, 
the effect of symptoms on 
individual’s life, and the severity 
of symptoms
30 items 45 minutes or 
more
Davidson Trauma 
Scale
Measures frequency and sever-
ity of PTSD symptoms
17 items 10 minutes
Posttraumatic 
Diagnostic Scale
Assesses for PTSD symptoms 
and severity of symptoms
49 items 10-15 minutes
State-Trait Anxiety 
Inventory
Measures current anxiety and 
propensity for anxiety
40 items 
Self-administered
10–20 minutes
Tampa Scale for 
Kinesiophobia
Measures pain-related fear 
of movement; may predict 
disability
17 items 
Self-administered
5 minutes
Symptoms for CNCP and PTSD often over-
lap (Asmundson et al., 2002). These include 
anxiety, hyperarousal, avoidance behavior, 
emotional lability, and elevated somatic focus. 
Both conditions are also characterized by 
hypervigilance, attentional bias, stress response, 
and pain amplification.
Symptoms may be mutually reinforcing. For 
example, if CNCP resulted from a trauma, the 
pain may trigger flashbacks. 
Somatization 
Somatization refers to inordinate preoccupation  
with and communication about physical symp-
toms. Although a diagnosis of somatization 
disorder is rare in patients who have chronic 
pain, multiple pain complaints are almost 
always present in somatization disorder. Many 
patients who have multiple unexplained symp-
toms have subsyndromal forms of somatization 
disorder. 
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This may be categorized as undifferentiated 
somatoform disorder. When psychological fac-
tors are thought to contribute to a pain syn-
drome, patients may be diagnosed with pain 
disorder with psychological factors or pain disor-
der with both psychological factors and a general 
medical condition. Patients who have chronic 
pain and medically unexplained symptoms are 
at risk for iatrogenic consequences of unneeded 
diagnostic tests, medications, and surgery. 
Suicide
Studies show an association between CNCP 
and suicidal ideation and suicide attempts 
that is not explained by the presence of co-
occurring SUDs (Braden & Sullivan, 2008) 
or co-occurring mental disorders (Braden 
& Sullivan, 2008; Ratcliffe, Enns, Belik, & 
Sareen, 2008; Scott et al., 2010; Tang & 
Crane, 2006). In their review of 12 articles on 
suicide (including suicidal ideation and suicide 
attempts) and CNCP, Tang & Crane (2006) 
found that the risk for suicide “appeared to be 
at least doubled” in patients who experienced 
CNPC (p. 575). (See CSAT [2009a], for 
information on addressing suicidal thoughts 
and behaviors in substance abuse treatment).
Assessing Ability To cope With 
chronic pain 
Coping and anxiety are closely related, from 
a clinical viewpoint. The patient who has 
CNCP may have anxiety because of maladap-
tive coping skills, for example. The concept of 
acceptance has been studied in CNCP. This 
concept refers to the patient’s belief that there 
is more to life than pain, that being completely 
free of pain is unrealistic, and that activities 
should be pursued, even at the price of some 
increase in pain (Risdon, Eccleston, Crombez, 
& McCracken, 2003). Patients who have high 
levels of acceptance report lower pain inten-
sity, less pain-related anxiety and avoidance, 
less depression, less physical and psychosocial 
disability, more daily uptime, and better work 
status than do patients who have not accepted 
pain.
Patients who have chronic pain who score 
high on measures of self-efficacy or have an 
internal locus of control report lower levels of 
pain, higher pain thresholds, increased exer-
cise performance, and more positive coping 
efforts (Asghari, Julaeiha, & Godarsi, 2008; 
Barry, Guo, Kerns, Duong, & Reid, 2003). 
Exhibit 2-12 lists tools to assess coping skills. 
Information on obtaining these instruments  
is provided in Appendix B.
exhibit 2-12 Tools To Assess coping
Tool purpose Format Administration 
Time
Chronic Pain 
Acceptance 
Questionnaire
Assesses willingness to 
experience pain and engage in 
activities
20 items  
Self-administered
5 minutes
Fear-Avoidance 
Beliefs Questionnaire
Assesses patients who have 
chronic low-back pain
16 items 
Self-administered
10 minutes
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evaluating risk of Developing 
problematic opioid Use 
When any patient with a behavioral health 
disorder is considered for opioid therapy for 
CNCP, the clinician must carefully weigh the 
risks and benefits of opioid use. Risk assess-
ment is made over time and may change over 
the course of treatment (Gourlay & Heit, 
2009). A patient’s risk level is a matter of 
clinical judgment. Exhibit 2-13 presents one 
risk assessment schema. All patients who have  
SUD histories have some risk, which in many 
cases can be safely managed. However, in some  
patients, the risks of opioid use are so great 
and the likely benefit so small that they should 
not be treated with chronic opioid therapies. 
Screening tools may be one element of a risk 
assessment. Two commonly used screening 
tools are the Screener and Opioid Assessment 
for Patients with Pain–Revised (SOAPP–R) 
and the Opioid Risk Tool (ORT). Both can 
be helpful for identifying patients at risk, but 
neither has been fully validated. Chapter 4 
describes tools for assessing patients who  
have already begun opioid therapy.
Screener and Opioid Assessment for 
Patients with Pain–Revised 
SOAPP–R can predict which patients who 
have CNCP are at high risk for problems with 
chronic opioid therapy (Exhibit 2-14) (Butler, 
Fernandez, Benoit, Budman, & Jamison, 
2008). It is a self-administered questionnaire 
answered on a 5-point scale ranging from 0 
(never) to 4 (very often). The numeric ratings 
are added; a score of 18 or higher suggests 
the patient is at high risk for problems with 
chronic opioid therapy.
Opioid Risk Tool  
Opioid Risk Tool (ORT; Webster & Webster, 
2005) identifies patients at risk for aberrant 
drug-related behaviors (ADRBs) if prescribed 
opioids for CNCP (Exhibit 2-15). Like 
SOAPP-R, ORT may help clinicians decide 
which patients may require close monitoring if 
opioids are prescribed for them. Most patients 
who have CNCP and histories of behavioral 
health disorders are likely to have elevated 
scores, indicating a high level of risk on opioid 
therapy. 
exhibit 2-13 risk of patient’s Developing problematic opioid Use
risk characteristics of patient
Low No history of substance abuse
Minimal, if any, risk factors
Medium History of non-opioid SUD
Family history of substance abuse
Personal or family history of mental illness 
History of nonadherence to scheduled medication therapy 
Poorly characterized pain problem 
History of injection-related diseases
History of multiple unexplained medical events (e.g., trauma, burns)
High Active SUD 
History of prescription opioid abuse
Patient previously assigned to medium risk exhibiting aberrant behaviors
Analgesic Research, personal communication, October 30, 2009.
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exhibit 2-14 soApp–r Questions 
1. How often do you have mood swings?
2. How often have you felt a need for higher doses of medication to treat your pain?
3. How often have you felt impatient with your doctors?
4. How often have you felt that things are just too overwhelming that you can’t handle 
them?
5. How often is there tension in the home?
6. How often have you counted pain pills to see how many are remaining?
7. How often have you been concerned that people will judge you for taking pain 
medication?
8. How often do you feel bored?
9. How often have you taken more pain medication than you were supposed to?
10. How often have you worried about being left alone?
11. How often have you felt a craving for medication?
12. How often have others expressed concern over your use of medication?
13. How often have any of your close friends had a problem with alcohol or drugs?
14. How often have others told you that you have a bad temper?
15. How often have you felt consumed by the need to get pain medication?
16. How often have you run out of pain medication early?
17. How often have others kept you from getting what you deserve?
18. How often, in your lifetime, have you had legal problems or been arrested?
19. How often have you attended an Alcoholics Anonymous or Narcotics Anonymous 
meeting?
20. How often have you been in an argument that was so out of control that someone 
got hurt?
21. How often have you been sexually abused?
22. How often have others suggested that you have a drug or alcohol problem?
23. How often have you had to borrow pain medications from your family or friends?
24. How often have you been treated for an alcohol or drug problem?
Reprinted from Butler et al., 2008. Validation of the revised screener and opioid assessment for patients with pain.  
Journal of Pain, 9, 360–372. Used with permission from Elsevier.
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exhibit 2-15 orT
Item mark each Box 
That Applies
Item score 
if Female
Item score 
if male
1. Family history of substance abuse
Alcohol 
Illegal drugs 
Prescription drugs
 
 

1 
2 
4
3 
3 
4
2.  Personal history of substance abuse
Alcohol 
Illegal drugs 
Prescription drugs
 
 

3 
4 
5
3 
4 
5
3. Age (mark box if 16–45)  1 1
4.  History of preadolescent sexual abuse  3 0
5. Psychological disease
Attention deficit disorder, obsessive- 
compulsive disorder, bipolar, schizophrenia
 2 2
6. Depression 
Total ______ ______
Total score risk category
Low risk: 0–3 
Moderate risk: 4–7 
High risk: ≥ 8
Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of 
the Opioid Risk Tool. Pain Medicine, 6(6), 432–442. Reproduced with permission of Blackwell Publishing, Ltd.
ongoing Assessment
Clinicians must assess all patients who have 
CNCP at regular intervals because a variety 
of factors can emerge that can alter treatment 
needs. For example, a patient may develop 
tolerance to a particular opioid, the underlying 
disease condition may change another physi-
cal or mental health problem, which might 
develop or worsen, or there may be changes  
in the patient’s cognitive functioning. 
Comparative data can be obtained by using  
the same assessment tools over time. For  
patients who have SUD histories or other  
behavioral health disorders, regular assessments 
should include checking for evidence of medi-
cation misuse. Chapter 4 provides a discussion 
on assessing and documenting the behavior of 
patients on opioid therapy. 
The clinician should regularly:
•	 Assess adherence to all the recommended 
treatment modalities.
•	 Assess patient reactions to the treatment 
regimen.
•	 Determine the extent of adherence to the  
prescribed regimen (otherwise, the reported 
response may inaccurately reflect on the 
therapies prescribed). 
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•	 Obtain the perspectives of significant 
others on the patient’s relief from pain, 
the effects of analgesia on function, and 
adherence to and safety with prescribed 
medications. (Permission to obtain col-
lateral information is a prerequisite for 
prolonged opioid treatment.)
Nicholson and Passik (2007) recommend that 
the elements in Exhibit 2-16 be documented 
and kept current in a patient’s record. The  
frequency with which these areas need to  
be assessed in individual patients is a matter  
of clinical judgment. 
Treatment setting
A clinician may conclude that optimal treat-
ment includes more specialized care, such as 
that provided at a pain clinic. Where distance, 
exhibit 2-16 elements To Document During patient visits
Area elements of Documentation
History and Physical Evaluation History of present illness
Pain score/intensity
Medication history
SUD/addiction history
Screening tool assessments 
Medical history
Physical examination
Mental status/cognition
Results of diagnostic studies
Diagnostic/Clinical Indication for 
Prescribing Opioids
Most probable pathological explanation of chronic pain
Treatment Plan Pharmacological treatments 
Nonpharmacological treatments (e.g., physical therapy, 
exercise, behavioral therapy, lifestyle changes)
Treatment goals and anticipated time course
Adherence measures (e.g., urine drug testing, pill counts)
Informed Consent and Agreements 
for Treatment
Informed consent (e.g., discussion of risks and benefits of 
treatment options)
Agreement specifying patient’s responsibilities and clinic 
policies
Periodic Review Pain score/intensity
Physical, occupational, and overall function; family and 
social relationships; and mood and sleep patterns
Side effects (including severity)
ADRBs
Medication
Mental status/cognitive changes 
Consultations and referrals As appropriate to provide comprehensive care
Adapted from Nicholson & Passik, 2007.
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costs, or other factors prohibit such a refer-
ral, the clinician must be resourceful, perhaps 
combining various local resources and sup-
port groups or suggesting specific electronic 
resources. Chapter 5 provides more details. 
The vast majority of chronic pain syndromes 
(e.g., lumbago, osteoarthritis) in patients 
who do not have major psychopathology or 
histories of SUDs (excluding tobacco) are 
managed by primary care physicians. When 
the pain syndrome is atypical, or when there 
is comorbid psychiatric illness or SUD history, 
specialty consultation may be indicated. In the 
presence of current or past SUD, addiction-
ology consultation may be necessary before 
instituting chronic therapy with scheduled 
medications. 
Key points
•	 Patients should receive a comprehensive initial assessment. 
•	 It is important to discover the cause of a patient’s chronic pain; however, clinicians 
should not assume a patient is disingenuous if the cause is not discovered. 
•	 The patient’s personal and family substance use histories and current substance use pat-
terns should be assessed. 
•	 It is crucial to obtain collateral information on the patient’s pain level and functioning, 
as well as SUD status.
•	 Comorbid psychological disorders should be assessed and treated.
•	 Assessment of the patient with co-occurring chronic pain and SUD or other behavioral 
health disorders should be ongoing.
In ThIs ChapTer
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•	Overview of Pain 
Management
•	The Treatment Team
•	Treating Patients in 
Recovery 
•	Nonpharmacological 
Treatments
•	Treating Psychiatric 
Comorbidities
•	Opioid Therapy
•	Treating Patients in 
Medication-Assisted 
Recovery
•	Treating Pain in Patients 
With Active Addiction
•	Acute Pain Episodes
•	Assessing Treatment 
Outcomes
•	Key Points
chronic pain 
management
overview of pain management 
Chronic noncancer pain (CNCP) is a major challenge for clinicians 
as well as for the patients who suffer from it. The complete elimina-
tion of pain is rarely obtainable for any substantial period. Therefore, 
patients and clinicians should discuss treatment goals that include 
reducing pain, maximizing function, and improving quality of life. 
The best outcomes can be achieved when chronic pain management 
addresses co-occurring mental disorders (e.g., depression, anxiety) 
and when it incorporates suitable nonpharmacologic and comple-
mentary therapies for symptom management. Exhibit 3-1 presents 
the consensus panel’s recommended strategy for treating CNCP in 
adults who have or are in recovery from a substance use disorder 
(SUD).
The Treatment Team
Chronic pain management is often complex and time consuming. It 
can be particularly challenging and stressful for clinicians working 
without input from other clinicians. The effectiveness of multiple 
interventions is augmented when all medical and behavioral health-
care professionals involved collaborate as a team (Sanders, Harden, 
& Vicente, 2005). A multidisciplinary team approach provides a 
breadth of perspectives and skills that can enhance outcomes and 
reduce stress on individual providers. Although it is ideal when all 
relevant providers work within the same system and under the same 
roof, often a collaborative team must be coordinated across a com-
munity. This combined effort requires identification of a designated 
lead care coordinator and a good system of communication among 
team members and the patient. A treatment team can include the 
following professionals: 
•	 Primary care provider
•	 Addiction specialist 
•	 Pain clinician
3
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exhibit 3-1 Algorithm for managing chronic pain in patients With sUD
•	 Nurse
•	 Pharmacist
•	 Psychiatrist
•	 Psychologist
•	 Other behavioral health treatment spe-
cialists (e.g., social worker, marriage and 
family therapist, counselor)
•	 Physical or occupational therapists
Addiction specialists, in particular, can make 
significant contributions to the management 
of chronic pain in patients who have SUDs. 
They can: 
•	 Put safeguards in place to help patients 
take opioids appropriately.
•	 Reinforce behavioral and self-care com-
ponents of pain management. 
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•	 Work with patients to reduce stress.
•	 Assess patients’ recovery support system.
•	 Identify relapse.
When the addiction specialist is the prescriber 
of analgesics, medical responsibilities (e.g., 
prescribing of analgesics, physical therapy, 
orthotics) should be coordinated with the 
clinician responsible for other components of 
pain treatment. In some States, consultation 
with an addiction specialist is required before 
scheduled medications can be prescribed on 
a long-term basis to patients who have SUD 
histories. State laws, regulations, and policies 
are available at http://www.painpolicy.wisc.
edu/.
The more complicated the case, the more 
beneficial a team approach becomes. However, 
many clinicians will have to treat complex 
patients who have little or no outside 
resources. 
Treating patients in recovery 
A thorough patient assessment (see Chapter 
2) provides information that allows the clini-
cian to judge the stability of a patient’s recov-
ery from an SUD. Goals for treating CNCP 
in patients who are in long-term recovery 
or whose SUD is in the distant past are as 
follows:
•	 Treat CNCP with non-opioid analgesics 
as determined by pathophysiology.
•	 Recommend or prescribe nonpharmaco-
logical therapies (e.g., cognitive–behavioral 
therapy [CBT], exercises to decrease pain 
and improve function). 
•	 Treat comorbidities.
•	 Assess treatment outcomes.
•	 Initiate opioid therapy only if the poten-
tial benefits outweigh risk and only for 
as long as it is unequivocally beneficial to 
the patient. 
Non-Opioid Analgesics 
Non-opioid pharmacological options include 
acetaminophen and nonsteroidal anti- 
inflammatory drugs (NSAIDs), as well as 
adjuvant medications—so called because they 
originally were developed for other purposes 
but have analgesic properties for certain con-
ditions. The primary adjuvant analgesics are 
antidepressants and anticonvulsants. Exhibit 
3-2 presents a summary of these analgesics as  
they pertain to patients who have SUDs. 
Benzodiazepines
Researchers disagree on the beneficial and 
harmful effects of benzodiazepines and ben-
zodiazepine receptor agonists on chronic pain. 
Several studies demonstrate increased pain 
exhibit 3-2 summary of non-opioid Analgesics 
Analgesic Addictive notes
Acetaminophen No Should normally not exceed 4 g/day; in adults with 
hepatic disease, the maximum dose is 2 g/day. 
Potentiates analgesia without potentiating respiratory 
and sedative side effects. 
NSAIDs No Are used to relieve numerous types of pain, espe-
cially bone, dental, and inflammatory, and enhance 
opioid analgesia. May cause gastrointestinal bleed-
ing and renal insufficiency.
Serotonin-Norepinephrine 
Reuptake Inhibitors 
(SNRIs)
No Are used to relieve several nonstructural types of 
pain (e.g., migraine, fibromyalgia, low back pain) and 
probably others.
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with benzodiazepines or reduced pain follow-
ing benzodiazepine antagonist use (Ciccone 
et al., 2000; Gear et al., 1997; Nemmani & 
Mogil, 2003; Pakulska & Czarnecka, 2001). 
All benzodiazepines have side effects, includ-
ing impaired coordination, reduced memory, 
and addiction liability. For the following rea-
sons, the consensus panel concludes that ben-
zodiazepines have no role in the treatment of 
CNCP in patients who have comorbid SUD, 
beyond very short-term, closely supervised 
treatment of acute anxiety states: 
•	 Guidelines from the American 
Psychiatric Association (2006) and the 
United Kingdom’s National Institute for 
Health and Clinical Excellence (Hughes 
et al., 2004) caution that benzodiazepines 
are not first-line medications. 
•	 Excellent options to benzodiazepines 
for treating anxiety exist (see Treating 
Psychiatric Comorbidities, below).
•	 Anxiolytic use in adults with CNCP is 
often protracted.
•	 Benzodiazepines pose significant risk 
for addiction relapse and functional 
impairment. 
The consensus panel recommends that clinicians 
treat comorbid anxiety and insomnia with 
antidepressants or anticonvulsants. Some 
antidepressants (e.g., trazodone, mirtazapine, 
amitriptyline, doxepin) may be useful sleep 
aids. Benzodiazepine weaning can be done 
in consultation with a psychiatrist or SUD 
treatment provider (see Center for Substance 
Abuse Treatment [CSAT], 2006). 
exhibit 3-2 summary of non-opioid Analgesics (continued)
Analgesic Addictive notes
Tricyclic Antidepressants No Have demonstrated efficacy in migraine prophylaxis, 
fibromyalgia, many neuropathic pains, vulvodynia, 
and functional bowel disorders. Watch for anticho-
linergic side effects and orthostatic hypotension (fall 
risk in older people).
Anticonvulsants No Some have demonstrated efficacy in relieving fibro-
myalgia, migraine prophylaxis, and neuropathic 
pains.
Topical Analgesics No Comprise several unrelated substances (e.g., 
NSAIDs, capsaicin, local anesthetics). Work locally, 
not systemically, and therefore usually have minimal 
systemic side effects.
Antipsychotics No Have no demonstrated analgesic effect, except to 
abort migraine/cluster headache. Risks include extra-
pyramidal reactions and metabolic syndrome.
Muscle Relaxants Carisoprodol 
(Soma) is 
addictive. 
Some others 
have sig-
nificant abuse 
potential.
Have not been shown to be effective beyond the 
acute period. Some potentiate opioids and are not 
recommended.
Benzodiazepines Yes Not recommended (see discussion).
Cannabinoids Yes Not recommended (see discussion).
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Cannabinoids 
At least two types of cannabinoid receptors are 
present in the human nervous system, and they 
interact with systems relevant to pain percep-
tion, including the serotonergic and dopami-
nergic systems. Cannabinoids are anti-inflam-
matory and increase levels of endogenous opi-
oids. They inhibit glutamatergic transmission 
and antagonize the N-methyl-D-aspartate 
(NMDA) glutamate receptor, both of which 
actions would be expected to inhibit pain 
(Burns & Ineck, 2006; McCarberg, 2006). 
The primary psychoactive chemical in  
marijuana responsible for its abuse potential 
is Δ9 tetrahydrocannabinol (THC). Synthetic 
THC (Marinol) is approved in the United 
States for chemotherapy-induced nausea and 
AIDS-induced anorexia. Sativex, a mixture of 
THC and cannabidiol, is an oromucosal spray 
that spares the lungs the toxicity of drugs and 
smoke. It is analgesic in neuropathic pain and 
is approved in Canada for the pain of multiple 
sclerosis. Nabilone is a synthetic drug similar 
to THC. Its reported analgesic effects were 
determined to be weaker than codeine in a 
controlled study of neuropathic pain (Frank, 
Serpell, Hughes, Matthews, & Kapur, 2008).
Although it is reasonable to conclude that 
modulating the human cannabinoid system 
shows promise for treating pain, there is no 
reason to believe that inhaled smoke is an 
acceptable delivery mode. The consensus panel 
does not recommend smoked marijuana for 
treating CNCP. 
nonpharmacological Treatments 
An approach to pain management that inte-
grates evidence-based pharmacological and 
nonpharmacological treatments can ease pain 
and reduce reliance on medication. 
Nonpharmacological treatments for CNCP 
(Hart, 2008; Simpson, 2006):
•	 Pose no risk of relapse.
•	 May be more consistent with the recover-
ing patient’s values and preferences than 
pharmacological treatments, especially 
opioid interventions.
•	 May reduce pain and improve quality  
of life in some patients who have CNCP.
•	 Should be included in most pain treat-
ment plans. 
Common nonpharmacological therapies for 
CNCP include:
•	 Therapeutic exercise.
•	 Physical therapy (PT).
•	 Cognitive–behavioral therapy (CBT).
•	 Complementary and alternative medicine 
(CAM; e.g., chiropractic therapy, massage 
therapy, acupuncture, mind–body therapies, 
relaxation strategies).
Appendix D provides information on how to 
find qualified practitioners who provide CAM. 
Therapeutic Exercise
A number of practitioners, including physicians, 
chiropractors, and physical therapists, frequent-
ly include exercise instruction and supervised 
exercise components in CNCP treatment. 
Therapeutic exercise can increase strength, 
aerobic capacity, balance, and flexibility; 
improve posture; and enhance general well-
being. Fitness can be an antidote to the sense 
of helplessness and personal fragility experi-
enced by many people with CNCP. Moderate 
evidence shows that exercise alleviates low 
back pain, neck pain, fibromyalgia, and other 
conditions. Furthermore, exercise reduces anxi-
ety and depression. Limited evidence suggests 
that exercise benefits individuals undergoing 
SUD treatment (Weinstock, Barry, & Petry, 
2008). 
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Physical Therapy
PT facilitates recovery from a large variety 
of medical conditions, including cardiopul-
monary, geriatric, pediatric, integumentary, 
neurologic, and orthopedic. Neurologic PT 
and orthopedic PT are most likely to be used 
to treat chronic pain. Physical therapists use 
various hands-on approaches to help patients 
increase their range of motion, strength, and 
functioning. They also offer training in move-
ment and exercises that help patients feel and 
function better. 
Many widely used interventions by physical 
therapists lack definitive evidence. For example, 
several Cochrane Collaboration reviews of a 
commonly used PT modality—transcutaneous 
electrical nerve stimulation—found inconsis-
tent evidence of effectiveness in a variety of  
chronic and acute pain conditions. Despite  
this lack of an evidence base, PT interventions  
have the advantages of being nonsurgical,  
bringing low risk of injury or dependence,  
and encouraging patients’ involvement in their 
own recovery.
Cognitive–Behavioral Therapy 
Several studies have shown that CBT can 
help patients who have CNCP reduce pain 
and associated distress, disability, depression, 
anxiety, and catastrophizing, as well as improve 
coping, functioning, and sleep (McCracken, 
MacKichan, & Eccleston, 2007; Thorn et al., 
2007; Turner, Mancl, & Aaron, 2006; Vitiello, 
Rybarczyk, Von Korff, & Stepanski, 2009). In 
addition to its salutary effects on pain syn-
dromes, CBT also benefits people who have 
SUD. In a meta-analysis of 53 controlled  
trials of CBT for alcohol or illicit drug disor-
ders, CBT was found to produce a small but 
significant benefit (Magill & Ray, 2009). 
Complementary and Alternative 
Medicine 
CAM includes health systems, practices, and 
products that are not necessarily considered 
part of conventional medicine (National 
Center for Complementary and Alternative 
Medicine, 2007). Surveys show that 27–60 
percent of chronic pain patients use CAM 
(Fleming, Rabago, Mundt, & Fleming, 2007; 
McEachrane-Gross, Liebschutz, & Berlowitz, 
2006; Nayak, Matheis, Agostinelli, & Shifleft, 
2001). Clinicians are urged to learn about 
these approaches to pain treatment not only 
because of their therapeutic promise, but also 
because many patients use CAM, raising the 
possibility of interactions with conventional 
treatments (Simpson, 2006). Exhibit 3-3  
presents one way to ask patients about their 
use of CAM. 
The evidence supporting CAM interventions 
for adults with comorbid CNCP and SUD is 
exhibit 3-3 Talking With patients About complementary and Alternative 
medicine
Clinician  “So many of my patients use alternative medicine that I always ask about it. Are you 
using vitamins, herbs, acupuncture, that sort of thing for pain or for anything else?”
Patient   “Yeah. Acupuncture really helped when I was in rehab, and I still get it now and then. 
She does the needles and gives me Chinese herbs once in a while.” 
Clinician  “That’s fine. If it helps, keep doing it. And when you take herbs or anything else she 
gives you, please tell me. I want to make sure that any herbs or medicines that you get 
from your acupuncturist won’t interfere with the treatment that you are getting here, 
okay?”
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ambiguous. These conditions are complex and 
multifactorial and, therefore, difficult to study. 
Many systematic reviews of CAM research 
note generally poor-quality reporting and het-
erogeneous methodology that precludes defin-
itive evidence-based conclusions (e.g., Gagnier, 
van Tulder, Berman, & Bombardier, 2006). Of 
the CAM interventions, manual therapies are 
the most widely used and the most studied 
(Simpson, 2006). Chiropractic and massage 
therapies are often covered by health insur-
ance, making these therapies accessible and 
compatible with conventional therapies. 
Treating psychiatric comorbidities
Research shows well-established associations 
among chronic pain, SUDs, and mental disor-
ders (e.g., depression, anxiety, post-traumatic 
stress disorder [PTSD], somatoform disorders) 
(Chelminski et al., 2005; Covington, 2007; 
Manchikanti et al., 2007; Saffier, Colombo, 
Brown, Mundt, & Fleming, 2007; Wasan et 
al., 2007). Psychiatric comorbidity is of special 
significance for two reasons. First, it is often 
occult. Second, untreated psychopathology is 
associated with poor pain treatment outcomes 
(Edwards et al., 2007; Williams, Jones, Shen, 
Robinson, & Kroenke, 2004). Therefore, 
management of patients who have CNCP 
must include intervention for co-occurring 
psychopathology. 
Because psychiatric comorbid disorders might 
be preexisting, or they may develop or worsen 
with chronic pain or SUDs, it is important to 
determine the onset of psychiatric symptoms 
during the screening and assessment process 
(see Chapter 2). The psychiatric disorder 
needs to be included in the comprehensive 
treatment plan that is developed for the 
patient in consultation with the patient’s 
treatment team (e.g., primary healthcare 
provider, substance abuse treatment counselor, 
pain management provider, mental health 
professional). CSAT (2005b) provides detailed 
information on treatment strategies and mod-
els for working with individuals with a wide 
spectrum of psychiatric co-occurring disorders. 
Benzodiazepines are generally indicated for 
short-term treatment of anxiety; however, anx-
iety associated with chronic pain commonly 
persists for years. Effective options include 
(Van Ameringen, Mancini, Pipe, & Bennett, 
2004): 
•	 Psychological and behavioral treatments. 
•	 Selective serotonin reuptake inhibitors 
(SSRIs). 
•	 SNRIs.
•	 Tricyclic antidepressants.
•	 Several anticonvulsants.
The anxiety that is often comorbid with 
CNCP can often be managed satisfactorily 
with adjuvants prescribed for the pain syn-
drome. Several anticonvulsants that are used 
for CNCP are strongly anxiolytic. In a review, 
Van Ameringen and colleagues (2004) found 
that the strongest evidence was for pregabalin 
(for social phobia and generalized anxiety 
disorder), gabapentin (for social phobia), 
lamotrigine (for PTSD), and valproic acid  
(for panic disorder). In addition, many anti-
depressants are effective for chronic pain and 
may be used to treat comorbid anxiety and 
depression, and both duloxetine and venlafax-
ine have been approved by the Food and Drug 
Administration for treatment of generalized 
anxiety disorder. Most tricyclic antidepressants 
are anxiolytic. Trazodone has also been found 
to be anxiolytic and is often used as a seda-
tive in patients for whom benzodiazepine-like 
agents are undesirable. Treating comorbidities 
with medications that also alleviate pain can 
reduce polypharmacy, drug interactions, non-
adherence, and, at times, financial costs. 
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The person who somatizes extensively may 
present a plethora of complaints. This situa-
tion may lead to the clinician’s inappropriate 
discounting of all the patient’s symptoms as 
trivial or imaginary. Clinicians should take the 
following steps in treating such a patient: 
•	 Complete an inventory of all the patient’s 
complaints.
•	 Emphasize history and physical examina-
tion in the evaluation.
•	 Validate the patient’s symptoms while 
assuring him or her about the absence  
of worrisome pathology.
•	 Minimize expensive or invasive tests and 
treatments.
•	 Minimize use of medications with abuse 
liability, especially short-acting medica-
tions used as needed (PRN).
•	 Minimize use of passive modalities of 
therapy.
•	 Schedule regular appointments rather 
than PRN visits.
•	 Adequately treat comorbid Axis I (i.e., 
major psychiatric) disorders. 
•	 Refer patients for counseling or relaxation 
training, as available.
opioid Therapy 
Limitations
Opioids are potent analgesics that may provide 
relief for many types of CNCP. However, even 
when effective, they have limitations, such as 
diminished efficacy over time (Ballantyne, 
2006; Noble, Tregear, Treadwell, & Schoelles, 
2008). Opioids also have adverse effects that 
many patients cannot tolerate (e.g., nausea, 
sedation,  constipation). Other drawbacks 
include risk of addiction or addiction relapse, 
opioid-induced hyperalgesia (OIH), and 
many potential drug interactions. Serotonin 
syndrome is a potential adverse effect of both 
opioids and some medications used to treat 
depression, obsessive-compulsive disorder, or 
other behavioral health disorders. Serotonin 
syndrome can cause agitation, confusion, fever, 
and seizures, and it can be lethal if undetected 
or untreated. Patients who take SSRIs, SNRIs, 
St. John’s Wort, monoamine oxidase inhibitors, 
lithium, or HIV medications are at increased 
risk of serotonin syndrome (U.S. Food and 
Drug Administration, 2006). In addition, 
patients who take opioids chronically are at 
increased risk of serotonin syndrome if medi-
cations such as fentanyl, meperidine, or pen-
tazocaine are needed in emergency or surgical 
care settings. 
Although opioids are an important treatment 
component for many patients, they are rarely 
sufficient. Chronic opioid therapy rarely shows 
more than one-third pain reduction in studies 
extending beyond 18 months, indicating that 
opioids are best used as one part of a multidi-
mensional approach for most patients. 
When an SUD co-occurs with CNCP, the 
benefits of opioids are not well established and 
risk of relapse is increased (Reid et al., 2002). 
Studies indicate that most patients who are 
currently addicted to prescription opioids had 
a prior SUD, suggesting that people in recov-
ery are at increased risk for relapse (Potter 
et al., 2004; Rosenblum et al., 2003). This 
may be especially true when the prior SUD 
involved opioids, because one of the most 
powerful triggers for relapse is exposure to 
the former drug of choice (Daley et al., 2003; 
Gardner, 2000). Trescot and colleagues (2008) 
provide a detailed review.
Before Initiating Opioid Treatment 
Exhibit 3-4 shows steps to take before initiat-
ing opioid therapy. Information about patient 
education, informed consent, and treatment 
plans is provided in Chapter 5. 
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Opioid Selection
For patients who have histories of SUDs, it is 
essential to minimize exposure to the euphoric 
effects of opioids. To reduce the likelihood of 
such effects, clinicians should: 
•	 Select opioids with minimal rewarding 
properties (e.g., tramadol, codeine), when 
effective. 
•	 Avoid prescribing supratherapeutic doses 
(usually demonstrated by presence of 
sedation, lethargy, functional impairment).
•	 If higher potency opioids are required, 
prescribe slow-onset opioids with 
prolonged duration of action (Mironer, 
Brown, Satterthwaite, Haasis, & 
LaTourette, 2000). 
Short-acting medications have been recom-
mended to be used preemptively before  
activities known to cause pain, such as PT,  
or for pain limited to certain times of day. 
There is controversy regarding the appropri-
ateness of this suggestion for patients who 
have CNCP (Devulder, Jacobs, Richarz, & 
Wigget, 2009), and the practice is especially 
hazardous in people with current or past 
SUDs.
The route of administration may influence  
addiction risk, so medications that are injected 
or easily convertible to forms that can be 
injected, smoked, or snorted are often avoided 
in patients who have SUD. Some clinicians  
favor transdermal medication, with an agree-
ment that refills are contingent on the patient’s 
returning the used patches to demonstrate that 
they were not punctured, cut, or diverted. 
Dose Finding 
Dose finding for the patient with an SUD, 
especially a history of abuse of or dependence 
on opioids, can be complicated because of 
existing or rapidly developing tolerance to 
opioids. Also, analgesics affect individuals dif-
ferently. A person who states that a particular 
opioid “doesn’t work for me,” whereas another 
opioid does, may be accurately reporting anal-
gesic response. 
Titration schedules appropriate for the patient 
with no SUD history may expose the patient 
in SUD recovery to a protracted period of 
inadequate relief. Although no schedule can 
be applied to everyone, a general guide is that, 
if low doses of opioids (other than metha-
done) are initiated for severe pain, they should 
be titrated rapidly to avoid subjecting the 
patient to a prolonged period of dose finding. 
However, if relatively high doses are initiated, 
titration should be slower and determined to 
a great extent by the half-life of the drug. For 
some patients, increasing the dose may lead to 
exhibit 3-4 steps To Take If opioid Therapy Is Indicated
Step 1.  Educate patient and family about treatment options, sharing the decision about the goal 
and expected outcome of therapy.
Step 2.  Discuss treatment agreement with the patient and family.
Step 3.  Obtain a written opioid agreement.
Step 4.  Determine and document the treatment plan.
Step 5. Initiate a trial of opioid therapy.
Step 6.  Document details of therapy and results.
Department of Veterans Affairs & Department of Defense, 2010.
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decreased functioning. It is essential that clini-
cians understand that dose finding for metha-
done can be dangerous (see Exhibit 3-5).
When an effective dose for a given patient 
has been determined, total opioid dose should 
thereafter be escalated very slowly, if at all, as 
tolerance develops. No study has ever shown 
that opioids eliminate chronic pain, other than 
in the very short term, so efforts to achieve 
a zero pain level with opioids will fail, while 
subjecting the patient to potentially intoxicat-
ing doses of the medication. 
Relapse
For patients on chronic opioid therapy who 
have minor relapses and quickly regain stabil-
ity, provision of substance abuse counseling, 
either in the medical setting or through a for-
mal addiction program, may suffice. Opioids, 
if their continuation is deemed safe, must be 
very closely monitored, with short dispensing  
intervals and frequent urine drug testing. 
Unfortunately, many addiction treatment pro-
grams are unwilling to admit patients who are 
taking opioid pain medications, interpreting 
their prescription opioid use as a sign of active 
addiction. 
Clinicians prescribing opioids need to establish 
relationships with substance abuse treatment 
providers who are willing to provide services 
for patients who need additional support in 
their recovery but do not require extensive 
services. For clinicians who treat a population 
with high levels of comorbid addiction, the 
development of onsite chemical dependence 
counseling services can be extremely helpful. 
For relapse in patients for whom opioid 
addiction is a serious problem, referral to 
an opioid treatment program (OTP) for 
methadone maintenance therapy (MMT) 
may be the best choice. Such programs will 
not generally accept patients whose primary 
problem is pain because they do not have 
the resources to provide comprehensive pain 
management services. Patients who have 
chronic pain likely will not obtain adequate 
pain control through the single daily dose 
of methadone that can be provided through 
an OTP. Such programs may, however, be 
willing to collaborate in the management of 
patients, providing addiction treatment and 
allowing the prescription of additional opioids 
for pain management through a medical 
provider. Such arrangements require close 
communication between the OTP and the 
prescribing clinician so that patients who do 
not respond to SUD treatment can be safely 
withdrawn from opioids prescribed for pain. 
CSAT (2005a) provides more information 
about OTPs. 
exhibit 3-5 methadone Titration
The titration of methadone for chronic pain is complex and potentially dangerous because metha-
done levels increase during the first few days of treatment. This risk is compounded by the variable 
half-life among individuals and the large number of drug interactions. In addition, cardiac toxicity 
(e.g., QT prolongation, torsade de pointes) is possible. The majority of deaths secondary to metha-
done occur in the first 14 days of use because:
•	The initial dose is too high.
•	 It is titrated too quickly.
•	 It interacts with other drugs or medications. 
Chou, Fanciullo, Fine, Adler, et al., 2009; Weschules, Baib, & Richeimer, 2008.
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Another option for patients who have comor-
bid active addiction and CNCP is replacement 
of full agonist opioids with the partial opioid 
agonist buprenorphine (Heit, Covington, & 
Good, 2004; Heit & Gourlay, 2008). Benefits 
of this treatment include that dose escalation  
does not provide reinforcement and that 
the effects of other opioid substances may 
be attenuated. Buprenorphine can prevent 
withdrawal symptoms, allowing patients to 
stabilize and facilitating their progression into 
non-opioid and nonpharmacologic forms of 
pain treatment. However, buprenorphine pre-
scribed specifically for pain is currently an off-
label use (see Treating Patients in Medication-
Assisted Recovery). 
Opioid Discontinuation 
Opioids should be discontinued if patient 
harm and public safety outweigh benefit. This 
situation may be apparent early in therapy, 
for example, if function is impaired by doses 
necessary to achieve useful analgesia. Harm 
also may outweigh benefit after a long period 
of successful treatment. Discontinuation of 
opioid therapy is addressed in Chapter 4. 
Treating patients in medication-
Assisted recovery
Goals for treating CNCP in patients who are 
in medication-assisted recovery are the same 
as for patients who are in recovery without 
medications: reduce pain and craving and 
improve function. As with other patients: 
•	 Start with recommending or prescribing 
nonpharmacological and non-opioid 
therapies.
•	 Treat comorbidities.
•	 Closely monitor treatment outcomes for 
evidence of benefit and harm.
Patients receiving opioid agonist treatment 
for addiction require special consideration 
when being treated for chronic pain. In these 
patients, the schedule and doses of opioid ago-
nists sufficient to block withdrawal and crav-
ing are unlikely to provide adequate analgesia. 
Because of tolerance, a higher-than-usual dose 
of opioids may be needed (in addition to the 
maintenance dose) to provide pain relief.
Buprenorphine 
Patients who have CNCP and are using  
sublingual buprenorphine treatment of opioid 
addiction pose special challenges. The drug 
is a partial mu agonist that binds tightly to 
the receptor. Because it is a partial agonist, its 
dose–response curve plateaus or even declines 
as the dose is increased. Thus, a ceiling dose 
limits both the available analgesia and the 
toxicity produced by overdose. Nevertheless, 
buprenorphine is an effective analgesic, and 
some patients who have addiction and CNCP 
may receive benefit for both conditions from 
it. To optimize analgesic efficacy, the drug 
should be given three times a day when pain 
reduction is a goal. High doses of buprenor-
phine can attenuate the effects of pure mu 
agonists given in addition to it. High doses 
tend to reduce the reinforcing effects of inap-
propriately consumed opioids but, at the same 
time, may reduce the effectiveness of opioids 
given for additional analgesia in the case of 
trauma or acute illness (Alford, Compton, & 
Samet, 2006).
Because buprenorphine has such high affinity 
for the mu receptor, it displaces full agonists 
and can induce acute opioid withdrawal; for 
example, if a patient on chronic methadone is 
given a dose of buprenorphine, acute opioid 
withdrawal may be precipitated (see CSAT 
[2004] for more information).
The use of buprenorphine for pain is off-
label, albeit legal. Whereas clinicians must 
obtain a waiver to prescribe buprenorphine 
for an SUD, only a Drug Enforcement 
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Administration (DEA) registration is required 
to prescribe buprenorphine for pain. To clarify 
(for pharmacists) that a prescription does not 
require the special DEA number, it is useful  
to specify on the prescription that the drug  
is “for pain.” 
Methadone
Patients who have chronic pain do not obtain 
adequate pain control through a single daily 
dose of methadone because the analgesic effects 
of methadone are short acting in comparison 
with its half-life. The dosing schedule for 
the treatment of opioid addiction does not 
effectively treat pain, although the single dose 
often provides transient analgesia. 
Methadone effects vary significantly from 
patient to patient, and finding a safe dose is 
difficult. Methadone’s analgesic effects last 
approximately 6 hours. However, its half-
life is variable and may be up to 36 hours in 
some patients. Pain patients may take 10 days 
or longer to stabilize on methadone, so the 
clinician must titrate very slowly and balance 
the risk of insufficient dosing with the life-
threatening dangers of overdosing (Heit & 
Gourlay, 2008) (Exhibit 3-5). It is critical for 
the clinician to advise patients to stop metha-
done treatment if they become sedated.
Methadone is an especially desirable analgesic 
for chronic use because of its low cost and 
its relatively slow development of analgesic 
tolerance; however, it is also especially toxic 
because of issues of accumulation, drug inter-
action, and QT prolongation. For these reasons,  
it should be prescribed only by providers who 
are thoroughly familiar with it. 
It is critical that patients starting methadone 
receive a thorough education in the dangers 
of inadvertent overdose with this medication. 
They must understand that a dose that seems 
initially inadequate can be toxic a few days 
later because of accumulation. They should be 
advised to keep the medication out of reach 
so that they cannot take a dose when sedated. 
Furthermore, they must be informed of the 
extreme danger if a child or nontolerant adult 
ingests their medication. Chapter 5 provides 
more patient education information, and 
CSAT (2009b) describes emerging issues  
in the use of methadone. 
Naltrexone
Patients taking naltrexone should not be 
prescribed outpatient opioids for any reason. 
Naltrexone is a long-acting oral or injectable  
mu antagonist that blocks the effects of opioids. 
It also reduces alcohol consumption by imped-
ing its rewarding effects. Because naltrexone 
displaces opioid agonists from their binding 
sites, opioid analgesics will not be effective 
in patients on naltrexone. Increasing the dose 
of opioids to overcome the blockade puts 
the patient at risk of respiratory arrest. Pain 
relief for these patients requires non-opioid 
modalities.
If patients on naltrexone require emergency  
opioids for acute pain, higher doses are required, 
which, if continued, can become toxic as nal-
trexone levels wane. In this situation, inpatient 
or prolonged emergency department monitoring 
is required (Covington, 2008). 
Tolerance and hyperalgesia 
Tolerance develops rapidly to the sedating, 
euphoric, and anxiolytic effects of opioids. 
It develops more slowly to their analgesic 
effects and seldom develops to their constipat-
ing effects. Tolerance can be characterized 
as decreased sensitivity to opioids, whereas 
OIH is increased sensitivity to pain resulting 
from opioid use. In a clinical setting, it may 
be impossible to distinguish between the two 
conditions, and they may coexist (Angst & 
Clark, 2006). Tolerance can develop in chronic 
opioid therapy regardless of opioid type, dose, 
route of administration, and administration 
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schedules (DuPen, Shen, & Ersek, 2007). 
Hyperalgesia has been found to result from 
the use of those opioids thus far studied (i.e., 
methadone, buprenorphine, sufentanyl, fentan-
yl, morphine, heroin). Patients in MMT expe-
rience analgesic tolerance and OIH. Clinical 
implications of these findings are unclear, as 
studies indicate that OIH may develop to 
some measures of pain (e.g., cold pressor test) 
and not to others (e.g., pressure) (Mao, 2002). 
When patients develop tolerance to the 
analgesic effects of a particular opioid, either 
dose escalation or opioid rotation may be 
useful (Exhibit 3-6). Opioid rotation, switch-
ing from one opioid to another, is a way to 
exploit incomplete cross-tolerance to achieve 
improved analgesia without an increase in 
(equivalent) doses.
If a patient requests an increase in opioid dose, 
it is important for the clinician to try to discern 
whether the patient is experiencing increased 
pain or analgesic tolerance or is seeking some 
other effect (e.g., sedation, reduced anxiety). 
In the patient seeking sedation or reduced 
anxiety, a larger opioid dose provides temporary 
anxiolytic or sedative effects, but tolerance soon 
develops, necessitating another dose increase. 
To avoid a cycle of dose increases, the clinician 
should evaluate the patient’s request. When 
nonanalgesic effects seem to be the basis for 
the request, alternative non-opioid medications 
should be provided and opioid doses should 
not be increased. 
As with tolerance, OIH appears to require 
increased doses of opioids to achieve previ-
ous levels of analgesia. However, with OIH, 
increased doses could exacerbate pain. Treating 
pain with a multimodal approach—in addition 
to analgesics—may reduce the need for opioids,  
thereby decreasing the risk of tolerance and 
OIH.
Treating pain in patients Who 
have Active Addiction
The presence of active addiction—whether to 
alcohol, opioids, or other substances—makes 
successful treatment of chronic pain improb-
able (Covington, 2008; Weaver & Schnoll, 
2007). For patients who have active addiction 
and CNCP, it may be impossible for clini-
cians in the primary care setting to provide 
the comprehensive services necessary to treat 
both conditions. Specifically, an active SUD 
indicates that the patient should be referred 
for formal addiction treatment. The clinician 
should work closely with the patient’s SUD 
treatment provider. 
If the patient refuses the SUD referral, the 
clinician can use motivational interviewing 
techniques. CSAT (1999b) provides more 
information on motivational interviewing. If 
the patient still does not consent to addiction 
treatment, he or she should not be prescribed 
scheduled medications, except for acute pain 
or detoxification. CSAT (2006) provides more 
information on detoxification.
exhibit 3-6 opioid rotation
When an opioid is ineffective, becomes ineffective, or produces intolerable side effects, it is com-
mon practice to rotate opioids. This practice is based on the observation that particular opioids 
affect people differently, primarily because of intraindividual and interindividual variability among 
opiate receptors, so-called mu-receptor polymorphism. Although most opioid analgesics are mu 
agonists, they affect some mu receptors differently from others. A Cochrane review (Quigley, 2004) 
looked at the evidence supporting the replacement of an opioid to which an individual has devel-
oped analgesic tolerance with a different opioid. The conclusion was that although evidence is 
scant, the practice appears to be efficacious. The most common opioid rotation, and most studied, 
is from morphine to methadone.
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Once the patient’s SUD recovery is stable, the  
likelihood of managing his or her pain increases. 
The need for formal addiction treatment often 
necessitates a change in the plan for opioids, 
by discontinuing them or by changing the 
treatment setting through which they are 
provided. 
Acute pain episodes
When patients who have CNCP and an SUD 
require acute pain management, such as for 
postoperative pain, precautionary steps can 
minimize risk of relapse.
Patients in recovery may benefit from non-
pharmacological pain control. Some patients 
in recovery from SUDs may prefer to avoid 
the use of any medication. Evidence shows 
that stress management, CBT, manual thera-
pies, and acupuncture offer effective relief for 
certain types of acute pain (Hurwitz et al., 
2008; Vernon, Humphreys, & Hagino, 2007).
Patients in recovery may benefit from being 
switched from short- to long-acting medica-
tions as quickly as appropriate (to minimize 
reinforcing effects). They may also benefit 
from bolstered recovery support during post-
operative periods (Covington, 2008).
Patients on agonist therapy for addiction or 
pain may be continued on their current opioid 
or on an equivalent dose of an alternative opi-
oid; however, this should not be expected to 
control acute pain, which requires supplemen-
tation with (often greater-than-usual doses of ) 
additional opioids. In this situation, adjuvant 
NSAIDs may allow clinicians to provide 
pain relief with a reduction in opioid dosage 
(Mehta & Langford, 2006), and multimodal 
analgesia should be considered (Maheshwari, 
Boutary, Yun, Sirianni, & Dorr, 2006). 
Patients on buprenorphine for opioid  
addiction may have reduced benefit from full 
agonist opioids used for acute pain, because 
the full agonist will be somewhat blocked. 
Non-opioid analgesics can be used, but in 
some cases buprenorphine will need to be dis-
continued so that full agonist opioids for pain 
can be used (Alford et al., 2006).
Patient-controlled analgesia should have 
relatively high bolus doses and short lockout 
intervals (specified intervals during which 
pressing the administration button results 
in no drug delivery), and patients should be 
closely monitored by medical staff. Pulse 
oximetry or end-tidal CO2 monitoring may 
provide an additional margin of safety when 
high doses of opioids are required. 
Patients who are dependent on opioids or 
sedatives (including benzodiazepines) should 
not be withdrawn from these medications 
while undergoing acute medical interventions.
Exhibit 3-7 provides a discussion of treating 
patients who have sickle cell disease (SCD), 
which brings recurring acute pain, often 
against a backdrop of persistent pain and 
hyperalgesia.
Other comorbidities that can complicate pain 
treatment result from other chronic illnesses. 
Exhibit 3-8 offers suggestions for providers 
for treating CNCP in patients who have HIV/
AIDS.
Assessing Treatment outcomes
Treatment of chronic pain is usually an evolving 
process, with medication and adjunctive thera-
pies attempted, monitored, and adjusted or 
abandoned as indicated by patient response. 
Chapter 2 provides information about ongoing 
assessments.
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exhibit 3-7 Treating patients Who have sickle cell Disease
SCD is characterized by crises of acute pain, attributed to vasoocclusion, that is typically nocicep-
tive but can be neuropathic as well. Opioids are the mainstay of treatment, although parenteral 
ketorolac may suffice in some crises and have opioid-sparing effects in others. 
Acute pain management is critical but is often poorly conducted. At times, mutual mistrust 
between the patient and the clinician may lead to fears of being discounted on the part of the 
patient and suspicions of symptom exaggeration on the part of the clinician. 
The development of CNCP further complicates the situation. When there is a clear structural 
explanation for pain (e.g., leg ulcers, avascular necrosis, osteomyelitis), appropriate (typically opi-
oid) therapy is usually provided. Many patients, however, report chronic pain in the absence of 
detectable peripheral pathology. This pain has been attributed to central sensitization as a result 
of multiple episodes of severe pain. It can also result from ischemic neuropathic conditions. A small 
percentage of patients who have SCD develop an SUD, which adversely impact their pain reports 
and treatment responses. 
It is generally accepted that appropriate treatment of an SCD crisis requires prompt and aggressive 
analgesia. Some hospitals and emergency departments keep a log of SCD patients that documents 
their degree of opioid tolerance, typically effective agents, and doses required so that near-imme-
diate relief can be provided to patients presenting for care. Chronic pain with persistent tissue 
pathology likely requires continuation of substantial opioid doses for acceptable relief, although 
peripheral and adjuvant agents should be used as appropriate. 
The treatment of chronic idiopathic pain in SCD often requires a multidisciplinary approach with 
emphasis on adjuvant analgesics and nonpharmacological therapies, including psychological thera-
pies (Ballas, 2007).
exhibit 3-8 Treating patients Who have hIv/AIDs
A vast range of pain syndromes are common in patients who have HIV/AIDS. Some are the result  
of HIV infection, others result from immunosuppression, and others are unrelated but comorbid 
with AIDS. Pain commonly results from painful neuropathy, Kaposi’s sarcoma, herpes zoster, can-
dida esophagitis, drug-induced pancreatitis, headache (including those resulting from meningitis), 
and numerous types of joint and myofascial pains. 
Patients are often both indigent and negatively viewed by clinicians—conditions that lead to 
reduced access to pain care. The patients may be sick, frail, and cachectic, creating challenges in 
the use of pharmacotherapies. A large number of patients have a comorbid SUD, which complicates 
the use of opioid analgesics. 
Core principles of treating CNCP, such as meticulous diagnosis of the pain mechanism and etiology 
and monitoring for benefits and adverse effects of treatment, and use of the World Health 
Organization’s pain ladder (see http://www.who.int/cancer/palliative/painladder/en/index.html) 
for titrating analgesics are applicable in this population. However, addressing the psychological 
aspects of the illness, as well as functional restoration, is especially important. Nonpharmacological 
therapies, including PT modalities, acupuncture, biofeedback training, and hypnosis, may be 
helpful.
Breitbart, 2003.
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Key points
•	 Pain treatment goals should include improved functioning and pain reduction.
•	 Treatment for pain and comorbidities should be integrated. 
•	 Non-opioid pharmacological and nonpharmacological therapies, including CAM, 
should be considered routine before opioid treatment is initiated.
•	 Opioids may be necessary and should not be ruled out based on an individual’s having 
an SUD history. 
•	 The decision to treat pain with opioids should be based on a careful consideration of 
benefits and risks.
•	 Addiction specialists should be part of the treatment team and should be consulted in 
the development of the pain treatment plan, when possible.
•	 A substantial percentage of patients with and without SUDs will fail to benefit from 
prolonged opioid therapy, in which case it should be discontinued, as with any other 
failed treatment. 
In ThIs ChapTer
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promoting Adherence
Clinicians should adopt a universal precautions approach toward 
their patients who have chronic noncancer pain (CNCP) (Exhibit 
4-1). The term universal precautions first emerged in the context of 
infectious disease treatment and referred to using infection control 
procedures with all patients. In the context of pain treatment, a 
universal precautions approach refers to a minimum standard of care 
applied to all patients who have CNCP, whatever their assessed risk 
(Gourlay, Heit, & Almahrezi, 2005). A universal precautions approach 
improves care and shows due diligence in an era of increasing illegal 
use of prescription opioids. 
Clinicians can help patients adhere to treatment plans by: 
•	 Employing treatment agreements.
•	 Regulating visit intervals.
4
exhibit 4-1 Ten steps of Universal precautions
1. Make a diagnosis with appropriate differential.
2. Perform a psychological assessment, including risk of addic-
tive disorders.
3. Obtain informed consent.
4. Use a treatment agreement.
5. Conduct assessments of pain level and function before and 
after the intervention.
6. Begin an appropriate trial of opioid therapy with or without 
adjunctive medications and therapies.
7. Reassess pain score and level of function.
8. Regularly assess the “4As” of pain medication (see 
Documenting Care, below).
9. Periodically review pain diagnosis and co-occurring condi-
tions, including addictive disorders. 
10. Document initial evaluation and followup visits.
Adapted from Gourlay et al., 2005.
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•	 Controlling medication supply.
•	 Conducting urine drug testing (UDT).
•	 To the degree possible, including the 
patient’s support network in monitoring 
efforts. 
Treatment Agreements 
A treatment agreement can be used to gauge 
and reinforce adherence to medication routines 
and to nonpharmacological therapies that can 
be critical for the patient’s return to normal 
function. It is unlikely that a patient can fol-
low every element of an agreement exactly at 
all times throughout chronic opioid therapy. 
The clinician’s role is to note departures from 
the plan, to make a differential diagnosis, and 
to adjust the plan as needed. 
Significant departures from the agreement may  
indicate that other members of the treatment  
team need to be consulted or that the patient’s 
care should be transferred to a specialist. Any  
actions the patient is expected to take to return  
to adherence should be clearly explained. 
Treatment agreements are discussed at length 
in Chapter 5.
Visit Intervals 
Patients on opioid therapy typically meet 
with a clinician monthly. However, patients 
who have histories of substance use disorders 
(SUDs) may require more frequent visits, such 
as weekly, whereas patients who are in stable 
recovery may be seen less often. Other factors 
that affect the frequency of visits include the 
complexity of the pain diagnosis, the status of 
the pain management, and the medications 
being prescribed. 
A schedule of routine visits has advantages 
over sporadic appointments arranged by the 
patient. It encourages the patient to consider 
the pain a manageable condition rather than 
an occasionally erupting crisis. Routine also 
allows for close monitoring of adherence.  
A patient who misses or reschedules appoint-
ments should be evaluated for relapse to an 
SUD. 
Medication Supply 
The Drug Enforcement Administration’s 
(DEA’s) “do not fill until” option allows clini-
cians to write a 3-month prescription that 
can be filled in spaced intervals (Exhibit 4-2). 
However, only rarely should a patient with 
an SUD history be seen as infrequently as 
every 3 months. Patients who find it difficult 
to adhere to treatment plans may be better 
served by more frequent visits during which 
prescriptions for smaller amounts of medica-
tion are provided. In this case, clinicians can 
use the “do not fill until” strategy to divide a 
month’s supply into, for example, three 10-day 
prescriptions for patients who cannot handle a 
month’s worth of medication. 
Clinicians also can promote adherence 
through pill counts or by recruiting (with 
the patient’s consent) a pharmacist or trusted 
family member to dispense medication daily. 
Patients who require tighter-than-weekly dis-
pensing of medication also probably require a 
exhibit 4-2 Issuance of multiple 
prescriptions for schedule II 
controlled substances
71 Federal Register 52724 allows clinicians 
to write multiple prescriptions—to be filled 
sequentially—for the same Schedule II con-
trolled substance. The multiple prescriptions, 
in effect, allow a patient to receive, over 
time, up to a 90-day supply of that scheduled 
medication. But the law can also be used 
to write sequential prescriptions for a much 
shorter period, which may be appropriate 
for patients who benefit from tight structure. 
Information on other aspects of the regula-
tion, as well as the conditions under which 
multiple prescriptions can be written, is at 
http://www.deadiversion.usdoj.gov/21cfr/
cfr/2106cfrt.htm.
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higher level of care and will often benefit from 
comanagement with an addiction specialist.  
Exhibit 4-3 presents a scenario regarding 
medication supply.
Urine Drug Testing
UDT can detect the presence of some prescribed  
and unprescribed substances and, therefore, 
can be a useful tool for improving patient 
care (Cone & Caplan, 2009; Heit & Gourlay, 
2004; McMillin & Urry, 2007). Couto, 
Romney, Leider, Sharma, and Goldfarb (2009) 
studied data from the urine tests of more than 
900,000 patients on chronic opioid treatment. 
The researchers found that 75 percent of the 
patients showed at least one sign of nonad-
herence to opioid regimens (e.g., having no 
detectable levels of the prescribed medication 
in their urine, having evidence of an illicit 
drug). As when using other tools, the clini-
cian must understand the limitations of UDT 
and interpret results in light of other clinical 
findings. 
There are two common kinds of urine drug 
tests: 
•	 Immunoassay (IA) screens, which use 
antibodies to detect a drug or metabolite 
(e.g., opioids) in urine 
•	 Specific substance identification tests, 
such as GC/MS (gas chromatography/
mass spectroscopy) or HPLC (high-
performance liquid chromatography), 
which use more sophisticated methods to 
detect the presence of specific substances
exhibit 4-3 Talking With patients About medication supply
Clinician  “I see that you are here because you ran out of your pain medication before you were 
due to pick up the next prescription.”
Patient  “I took extra pills for a few days and now I’m out. I’m hurting more because I don’t have 
any pills.”
Clinician  “Can you tell me what happened?”
Patient  “I fell and hurt my knee, and it was really bothering me, so I took more than I usually 
do.”
Clinician  “We have a written agreement that you’ll take your medications only as prescribed.”
Patient “Yeah, but it made sense because my knee hurt so bad.” 
Clinician  “Knee pain is a different kind of pain, and increasing your opioid medication is not nec-
essarily the best treatment for that. Next time, please call me first as we agreed.”
Patient  “Okay, I’m sorry.” 
Clinician  “Whenever one of my patients breaks the agreement for any reason, I always ask for a 
urine sample. When did you last take your medicine?”
Patient “I just ran out yesterday.” 
Clinician  “So you did not take anything else when you ran out of your prescription?”
Patient “No! I didn’t have anything else to take.”
Clinician  “Okay. I’ll write your prescription while you go see the nurse. If your urine sample is 
okay, I’ll give you the prescription.”
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Immunoassays
Heit and Gourlay (2004) recommend testing 
for the following substances during routine 
screening: cocaine, amphetamines/metham-
phetamine, opioids, methadone, marijuana, 
and benzodiazepines.
Although IA screens are sensitive to natural 
opioids, they have limited ability to detect 
synthetic and semisynthetic opioids (e.g., 
hydrocodone, fentanyl, oxycodone, metha-
done). If an IA screen fails to detect the 
presence of expected opioids, the results can 
be confirmed with a more specific substance 
identification test. 
IA screens can be conducted at the point of 
care (POC) or in a laboratory. Exhibit 4-4 lists 
the benefits and limitations of POC testing. 
POC results that are positive for an illicit sub-
stance or negative for the prescribed substance 
class can be verified with a confirmatory test. 
Specific Substance Identification 
Tests
Because IA screens cannot reliably detect 
synthetic and semisynthetic opioids, they have 
limited utility for monitoring adherence to 
opioid treatment. However, they can detect 
whether the patient on chronic opioid therapy 
is using, for example, marijuana, amphet-
amines, or cocaine. GC/MS or HPLC provide 
specific information about what compounds 
were consumed. Substance identification tests 
can also confirm the results of an IA screen. 
It is useful for clinicians prescribing chronic 
opioid therapy to maintain a relationship with 
the testing laboratory that they use so that 
they can communicate specific needs, such as 
a “no limits” test to identify small amounts of 
substances or specifically sought substances 
that may not routinely be assessed. 
Urine Drug Testing Results
UDT is subject to false-positive and false-
negative results. The clinician must interpret 
results carefully and explore the possible 
causes of unexpected findings before taking 
action. For example, prescribed medication 
may not show up in a UDT result because 
(Gourlay et al., 2006): 
•	 The patient did not use medications  
or did not use them recently.
exhibit 4-4 poc Testing Benefits and limitations
category Description
Benefit Convenient
Fast
Single-use kits available
Requires little training
Limitation Identifies only drug class or metabolite, so of limited use for adherence 
monitoring
Clinicians must clearly understand cutoff scores and whether they are appropriate
Subject to cross-reactivity (false-positive results)
Testing instructions and cutoff scores vary
Little quality control
Little or no technical support
Adapted from Gourlay, Heit, & Caplan, 2006.
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•	 The patient excretes medications or 
metabolites at a rate different from 
normal.
•	 The test was not sufficiently sensitive to 
detect the medications at the concentra-
tions present.
•	 There was a clerical error.
If the results of UDT are unexpected, the 
clinician may want to take the following steps, 
recommended by Gourlay and Heit (2009):
•	 Contact the laboratory to confirm there 
was no clerical error.
•	 Discuss with the laboratory what type of 
followup test or confirmatory test should 
be conducted.
•	 Discuss the results with the patient and 
document the UDT results and discus-
sion in the patient’s medical record.
•	 Confirm disputed results with the recom-
mended laboratory test.
An unexpected result should be discussed 
face-to-face with the patient (Exhibit 4-5). 
The presence of unprescribed or illicit sub-
stances does not render a patient’s pain com-
plaints illegitimate, but it may suggest abuse or 
addiction. Repeated unexpected results suggest 
the need for evaluation by an addiction spe-
cialist. If a patient with CNCP is diagnosed 
with a comorbid SUD, the patient must be 
willing to accept treatment for both disorders. 
It is reasonable for the clinician, without get-
ting into a dispute about patients’ rights to use 
substances or the benefits of medical marijua-
na, to make access to opioid therapy contin-
gent on the patient’s willingness to relinquish 
use of illicit substances. This can be presented 
simply as a way to ensure the patient’s access 
to treatment and the clinician’s continued abil-
ity to prescribe. If the person is unwilling to 
relinquish recreational use, the pain problem 
may not warrant chronic opioid therapy. If the 
patient is unable to relinquish the drugs, then 
addiction treatment is indicated (Covington, 
2008). 
exhibit 4-5 Talking With patients About Aberrant Urine Drug Testing results
Clinician “It seems you have not been taking your medications.”
Patient A “Yes, I have.”
Clinician “Some of it should be showing up in your urine, but it’s not.”
Patient A  “My husband twisted his ankle last week. I might have given him a couple of tablets.”
Clinician  “You must take your medications as prescribed. That’s the only way I can determine 
whether they are effective in treating your pain. And I need to explain to you again the 
harm that can result when someone else takes medication that has been prescribed to 
you based on your body’s needs.” 
_______________________________________________________________________________________
Clinician “It seems you have been taking medications that I haven’t prescribed.”
Patient B “No, I haven’t.” 
Clinician  “Your last urine test was positive for benzodiazepines. Can you think of any reasons why 
they might have appeared?”
Patient B  “Oh, that. I was stressed out because my pain was so bad. My buddy gave me a pill.” 
Clinician  “There are several reasons why your pain may have gotten worse. It’s really important 
that I know what medications you are taking and that you don’t take medications that I 
have not prescribed for you.”
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Intervals for UDT depend on the degree of 
oversight the patient requires. The tests can 
be scheduled or random, depending on the 
patient’s risk level; however, if patients are 
tested selectively, there is a risk of overtesting 
minorities and other marginalized groups and 
failing to detect substance abuse in patients 
whose ethnicity and socioeconomic status  
mirror those of the clinician. 
Clinicians should help patients understand 
that UDT helps protect their recovery, their 
access to analgesia, and the clinician’s ability to 
prescribe and that urine drug tests are neither 
punitive nor discriminatory because they are 
expected of all patients who receive chronic 
opioid therapy. Exhibit 4-6 presents sample 
scenarios for addressing UDT with patients.
Inclusion of Family, Friends, and 
others 
With support from others, the patient may be 
better able to comply with pain treatment. Just 
as important, the inclusion of others enables 
the clinician to obtain a clearer picture of the 
patient’s response to treatment, including his 
or her ability to adhere to an opioid medica-
tion regimen, any loss of function, or develop-
ment of aberrant behaviors that may indicate 
relapse. When a patient has a history of an 
SUD, it is crucial that the prescribing clinician 
obtain collateral information from household 
members, physical therapists, pharmacists, 
and other members of the patient’s healthcare 
team. Given that patients may not always 
realize or disclose their problems with drugs, 
safety considerations require that prescriptions 
for addictive substances be contingent on 
the clinician’s unrestricted access to collateral 
information. 
nonadherence 
At some point in the treatment of chronic pain, 
patients are likely to fail to adhere to their 
treatment agreement. Behavior that suggests 
substance misuse, abuse, or addiction is known 
as aberrant drug-related behavior (ADRB). 
ADRB includes: 
•	 Being more interested in opioids (espe-
cially immediate-release and nongeneric) 
than in other medications or in any other 
aspect of treatment.
•	 Taking doses larger than those prescribed 
or increasing dosage without consulting 
the clinician.
•	 Insisting that higher doses are needed.
•	 Resisting UDT, referrals to specialists, 
and other aspects of treatment.
•	 Resisting changes to opioid therapy.
•	 Repeatedly losing medications or pre-
scriptions or seeking early refills. 
•	 Making multiple phone calls about 
prescriptions.
•	 Attempting unscheduled visits, typically 
after office hours or when the clinician is 
unavailable.
•	 Appearing sedated.
•	 Misusing alcohol or using illicit drugs.
•	 Showing deteriorating functioning and 
beginning to experience adverse conse-
quences from medications (e.g., problems 
at home or on the job). 
•	 Injecting (having track marks) or snorting 
oral formulations. 
•	 Obtaining medications illegally (e.g., 
from multiple clinicians, street dealers, 
family members, the Internet, forged 
prescriptions). 
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exhibit 4-6 Talking With patients Who Are resistant to Urine Drug Testing 
Patient A “I can’t give you a urine sample today. I just peed.” 
Clinician  “Not a problem. There’s a water fountain in the hallway. Why don’t you take in some 
fluids and come back when you’re ready. I’ll leave your refill prescription with the recep-
tionist, and you can pick it up after we’ve run your screen.” 
_______________________________________________________________________________________
Patient B “Why do I need to give you a urine sample? Don’t you trust me?”
Clinician  “The urine sample gives me a great deal of useful information about how you are using 
your medications and whether you are running into problems with other substances.”
Patient B “It’s spying.”
Clinician  “It may seem like that to you, but it’s a standard part of care for all my patients. Any 
level of substance use can affect a patient’s life and the management of the pain. Is 
there something we need to talk about?”
_______________________________________________________________________________________
Patient C  “My problem was alcohol, doc. I was never a drug addict. You don’t have to treat me 
like one.”
Clinician  “I’m sorry if this gives you the impression that I am judging you. As your doctor, I have a 
job to identify and resolve any issues that may interfere with your pain treatment, sooner 
rather than later. The drug screen helps me do that.”
_______________________________________________________________________________________
Patient D “I’m philosophically opposed to drug tests.”
Clinician “I understand. I’ve had other reluctant patients. Can you tell me why you feel this way?”
Patient D “It just seems like an invasion of privacy.”
Clinician  “Yes, it does. A lot of things that happen in the doctor’s office can seem like an invasion 
of privacy. But our treatment options are limited if we can’t run the test.” 
Patient D “That’s not fair.”
Clinician  “I will still work with you as your pain doctor, no matter what the test reveals. That’s fair, 
isn’t it?”
Patient D “I still don’t want to do it.”
Clinician  “I’d like to have you talk with Joe [the addiction counselor on the patient’s treatment 
team]. He can help you sort this out.”
_______________________________________________________________________________________
Patient E “I hate tests.”
Clinician  “There are no passing or failing grades here. I am not going to flunk or fire you based 
on what I learn. In fact, we go over the results together, and we decide together how to 
interpret them and what to do if anything shows up unusual. How does that sound?”
_______________________________________________________________________________________
Patient F “But I gave you a urine sample last time I was here.”
Clinician  “Yes, you did. Let’s look at your treatment agreement. Here it is: Item 5. We agreed that 
you might be asked for a screen at every appointment.”
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•	 Behaving in an intimidating or threaten-
ing manner.
•	 Having urine drug tests that do not show 
the presence of prescribed opioids.
•	 Not adhering to nonpharmacological 
components of treatment.
Patient behavior is highly variable and depen-
dent on circumstances, and the evidence base 
does not decisively implicate any single behav-
ior or set of drug-related behaviors as being 
indicative of addiction. ADRB can be driven 
by other causes, including:
•	 Misunderstanding instructions. 
•	 Seeking euphoria.
•	 Using medications to deal with fear, 
anger, stress, sleep problems, or other 
issues.
•	 Diverting medications for profit.
•	 Coping with untreated mental disorders.
•	 Coping with undertreated pain, also 
known as pseudoaddiction (Exhibit 4-7).
•	 General nonadherence.
ADRBs that clinicians are most likely to 
observe (or that patients are most likely to 
report) are often the behaviors that are most 
ambiguous (e.g., not following a medication 
regimen precisely, running out of a prescrip-
tion early). The extreme behaviors that are 
easier to interpret (e.g., selling prescriptions, 
altering the medication’s delivery mode) are 
ones that may elude observation during an 
office visit. The development of a strong ther-
apeutic relationship facilitates these often dif-
ficult conversations when and if ADRBs occur. 
Tools To Assess Aberrant Drug-
related Behaviors
Tools exist to help clinicians assess ADRBs in 
patients on chronic opioid therapy. However, 
evidence for their validity is limited (Chou, 
Fanciullo, Fine, Miaskowski, et al., 2009). The 
Addiction Behaviors Checklist (Wu et al., 
2006) helps determine whether opioids have 
become a problem for the patient (Exhibit 
4-8). It is for ongoing evaluation and can flag 
addiction problems as they develop. The tool 
can be quickly administered at each office 
visit; three or more “yes” responses should trig-
ger more careful monitoring or intervention. 
The Current Opioid Misuse Measure 
(Butler et al., 2007) asks patients about their 
behavior in the 30 days before the appoint-
ment (Exhibit 4-9). Butler and colleagues 
recommend a conservative cutoff score of 9, 
which yields some false-positive results, but 
misses fewer patients who may be misusing 
medications.
exhibit 4-7 pseudoaddiction 
Patients sometimes display ADRB in response to undertreated pain. This phenomenon has been 
termed pseudoaddiction (Weissman & Haddox, 1989). It is often unclear how to determine the 
presence of pseudoaddiction in a patient, and the explanation of pseudoaddiction must be applied 
cautiously in patients who have a known SUD. Clinicians may never know with certainty what moti-
vates ADRB in patients.
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exhibit 4-8 Addiction Behaviors checklist
Item Yes no not Assessed
Addiction Behaviors Since Last Visit
1.  Patient used illicit drugs or evidences problem drinking
2. Patient has hoarded medication
3. Patient used more opioids than prescribed
4. Patient ran out of medications early
5. Patient has increased use of opioids
6.  Patient used analgesics PRN when prescription is for 
time-contingent use
7. Patient received opioids from more than one provider
8. Patient bought medications on the streets
Addiction Behaviors Within Current Visit
1.  Patient appears sedated or confused (e.g., slurred 
speech, unresponsive)
2. Patient expresses worries about addiction
3.  Patient expresses a strong preference for a specific type 
of analgesic or a specific route of administration
4.  Patient expresses concern about future availability of 
opioid
5. Patient reports worsened relationships with family
6. Patient misrepresents analgesic prescription or use
7.  Patient indicates she or he “needs” or “must have”  
analgesic medications
8.  Discussion of analgesic medications is the predominant 
issue of visit
9.  Patient exhibits lack of interest in rehabilitation or 
self-management
10.  Patient reports minimal/inadequate relief from opioid 
analgesic
11.  Patient indicates difficulty with using medication 
agreement
Other
1.  Significant others express concern over patient’s use of 
analgesics
Reprinted from Wu et al., 2008. The Addiction Behaviors Checklist: Validation of a new clinician-based measure of inap-
propriate opioid use in chronic pain. Journal of Pain and Symptom Management, 32(4), 342–351. Adapted with permission 
from Elsevier. 
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Documenting care
Meticulous documentation of chronic opioid 
therapy is essential. It is both a Federal and 
State requirement, and the quality of docu-
mentation can determine whether a clinician 
is judged to be practicing medicine or traffick-
ing in drugs. In addition, longitudinal docu-
mentation is essential to permit a determina-
tion over time of the extent to which treat-
ment is an asset or a liability to the patient. 
Documentation also provides protection for 
the clinician if drug enforcement authorities 
conduct an investigation. 
The practitioner must be familiar with the 
requirements of the State in which he or 
she practices; however, generally there must 
be documentation of an adequate medical 
workup of the condition being treated, an 
evaluation for psychiatric comorbidity includ-
ing SUD, a plan of care, amounts of scheduled 
medications prescribed, and instructions for 
use of medications. Some States require that 
chronic opioid therapy be used only if other 
treatments are ineffective or ill-advised. The 
University of Wisconsin’s Pain and Policy 
Studies Group maintains a Web site that 
describes the regulations of different States 
regarding opioid prescribing (http://www.
painpolicy.wisc.edu/). 
exhibit 4-9 current opioid misuse measure
(Measured on a Scale of 0=Never to 4=Very Often)
1. How often have you had trouble with thinking clearly or had memory problems?
2. How often do people complain that you are not completing necessary tasks (i.e., doing 
things that need to be done, such as going to class, work, or appointments)?
3. How often have you had to go to someone other than your prescribing physician to get suf-
ficient pain relief from your medications (i.e., another doctor, the emergency room)?
4. How often have you taken your medications differently from how they are prescribed?
5. How often have you seriously thought about hurting yourself?
6. How much of your time was spent thinking about opioid medications (having enough, taking 
them, dosing schedule, etc.)?
7. How often have you been in an argument? 
8. How often have you had trouble controlling your anger (road rage, screaming, etc.)?
9. How often have you needed to take pain medications belonging to someone else?
10. How often have you been worried about how you’re handling your medications?
11. How often have others been worried about how you’re handling your medications?
12. How often have you had to make an emergency phone call or show up at the clinic without 
an appointment?
13. How often have you gotten angry with people? 
14. How often have you had to take more of your medication than prescribed?
15. How often have you borrowed pain medication from someone else?
16. How often have you used your pain medicine for symptoms other than for pain (to help you 
sleep, improve your mood, relieve stress, etc.)?
17. How often have you had to visit the emergency room?
Reprinted from Butler, et al., 2007. Development and validation of the Current Opioid Misuse Measure. Pain, 130, 144–
156. Used with permission from Elsevier.
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Like other treatments, opioid therapy should 
be continued only so long as it is effective. 
Many clinicians have found it useful to moni-
tor and document opioid response using the 
“4As” of Passik and colleagues (2004): analge-
sia, activities of daily living, adverse events, and 
ADRBs. 
managing Difficult conversations
Patients who have CNCP can be especially 
difficult to treat because their condition often 
eludes diagnosis and because unremitting pain 
itself can affect their ability to be civil. When 
an SUD or other co-occurring disorder is 
overlaid onto the pain, the likelihood of diffi-
cult behavior from the patient increases. Such 
a patient has complex and intense needs that 
are best served by a treatment team approach 
that allows for frequent assessment and care 
of the patient without overburdening any one 
member of the team (see Chapter 3).
The following activities can help build a 
therapeutic relationship between the treatment 
team and the patient:
•	 Listening actively 
•	 Asking open-ended, nonjudgmental 
questions 
•	 Restating a patient’s report to make sure 
it has been understood
•	 Using clarification statements (“It sounds 
as if the pain is worse than usual for you”)
•	 Demonstrating empathy
•	 Using feeling statements (“This must be 
very difficult for you”)
One strategy for demonstrating empathy is to 
specifically acknowledge the effort required 
simply to cope with pain daily. The clinician 
should not promise overly optimistic results 
and should educate patients so that they form 
reasonable expectations about outcomes. It  
may also help to suggest that patients focus  
on improvements in functioning and avoid 
defining their lives by their pain. 
Patients who have chronic pain, as well as those 
with SUDs, and perhaps especially those with 
both, can elicit strong negative responses from 
treatment providers. These negative reactions 
impede efforts to experience and communicate 
empathy. It is useful, first of all, for the clini-
cian to recognize these reactions and to seek 
to understand them. Frequently, they are simply 
a result of the frustration attendant on treat-
ing difficult or intractable problems. They may 
result from feelings that the clinician is work-
ing harder for the patient’s wellness than is the 
patient. It may help for the clinician to remind 
himself or herself that, no matter how lacking 
in motivation the patient seems, no one would 
ever wish for a typical life of a person with 
comorbid pain and addiction. 
Workplace safety
Clinicians and their patients must be protected 
from violence in the workplace. Clinic staff 
members should be encouraged to be proac-
tive and aware of their surroundings, report 
suspicious activity, and use common sense to 
make good decisions about aggressive patients 
or family members. Clinicians should plan for 
occasional disruptive or aggressive behavior 
and position themselves in the examination 
room between the patient and the door. If a 
patient becomes threatening, security person-
nel or law enforcement may be needed. The 
consensus panel recommends that clinicians 
develop crisis management policies and plans 
and ensure that staff members are trained and 
drilled on their implementation. A plan should 
be developed for contacting public safety 
officials (discreetly, if necessary) in urgent or 
emergent situations. The plan should include 
a distress signal to alert all staff members. 
Contact information for public safety officials 
should be readily available. 
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Drug Diversion
Some patients sell or trade their medications, 
and sometimes patients give their medica-
tions to family or friends for various reasons. 
Medications taken by people other than for  
whom they are prescribed are said to be 
“diverted.” 
Unequivocal evidence of diversion is rare, 
although patients often acknowledge it when 
confronted. All members of the treatment 
team should be alert to the patient who:
•	 Is known to have contact with people 
with active SUDs.
•	 Cannot produce the remainder of a par-
tially used prescription when asked for a 
pill or patch count.
•	 Has attempted to alter or forge 
prescriptions.
•	 Has been “doctor shopping” to obtain 
additional medications.
•	 Does not comply with the nonpharma-
cological components of recommended 
treatment.
•	 Strongly prefers brand name drugs or 
drugs with high street value.
•	 Fails to demonstrate the presence of 
prescribed opioids in appropriate UDT 
results.
Clinicians should know which drugs are popular 
in their communities and be vigilant when 
prescribing medications that have high street 
value (Exhibit 4-10). Many clinicians scrupu-
lously avoid prescribing medications with high 
marketability to patients who have an addiction 
disorder or histories of diversion.
Clinicians should remind patients of their 
responsibility to protect their medications 
against theft and diversion (see Chapter 
5). Clinicians must understand and comply 
with State laws regarding prescribing prac-
tices. State laws on the amount of opioids 
prescribed and prescription expiration may 
be more restrictive than Federal laws. State 
laws can be found at the Federation of State 
Medical Boards Web site (http://www.fsmb.
org).
Some clinicians have inordinately restricted 
their prescribing because of a false belief that 
there has been a “crackdown” on clinicians 
prescribing opioids for pain. DEA’s policy 
statement on dispensing scheduled medica-
tions for the treatment of pain, which includes 
a response to concerns of a crackdown, is 
found at http://www.deadiversion.usdoj.gov/
fed_regs/notices/2006/fr09062.htm.
Strict boundaries should be placed around 
a patient who pushes for medications that 
the clinician believes are unwise choices. In 
this situation, the clinician’s responsibility is 
to prescribe what is indicated and not what 
the patient desires. Although all diversion is 
unlawful, there are degrees of seriousness; for 
example, a patient who gives a hydrocodone 
tablet to a spouse who sustained a back sprain 
should not be treated in the same way as a 
“pseudo-patient” who seeks medications to 
resell. If diversion is suspected, treatment 
monitoring must be tightened. Clinicians 
exhibit 4-10 resources for Information on Drug Use Trends
resource Web site
National Institute on Drug Abuse’s 
Community Epidemiology Work Group
http://www.drugabuse.gov/about/organization/
CEWG/CEWGHome.html
Drug Abuse Warning Network http://dawninfo.samhsa.gov
Centers for Disease Control and Prevention 
National Center for Health Statistics
http://www.cdc.gov/nchs
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should not tolerate any serious diversion, 
which is a breach of trust that usually calls 
for cessation of opioid therapy or even ending 
the clinician–patient relationship. Evidence of 
diversion should be documented. 
State prescription monitoring programs, which 
currently operate in 38 States, may be useful 
to clinicians who suspect a patient of “doc-
tor shopping,” that is, obtaining scheduled 
medications from multiple clinicians (Wang 
& Christo, 2009). Information regarding pro-
grams and a list of States that have active pro-
grams are at http://www.namsdl.org/presdrug.
htm. 
Discontinuation of opioid 
Therapy 
The best reason to discontinue opioid therapy 
is that the pain has resolved, but that is often 
not the case. Other likely reasons for discon-
tinuation include the following:
•	 Opioids are no longer effective.
•	 Opioids no longer stabilize the patient  
or improve function.
•	 The patient loses control over the 
medication.
•	 The patient is diverting the medication. 
•	 The patient is using alcohol, benzodiaz-
epines, or illicit drugs.
•	 Adverse effects are unmanageable. 
When the benefits of opioid therapy are  
outweighed by its harms, therapy should be 
discontinued. Of course, this statement applies  
to all medications, of whatever category. Exhibit 
4-11 presents an algorithm for discontinuing 
chronic opioid therapy.
Patients tapering off opioids may experience 
both short-term withdrawal (which occurs 
immediately) and protracted withdrawal. 
Short-term withdrawal begins when the 
level of opioid in the blood falls below the 
accustomed level for the patient. It usually 
abates after a few days or a week (depending 
on the half-life of the medication). Patients 
may experience increased pain and withdrawal 
hyperalgesia. Symptoms and signs of opioid 
withdrawal are as follows.
Symptoms include:
•	 Abdominal cramps, nausea, vomiting, 
diarrhea
•	 Bone and muscle pain
•	 Anxiety
•	 Insomnia
•	 Increased pain sensitivity in the original 
painful site
Signs include:
•	 Tachycardia
•	 Hypertension
•	 Fever
•	 Mydriasis
•	 Hyperreflexia
•	 Diaphoresis
•	 Piloerection
•	 Lacrimation, yawning
•	 Rhinorrhea
•	 Myoclonus
Protracted withdrawal from opioids includes 
anxiety, depression, sleep disturbances, fatigue, 
dysphoria, and irritability, which can last 
for weeks or months following withdrawal 
from short- and long-acting opioids (Collins 
& Kleber, 2004; Satel, Kosten, Schuckit, & 
Fischman, 1993). These symptoms can be 
attenuated with tricyclic antidepressants, 
gabapentin, and other nonaddicting agents. 
Discomfort may develop at any time during 
the weaning process, so patients should be 
monitored until the process is complete and 
any symptoms addressed. Cognitive–behavioral 
therapy may help with cravings. Not all 
patients experience protracted withdrawal. 
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exhibit 4-11 exit strategy
Note: This algorithm does not indicate a maximum trial dose, as none has been established by research. However, it can 
be said that doses above 200 mg morphine equivalents per day have not been studied systematically, and higher doses 
are more likely to be associated with active addiction than are lower doses (Ballantyne, 2006). Some clinicians have recom-
mended doses up to 300 mg morphine equivalents per day. Analgesic Research, personal communication, October 30, 
2009; Covington, personal communication, October 30, 2009.
63
4—Managing Addiction Risk In Patients Treated With Opioids
For patients whose active addiction necessitates 
discontinuation of opioid therapy, referral for 
specialized addiction treatment is crucial. 
There are many reasons for discontinuing 
scheduled medications but very few for 
discontinuing care of the patient. When 
opioids are a liability, whether because of 
poor analgesic efficacy or patient ADRB, the 
clinician should usually offer to continue to 
provide non-opioid therapies and treatment; 
that is, stopping opioids does not mean 
stopping treatment. 
The clinician who elects to discharge a patient 
from his or her practice should inform the 
patient in writing. To avoid charges of aban-
donment, the clinician should provide the 
patient with contact information for other cli-
nicians, along with a written tapering schedule 
and prescriptions for the medications that 
require a taper. In cases in which the clinician–
patient relationship is hostile or dangerous or 
in which the patient presents a danger to the 
clinician, a letter alone can suffice. 
Key points
•	 Patients on chronic opioid therapy should be monitored closely for signs of benefit, 
harm, and ADRBs. 
•	 All ADRBs should be documented, investigated, and acted on. 
•	 Difficult conversations should be managed with compassion and empathy. 
•	 Clinicians should establish and respectfully maintain strict limits with patients who 
insist on opioids.
•	 Clinicians should establish relationships with drug-testing laboratory staff and addic-
tion specialists.
•	 When it is necessary to discontinue chronic opioid therapy, a conscientious tapering 
plan should be provided. 
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In ThIs chApTer
•	The Value of Patient 
Education
•	Providing Effective 
Education
•	The Internet as a Source 
of Patient Education
•	Education Content 
•	Opioid Information
•	Methadone Maintenance 
Therapy Information
•	Treatment Agreements 
•	Key Points
patient education and 
Treatment Agreements
The value of patient education
No randomized controlled trials have specifically evaluated the  
effect of patient education on treatment outcomes; however, Brox 
and colleagues (2006) studied 60 patients who had persistent low 
back pain at least a year after surgery for disc herniation. Patients 
were randomized to receive either lumbar fusion with transpedicular 
screws or cognitive intervention, which consisted largely of educa-
tion on back hygiene and exercises. Outcomes were essentially the 
same for the two groups. 
The potential value of patient education is also supported by ad 
hoc reviews in the medical literature. For instance, VA/DoD Clinical 
Practice Guideline for the Management of Opioid Therapy for Chronic 
Pain (Department of Veterans Affairs & Department of Defense 
[VA/DoD], 2010) recommends both patient and family educa-
tion, as do other pain treatment guidelines (Chou, Fanciullo, Fine, 
Adler, et al., 2009; Institute for Clinical Systems Improvement, 
2007). Patient education is also necessary for truly informed con-
sent. Geppert (2004, p. 163) defines informed consent as follows: 
“Informed consent encompasses the capacity to understand the risks, 
benefits, and alternatives of a treatment, to communicate a choice 
regarding therapy, to deliberate and reason about the consequences 
of the proposed medication, and to appreciate how the treatment 
will affect life and values.” Informed consent is particularly impor-
tant when clinicians are prescribing potentially addictive medica-
tions to patients who have histories of substance use disorders 
(SUDs) and other behavioral health disorders. 
Providing culturally sensitive and linguistically appropriate education 
can: 
•	 Improve adherence.
•	 Help the patient understand medication responses that are 
expected and normal and those that are of concern and warrant 
a phone call.
•	 Allay fears about particular treatments or medications.
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•	 Increase satisfaction with treatment by 
promoting realistic expectations.
•	 Provide an opportunity to discuss any 
concerns.
•	 Strengthen the clinician–patient rela-
tionship by demonstrating respect and 
enhancing patient feelings of self-efficacy.
•	 Improve health, well-being, and 
outcomes.
In addition, patient education provides a 
forum in which clinicians can ask patients 
about their perceptions of their condition and 
explore patients’ conceptions and misconcep-
tions about their condition and its treatment. 
Clinicians should encourage patients to  
talk about their use of complementary and 
alternative medicine (CAM) and other non-
pharmacological approaches to pain.
Providing education and soliciting questions 
require an initial time commitment; however, 
these efforts ultimately save time. A patient 
is less likely to make unnecessary emergency 
appointments when he or she clearly under-
stands what to expect from a medication or 
treatment and has a specific plan for what 
actions to take when pain flares. 
providing effective education
Effective education is a process that begins at 
treatment initiation and continues throughout 
treatment. The treatment needs of patients 
who have chronic noncancer pain (CNCP) 
and SUD change over time, necessitating 
ongoing education. Family members, especially 
caregivers, frequently play important roles in 
pain treatment (Glajchen, 2001) and ought to 
be involved in educational efforts. 
Educational approaches must be tailored to 
each patient’s needs. The clinician or other 
members of the treatment team should  
develop a repertoire of educational materials 
and approaches to meet the differing needs  
of patients. Approaches should consider: 
•	 Primary languages spoken by patients.
•	 Culture, gender, race/ethnicity, and age of 
patients.
•	 Resources in the local community (e.g., 
availability of hospitals, pharmacies).
•	 Educational, general literacy, and health 
literacy levels of patients.
•	 Cognitive function of patients.
Health literacy has been defined as “the 
capacity to obtain, process, and understand 
basic health information and services needed 
to make appropriate health decisions” (U.S. 
Department of Health and Human Services, 
2000, p. vi). Online sources for more infor-
mation and training on health literacy are in 
Exhibit 5-1.
exhibit 5-1 selected online sources of Information on health literacy
organization Web site
American Medical Association Health Literacy Kit 
(continuing medical education credits available)
http://www.ama-assn.org/ama/pub/ 
physician-resources.shtml
Health Resources and Services Administration 
(HRSA) Unified Health Communication 
101: Addressing Health Literacy, Cultural 
Competency, and Limited English Proficiency
http://www.hrsa.gov/healthliteracy/default.htm
Center for Health Care Strategies, Inc., Health 
Literacy Fact Sheets
http://www.chcs.org/usr_doc/ 
Health_Literacy_Fact_Sheets.pdf 
Institute of Medicine Health Literacy: A 
Prescription to End Confusion
http://www.iom.edu/Reports/2004/ 
Health-Literacy-A-Prescription-to-End-Confusion.
aspx
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To enhance communication with a diverse 
patient population, HRSA recommends that 
the treatment team (http://www.hrsa.gov/
healthliteracy): 
•	 Use simple language and short sentences 
and define technical terms. 
•	 Supplement instruction with appropriate 
materials (e.g., videos, models, pictures). 
•	 Ask patients to explain or demonstrate 
the clinician’s instructions (teach-back 
method; see Exhibit 5-2). 
•	 Ask open-ended questions that begin 
with “how” and “what,” rather than 
closed-ended, yes/no questions. 
•	 Organize information so that the most 
important points stand out and repeat 
this information. 
•	 Consider gender; age; and the cultural, 
ethnic, and racial diversity of patients 
when selecting or designing educational 
materials. 
•	 Offer assistance with completing forms.
Oral communication can be supplemented 
with charts, diagrams, and other visual aids. 
These can help patients with limited English 
proficiency or low-literacy skills as well as 
those who learn more efficiently from graphic 
representations. Patient education materials 
are available in several languages at  
http://www.healthinfotranslations.org.  
In some cases, a translator may be necessary. 
Communication also can be enhanced by 
using the teach-back method (or “interactive  
communication loop”) (Schillinger et al., 
2003). This method can be effectively used 
with any patient but may be particularly help-
ful with those who have low general knowl-
edge or health literacy or who are in early 
recovery from an SUD. 
The method involves the clinician’s explaining 
or demonstrating an instruction or concept to 
the patient, then asking the patient to repeat 
the instruction or information back in his or 
her own words (not verbatim) or to repeat the 
demonstration. When asking, the clinician 
takes responsibility for any misunderstanding 
(e.g., “I want to be sure I explained this well 
enough”). If the patient cannot demonstrate  
or does not appear to understand the instruc-
tion, the clinician tries again. This is repeated 
until the patient clearly understands what he 
or she is expected to do. Exhibit 5-2 offers a 
sample teach-back dialog. 
exhibit 5-2 Talking With patients Following a Teach-Back Approach
Clinician   “You’re going to take this medicine, the green pill, two times each day: once in the 
morning, once at bedtime. Now, to be sure I explained this well enough, please tell me 
in your own words how you’ll take this medicine.”
Patient   “Uh ... I’m going to take two green pills in the morning and two green pills when I go to 
bed.” 
Clinician   “Well, no. I’m sorry I wasn’t clear. You will take one pill in the morning and one pill 
before you go to bed. Now, tell me again how you’ll take this medication.”
Patient   “Okay, I think I’ve got it now. I’m going to take one pill in the morning and one pill 
before bed.”
Clinician   “That’s it. I am also going to write the instructions out for you. I also want to go over 
some information on when to call me. I am going to attach this information to your pre-
scription. Please call me with any questions or concerns.”
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Take-home handouts and pamphlets may 
aid recall and provide additional information. 
Clinicians can prepare their own handouts, but 
many can be found online. University medical 
centers and government Web sites are a good 
source of reliable patient education resources, 
and pharmaceutical companies almost always 
offer patient education sheets on specific med-
ications. Professional associations also often 
have useful materials, such as patient commu-
nication aids (e.g., Pain Log, Quality of Life 
Scale). Clinicians should review these docu-
ments for appropriateness, print them out, go 
over them with patients, and allow patients to 
take them home. 
The Internet as a source of 
patient education
Many patients use the Internet as a source of 
health information. Although the Internet can 
be a useful adjunct to in-office education, it 
is also a source of much misinformation and 
marketing disguised as education.
Clinicians can offer guidance and recommend 
Web sites with reliable content on chronic pain 
management and SUDs. Exhibit 5-3 lists a few  
such Web sites with information on chronic 
pain, and Exhibit 5-4 lists Web sites with 
information on SUDs.
exhibit 5-3 reliable Web sites With Information on chronic pain and pain 
Treatment
organization Web site
Aetna Intellihealth http://www.intellihealth.com 
Agency for Healthcare Research and Quality http://www.ahrq.gov
American Academy of Family Physicians http://www.familydoctor.org
American Academy of Pain Medicine http://www.painmed.org
American Cancer Society http://www.cancer.org
American Chronic Pain Association http://www.theacpa.org
American Pain Foundation http://www.painfoundation.org
American Pain Society http://www.ampainsoc.org
American Society of Anesthesiologists http://www.asahq.org
Arthritis Foundation http://www.arthritis.org
Breastcancer.org http://www.breastcancer.org 
Emerging Solutions in Pain http://www.emergingsolutionsinpain.com
Komen Foundation http://ww5.komen.org
MedicineNet, Inc. http://www.medicinenet.com
National Cancer Institute http://www.cancer.gov (click PDQ, physician data 
query)
National Institutes of Health http://www.nih.gov
National Pain Foundation http://www.nationalpainfoundation.org
Veterans Affairs http://www.va.gov/painmanagement
WebMd http://www.webmd.com
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education content
General Information
The specifics of patient education vary from 
patient to patient and over time. However, 
general content areas for patient education 
include information about: 
•	 The patient’s condition and the nature of 
the patient’s chronic pain.
•	 Treatments available, including nonphar-
macological options.
•	 The risks and benefits of treatment 
options.
•	 How and when to take medications.
•	 How to keep medications safely away 
from children (out of reach or locked up).
•	 The patient’s responsibility for keeping 
track of medications and not losing them 
or giving them to others.
•	 Any medication interactions.
•	 Common side effects of medication, their 
expected duration, and ways to manage 
them (e.g., a high-fiber diet to manage 
constipation common to opioid use).
•	 Warnings and potential adverse events 
associated with medications and other 
treatments. 
•	 Pros and cons of CAM.
•	 Risks to pregnant and lactating women.
•	 The degree of pain relief the patient can 
realistically expect from a treatment.
•	 How to use treatment apparatus (e.g., 
transcutaneous electrical nerve stimula-
tion machine).
•	 How best to use the Internet to find 
information and sources of support. 
•	 Under what conditions the patient should 
immediately call the clinician or go to the 
emergency department.
•	 How to deal with episodes of acute pain 
(e.g., from surgery or trauma), as well as 
flareup pain.
Patients may benefit from referrals to psychol-
ogists for assistance in basic coping skills and 
to physical therapists and other professionals 
(Naliboff, Wu, & Pham, 2006) for therapies 
that can be used in place of or in addition 
to medication (e.g., meditation, relaxation, 
stretching, distraction). 
opioid Information
Use of opioids requires additional educational 
efforts. To give informed consent, patients 
must understand the expected benefits as well 
as the uncertainties of chronic opioid therapy. 
Specifically, they must understand that excel-
lent analgesia can almost always be provided 
by starting opioids; however, long-term studies 
are limited and often of poor quality. They 
exhibit 5-4 reliable Web sites With Information on substance Use Disorders
organization Web site
National Institute on Alcohol Abuse and 
Alcoholism
http://www.niaaa.nih.gov
National Institute on Drug Abuse http://www.drugabuse.gov
National Library of Medicine http://www.nlm.nih.gov
Parents. TheAntiDrug.com http://www.theantidrug.com 
Partnership for a Drug-Free America http://www.drugfree.org
Substance Abuse and Mental Health Services 
Administration
http://www.samhsa.gov
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suggest that benefit diminishes with time; 
after 1½ years, about one-half of patients 
dropped out of opioid therapy because of side 
effects or the therapy’s loss of efficacy. Those 
continuing to take opioids had about 30- 
percent pain reduction (Kalso, Edwards, 
Moore, & McQuay, 2004). 
Patients must also understand the risks of 
therapy, which include overdose (by patient, 
others, pets), constipation, sedation, and hor-
mone changes, and the hazards of combin-
ing opioids with sedating drugs or alcohol. 
Finally, they should understand that tolerance 
and physical dependence are expected conse-
quences of extended therapy, that these condi-
tions do not necessarily indicate the presence 
of an addictive disorder, but that they do 
require that arrangements be made to prevent 
abrupt withdrawal when either the patient 
or clinician is out of town or the clinician is 
otherwise unavailable. Policies of the clinician 
or program (e.g., requirements for urine drug 
testing, responses to lost or stolen prescription 
reports, early refill requests) should be  
communicated in advance. 
In addition, patients need to understand (VA/
DoD, 2010):
•	 The titration process, how soon the 
patient can expect maximum effective-
ness, and why taking medications exactly 
as prescribed is important to the titration 
process. 
•	 The risks of discontinuing the medication 
abruptly (e.g., withdrawal symptoms). 
•	 How medication will be safely discontinued 
(e.g., tapering, managing withdrawal 
symptoms). 
•	 That drowsiness is a common side effect 
during titration and that patients should 
not try to drive or operate heavy machin-
ery until drowsiness is cleared. 
•	 How to discuss pain therapy, analgesic 
needs, and recovery status with other 
health professionals (e.g., dentists, anes-
thesiologists). (See Exhibit 5-5.) 
exhibit 5-5 Talking With patients Before surgery
Anesthesiologist:   “I understand you are scheduled for knee-replacement surgery. Is there 
anything else you would like me to know about your health?”
Patient:     “Yes, I was addicted to Vicodin many years ago. I still have chronic low 
back pain even though I had a laminectomy and fusion about 5 years ago. 
The pain following surgery was terrible. I do not want to go through that 
again. Doctor, I do not want to suffer. ”
Anesthesiologist:  “I see. Please tell me more. I want to make sure that I have all the informa-
tion so that your surgeon and I can develop a pain management plan to 
address your concerns.”
Patient:   “I take buprenorphine. It works very well for me.”
Anesthesiologist:  “Thank you for sharing this information. Knee surgery patients can feel a 
lot of pain afterward. Since we have 2 days before your surgery, we should 
be sure the doctor prescribing your buprenorphine knows that you are 
scheduled for surgery. She may want to change your buprenorphine dose. 
Also, we will consider using other pain medications or techniques to man-
age your pain. We’ll need to closely monitor you and assess your pain. We 
will also want to be sure that your support people are aware of the plan 
and are available to help you. May I contact your doctor and nurses?” 
71
5—Patient Education And Treatment Agreements
Patients also need to know about legal and 
regulatory issues (VA/DoD, 2010), including:
•	 The legal responsibilities of the clinician. 
•	 That it is illegal to give away, trade, share, 
or sell prescription opioids.
•	 The potential effect of regulatory 
issues on occupation, lifestyle, and use 
(e.g., pilots, commercial drivers; Chou 
and colleagues [2009] provide more 
information).
•	 The responsibility of the patient to report 
stolen medications both to the police and 
to the clinician. 
methadone maintenance Therapy 
Information
Patients on methadone maintenance therapy 
(MMT) for opioid dependence need to under-
stand how pain treatment will affect their 
MMT and vice versa. Patients also need to 
understand that long-term use of opioids can 
bring tolerance, may cause them to become 
more sensitive to pain (to have opioid-induced 
hyperalgesia), and can cause the opioids to 
become ineffective over time. (Chapter 3  
provides more information on opioid-induced 
hyperalgesia.)
In general, when patients receiving MMT 
have inadequate pain control, options include 
non-opioid therapies and dividing the daily 
methadone dose into three-times-a-day  
dosing. If a decision is made to increase the  
dose of methadone by the pain-treating  
clinician, it should be done only in concert 
with the MMT program. The patient must  
be monitored for continued participation in  
an aggressive recovery program and for evi-
dence that the increased dose of methadone 
leads to demonstrable reductions in pain or 
improvements in function. 
Treatment Agreements 
As with patient education, opioid treatment 
agreements (contracts) have had no random-
ized controlled trials that have specifically 
evaluated their effect on treatment outcomes. 
Such agreements are, however, recommended 
in clinical guidelines and are frequently used 
in practice. Although written agreements spe-
cific to prescribed opioids are most frequently 
discussed, agreements can be used for other 
treatment modalities (e.g., exercise regimens). 
Disagreement exists about the use of agreements  
when prescribing opioids (Heit, 2003). Some 
guidelines recommend opioid agreements only 
when the patient has or is at risk for an SUD. 
Others are concerned that “opioid contracts 
may diminish patient autonomy; autonomy and  
adherence may sometimes represent conflict-
ing values in chronic opioid therapy” (Arnold, 
Han, & Seltzer, 2006, p. 294). 
These concerns can be mitigated somewhat 
by the way in which treatment agreements 
are established. Patients can be informed that 
treatment agreements are mutually agreed-on 
plans and courses of action. Providing educa-
tion on options and involving the patient in 
planning and writing treatment agreements can 
preserve patient autonomy while establishing 
necessary guidelines. Arnold and colleagues 
(2006) suggest that, if a clinician chooses to 
use an opioid agreement, it should:
•	 Use neutral, nonconfrontational language.
•	 Be written so that the patient can under-
stand it.
•	 Emphasize opioids as a part of a com-
prehensive pain management plan that 
also includes physical therapy, counseling, 
and other medications for co-occurring 
disorders, as needed.
•	 Emphasize the clinician’s responsibility to 
work with the patient to alleviate his or 
her symptoms.
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•	 Explain that the agreement protects the 
patient’s access to scheduled medications 
and protects the clinician’s license to 
prescribe them.
•	 Describe behaviors that are incompatible 
with chronic opioid therapy (e.g., getting 
prescriptions from other clinicians, losing 
medications).
•	 Describe the actions the clinician may 
take in response to these behaviors up 
to and including cessation of opioid 
prescribing.
As when treating all patients, the clinician 
can assess the ability of the patient with or in 
recovery from an SUD to make an informed 
decision (Longo, Parren, Johnson, & Kinsey, 
2000). If the clinician becomes aware of limi-
tations, he or she can (in addition to or instead 
of having a written agreement) involve the 
patient’s family in treatment, with the patient’s 
permission (Geppert, 2004). 
Treatment agreements vary considerably 
from practice to practice and from patient to 
patient. However, some common elements of 
agreements include the following (Fishman, 
2007; Heit, 2003; Jacobson & Mann, 2004; 
VA/DoD, 2010; Ziegler, 2007):
•	 Timeframe of the agreement
•	 Goals of therapy
•	 Risks and benefits of chronic opioid 
therapy
•	 Requirement for obtaining prescriptions 
from a single clinician and a named 
pharmacy
•	 Activities for pain management (e.g., 
exercise, CAM)
•	 Risk and benefit statement, including lists 
of possible side effects
•	 Proscription against changing medication 
dosage without permission
•	 Schedule for regular medical visits for 
evaluation of the agreed-on treatment
•	 Requirement of complete, honest self-
report of pain relief, side effects, and 
function at each medical visit
•	 Limits on medication refills
•	 Limits on replacing lost medications or 
prescriptions
•	 Consent for random urine drug testing 
and other specified testing
•	 Required pill counts
•	 Consent for appropriate release of infor-
mation (e.g., from family members, other 
clinicians, counselors, substance abuse 
treatment programs)
•	 Participation in agreed-on SUD recovery 
activities (e.g., treatment, continuing care, 
mutual-help groups) 
•	 Requirements of the clinician
•	 Participation in agreed-on psychiatric 
treatment activities
•	 Possible consequences of not following 
the treatment agreement
A useful treatment agreement should be revised 
as the patient’s needs and circumstances change. 
An opioid agreement by American Academy 
of Pain Management is online at http://
www.aapainmanage.org. Exhibit 5-6 presents 
another sample pain treatment agreement for 
a woman in recovery from an SUD.
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5—Patient Education And Treatment Agreements
exhibit 5-6 sample pain Treatment Agreement
Patient: Irene Simpson   Doctor: Dr. Miller   Date: 1-19-10
This treatment plan has been developed to manage neck pain and tension headaches. It is open to 
changes when both the doctor and I agree that the changes are in my best interest and are likely 
to improve my pain management or overall health. A primary goal of the plan is to protect my 
recovery from addiction.
1. My daily medications:  
gabapentin, 1,200 mg three times daily. 
duloxetine, 90 mg every morning. 
topiramate, 100 mg at bedtime.
2. At the first indication of a headache, I will take ibuprofen (600 mg).
3. If possible, I will lie down in a darkened room with an ice pack to my neck and shoulders for 
15 to 20 minutes to give the medication time to work; if the headache is still present in 30 
minutes, I will take acetaminophen (500 mg). Use of opioid medications can be considered if 
this plan is unsuccessful. However, under no circumstances will I seek these medications from 
other doctors, friends, or the Internet. Instead, I will discuss my cravings and sense that the 
plan is not working with Dr. Miller, Joan Small, and my sponsor.
4. I will see Dr. Wong weekly or as recommended for acupuncture treatments.
5. I will walk 15 to 30 minutes daily.
6. I will attend the pain management group with Joan weekly and see Joan for individual  
sessions as indicated.
7. I will obtain all prescriptions for headache or other pain and for addiction recovery from  
Dr. Miller, and I will fill all prescriptions at the Main Street Pharmacy.
8. I will not visit other physicians or the emergency department without first talking to Dr. Miller 
or to the doctor who is covering for him.
9. I will attend my home group (Tuesday Night Women’s Group) weekly, plus two other weekly 
Narcotics Anonymous (NA) meetings of my choice; I will talk with my sponsor at least weekly 
and will call her when I feel despondent or have cravings to drink or take opioid pills.
10. My daily meditation will focus on removing myself from conflicts where I do not have a direct 
role to play. I will try to remind myself when “I don’t have a horse in this race” at work or at 
home.
Important Phone Numbers:
Dr. Miller’s Office ................................... 222-3800
Dr. Miller’s Answering Service ............... 222-9000
Main Street Pharmacy ............................380-2000
Joan Small’s Office ................................ 380-2132
NA Hotline ............................................. 234-0081
Abby (sponsor) .......................................382-9970
Patient: _______________________________  Doctor:___________________________  Date:_________
Sample Pain Treatment Agreement ©MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.
Ziegler, P. Treating Chronic Pain in the Shadow of Addiction. Monograph 2007. Available at:  
http://www.emergingsolutionsinpain.com/index.php?option=com_continued&view=dispfm&Itemid=280&course=42
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Key points
•	 Patient education is necessary for informed consent, and it equips patients to take an 
active role in their pain management.
•	 Education must be tailored to the individual patient. More research is needed on tailor-
ing education to patients who have CNCP.
•	 Clinicians should take time to educate their patients and make sure patients understand 
how to help themselves.
•	 People learn in different ways; clinicians should have a variety of learning materials at 
their disposal.
•	 Treatment agreements document the treatment plan and the responsibilities of the 
patient and the clinician.
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Appendix B—Assessment 
Tools and resources
exhibit B-1 Tools To Assess pain level
Tool resource
Faces Pain Scale http://painsourcebook.ca/docs/pps92.html
Numeric Rating Scale http://www.rnao.org/pda/pain/page4.html
Verbal Rating Scale/Graphic 
Rating Scale
http://www.rnao.org/pda/pain/page4.html
Visual Analog Scale http://www.rnao.org/pda/pain/page4.html
exhibit B-2 Tools To Assess several Dimensions of pain
Tool resource
Brief Pain Inventory http://www.mdanderson.org (long and short 
forms)
McGill Pain Questionnaire Centre for Evidence Based Physiotherapy
http://www.cebp.nl/vault_public/
filesystem/?ID=1400 (long form)
Center for Gerontology & Health Care Research 
at Brown University
http://www.chcr.brown.edu/pcoc/
SHORTMCGILLQUEST.PDF (short form)
exhibit B-3 Tools To Assess pain Interference and Functional 
capacities
Tool resource
Katz Basic Activities of Daily 
Living Scale
University of Texas School of Nursing at 
Houston
http://son.uth.tmc.edu/coa/FDGN_1/
RESOURCES/ADLandIADL.pdf 
Pain Disability Index Pain Balance
http://www.painbalance.org/pages/search.
aspx?q=pain+disability+index
Roland-Morris Disability 
Questionnaire
National Primary Care Research and 
Development Centre, University of Manchester, 
UK
http://www.rmdq.org 
WOMAC index http://www.womac.org
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exhibit B-4 Tools To screen for substance Use Disorder
Tool resource
Alcohol, Smoking, and Substance 
Involvement Screening Test
World Health Organization
http://www.who.int/substance_abuse/activities/assist/en/
index.html 
Alcohol Use Disorders 
Identification Test (AUDIT)
World Health Organization, Department of Mental Health and 
Substance Dependence
http://whqlibdoc.who.int/hq/2001/who_msd_msb_01.6a.pdf 
AUDIT-C Department of Veterans Affairs
http://www.hepatitis.va.gov/vahep?page=prtop03-audit_c 
CAGE Adapted to Include Drugs 
(CAGE-AID)
Michigan Quality Improvement Consortium
http://www.mqic.org/pdf/CAGE_CAGE_AID_
QUESTIONNAIRES.pdf
Drug Abuse Screening Test Project Cork
http://www.projectcork.org/clinical_tools/html/DAST.html 
Michigan Alcoholism Screening 
Test (MAST) (MAST-G for older 
patients)
National Institute on Alcohol Abuse and Alcoholism
http://pubs.niaaa.nih.gov/publications/assesing%20alcohol/
instrumentpdfs/42_mast.pdf
exhibit B-5 Tools To Assess emotional Distress, Anxiety, pain-related Fear, and 
Depression
Tool resource
Beck Depression Inventory (BDI) It is possible to download the 1961 BDI version, the copyright 
for which is held by the American Psychological Association 
rather than Pearson Education. The original BDI is widely 
available to academic researchers via interlibrary loan, under 
fair use provisions of international copyright law: Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961. 
Order BDI-II through Pearson at http://pearsonassess.com/
HAIWEB/Cultures/en-us/default 
Brief Patient Health Questionnaire Department of Defense/Veterans Health Administration 
http://www.pdhealth.mil/guidelines/downloads/appendix1.pdf 
Center for Epidemiologic Studies 
Depression Scale
Counselling Resource
http://counsellingresource.com/quizzes/cesd/index.html 
Geriatric Depression Scale Stanford University
http://www.stanford.edu/~yesavage/GDS.html (long form) 
http://www.stanford.edu/~yesavage/GDS.english.short.html 
(short form)
Profile of Chronic Pain: Screen http://shop.goalistics.com/products/profile-of-chronic-pain
Clinician Administered PTSD Scale U.S. Department of Commerce National Technical Information 
Service
http://www.ntis.gov/search/product.
aspx?ABBR=AVA21105CDRM
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exhibit B-5 Tools To Assess emotional Distress, Anxiety, pain-related Fear, and 
Depression (continued)
Tool resource
Davidson Trauma Scale Multi-Health systems, Inc. 
http://www.mhs.com/product. 
aspx?gr=cli&prod=dts&id=overview
Posttraumatic Diagnostic Scale Pearson Assessments
http://www.pearsonassessments.com
State-Trait Anxiety Inventory Mind Garden
http://www.mindgarden.com/products/staisad.htm 
Tampa Scale for Kinesiophobia http://www.medicalpanels.vic.gov.au/wps/wcm/connect/
wsinternet/worksafe/home/forms+and+publications/
educational+material/tampa+scale+for+kinesiophobia
exhibit B-6 Tools To Assess coping
Tool resource
Chronic Pain Acceptance 
Questionnaire
http://www.somasimple.com/pdf_files/acceptance_pain.pdf 
(appendix to McCracken, Vowles, & Eccleston, 2004)
Fear-Avoidance Beliefs 
Questionnaire
WorkSafe Victoria
http://www.workcover.vic.gov.au
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Appendix c—cFr sample 
consent Form and list of 
personal Identifiers
I, __________________, authorize XYZ Clinic to receive from/disclose to ___________________ 
   (Name of patient/participant)            (Name of person/organization) 
for the purpose of ________________________________________ the following information 
     (Need for disclosure)
______________________________________________________________________________. 
     (Nature of the disclosure)
I understand that my records are protected under the Federal and State Confidentiality 
Regulations and cannot be disclosed without my written consent unless otherwise provided  
for in the regulations. I also understand that I may revoke this consent at any time except to  
the extent that action has been taken in reliance on it and that in any event this consent expires  
automatically on ________________________________ unless otherwise specified below. 
    (Date, condition, or event)
Other expiration specifications:_____________________________________________________
_______________________________________________      ______________ 
  Signature of patient/participant            Date 
_______________________________________________      ______________ 
  Signature of parent/guardian, where required            Date
sample consent Form
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Individual Identifiers Under the 
privacy rule
The following 18 identifiers of a person or of 
relatives, employers, or household members 
of a person must be removed, and the cov-
ered entity must not have actual knowledge 
that the information could be used alone or 
in combination with other information to 
identify the individual, for the information to 
be considered de-identified and not protected 
health information (PHI):
•	 Names 
•	 All geographic subdivisions smaller than 
a State, including county, city, street 
address, precinct, ZIP Code,* and their 
equivalent geocodes
•	 All elements of dates (except year) 
directly related to an individual: all  
ages >89 and all elements of dates 
(including year) indicative of such age 
(except for an aggregate into a single 
category of age >90)
•	 Telephone numbers
•	 Fax numbers
•	 Email addresses
•	 Social Security numbers
•	 Medical record numbers
•	 Health-plan beneficiary numbers
•	 Account numbers
•	 Certificate and license numbers
•	 Vehicle identifiers and serial numbers, 
including license plate numbers
•	 Medical device identifiers and serial 
numbers
•	 Internet universal resource locators 
(URLs)
•	 Internet protocol (IP) addresses
•	 Biometric identifiers including finger-
prints and voice prints
•	 Full-face photographic images and any 
comparable images
•	 Any other unique identifying number, 
characteristic, or code, except that covered 
identities may, under certain circumstanc-
es, assign a code or other means of record 
identification that allows de-identified 
information to be re-identified 
 
Source: 45 CFR § 164.514 [b][2][i].
* The first three digits of a ZIP Code are excluded from the PHI list if the geographic unit 
formed by combining all ZIP Codes with the same first three digits contains >20,000 people.
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Appendix D—resources 
for Finding complementary 
and Alternative Therapy 
practitioners
Type of Therapy resource
Acupuncture American Association of Acupuncture and Oriental 
Medicine (AAAOM) 
http://www.aaaomonline.org 
National Certification Commission for Acupuncture 
and Oriental Medicine (NCCAOM)
http://www.nccaom.org 
Biofeedback Association for Applied Psychophysiology and 
Biofeedback 
http://www.resourcenter.net/Scripts/4Disapi9.dll/ 
4DCGI/resctr/search.html 
Chiropractic American Chiropractic Association
http://www.acatoday.org 
Massage American Massage Therapy Association
http://www.amtamassage.org/findamassage/ 
locator.aspx 
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Appendix e—Field reviewers
Jane C. Ballantyne, M.D., FRCA
Professor, Anesthesiology and Critical 
Care
Penn Pain Medicine Center 
Philadelphia, Pennsylvania 
Declan T. Barry, Ph.D.
Associate Research Scientist
Yale University School of Medicine
New Haven, Connecticut 
Sharon M. Freeman, Ph.D., M.S.N., 
PMHCNS-BC, CARN-AP
CEO 
Center for Brief Therapy, P.C.
Fort Wayne, Indiana
Cynthia M. A. Geppert, M.D., 
Ph.D., M.P.H., FAPM, DAAPM
Chief 
Consultation Psychiatry & Ethics 
New Mexico Veterans Affairs Health 
Care System 
Associate Professor of Psychiatry
Director of Ethics Education 
University of New Mexico School of 
Medicine
Albuquerque, New Mexico
 
Patricia M. Good
Chief (retired)
Liaison and Policy Section
Office of Diversion Control 
Drug Enforcement Administration
Arlington, Virginia
Douglas Gourlay, M.D., M.Sc., 
FRCP(C), FASAM 
Director
Pain and Chemical Dependency 
Division
Wasser Pain Centre
Mount Sinai Hospital 
Centre for Addiction and Mental 
Health
Toronto, Canada 
Howard A. Heit, M.D., FACP, 
FASAM
Assistant Clinical Professor of 
Medicine
Georgetown School of Medicine
Fairfax, Virginia 
 
Nathaniel Katz, M.D., M.S.
Adjunct Assistant Professor of 
Anesthesia
Tufts University School of Medicine 
President & CEO
Analgesic Research
Needham, Massachusetts
Kenneth L. Kirsh, Ph.D.
Assistant Professor
Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky
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Director
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Pain Consultant
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Medical Director
Methadone Maintenance Treatment Program
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New York, New York
Barbara St. Marie, ANP, GNP
Nurse Practitioner
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Mark D. Sullivan, M.D., Ph.D.
Professor of Psychiatry and Behavioral 
Sciences
University of Washington
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Professor
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Director 
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treatment strategies and models for working 
with individuals with psychiatric  
comorbidities, 39
Chiropractic
pain management issues, 39
Chronic noncancer pain. See also Pain
anxiety and, 25
assessing pain and function, 15–20
basics of, 4
causes, 6
commonalities with addiction, 4
cross-addiction and, 9
cycle of chronic pain and addiction, 9–10
definition, 2–4, 3
depression and, 25
feedback cycles, 7
identification of the source of, 6
impact of, 1
mixed nociceptive and neuropathic type, 6
multidimensional nature of, 1, 13
negative reinforcement of substance use 
and, 9
neuropathic type, 6
nociceptive type, 6
pain management, 33–48
paradoxical reactions to substances used to 
treat, 10
physiological and psychological effects, 7
positive reinforcement of substance use 
and, 9
post-traumatic stress disorder and, 25–26
prevalence of, 1, 2
psychiatric comorbidities, 24–27
rebound symptoms, 10
statistics on substance use and chronic 
pain in the United States (exhibit), 1
suicide and, 27
tolerance to analgesic and anxiolytic 
substances and, 9–10
types of (exhibit), 6
Chronic pain syndrome
definition, 3
CNCP. See Chronic noncancer pain
Cocaine
dopamine and, 8
Cochrane Collaborations
physical therapy reviews, 38
review of opioid rotation, 45
Cognitive-behavioral therapy
discontinuation of opioid therapy and, 61
pain management issues, 38
Collateral information
managing addiction risk in patients treated 
with opioids and, 54
patient assessment and, 13
Complementary and alternative medicine
benefits of, 38–39
description, 38
resources for finding practitioners, 93
talking with patients about CAM  
(exhibit), 38
Coping with pain
acceptance concept and, 27
cognitive-behavioral therapy and, 38
referral to psychologists for assistance  
with, 69
tools to assess coping (exhibit), 27
Crane, C.
suicide risk in patients with chronic 
noncancer pain, 27
Cross-addiction
description, 9
SUD involving any drug and susceptibility  
to developing a cross-addiction with  
opioids, 22
CSAT. See Center for Substance Abuse 
Treatment
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Cuoto, J. E.
urine drug testing data, 51
Current Opioid Misuse Measure
description, 56
elements of (exhibit), 58
D
DEA. See Drug Enforcement Administration
Depression
addiction risk factor, 9
anxiety and, 25
chronic noncancer pain and, 25
tools to assess emotional distress, anxiety, 
pain-related fear, and depression  
(exhibit), 26, 88–89
withdrawal and, 10
Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision
substance dependence criteria, 20–21
Documentation requirements
assessing pain and function, 15–16
chronic opioid therapy, 58–59
elements to document during patient visits 
(exhibit), 31
Drug diversion
description, 60
legal and regulatory issues, 71
patient responsibility for protecting their 
medication supply, 60
resources for information on drug use 
trends (exhibit), 60
treatment monitoring and, 60–61
Drug Enforcement Administration
“do not fill until” option for prescriptions, 50
buprenorphine treatment and, 43–44
policy statement on dispensing scheduled 
medications, 60
DSM-IV-TR. See Diagnostic and Statistical 
Manual of Mental Disorders, Fourth 
Edition, Text Revision
Duloxetine
anxiety treatment, 39
depression treatment, 39
E
Environmental factors
addiction, 9, 10
F
Food and Drug Administration
anxiety treatments, 39
G
Gabapentin
anxiety treatment, 39
withdrawal from opioids and, 61
Gender factors
“drink” definitions, 19
Genetic factors
addiction, 8–9, 10
Geppert, C. M.
informed consent, 65
Gourlay, D. L.
urine drug testing, 52, 53
H
Health Insurance Portability and 
Accountability Act
patient privacy and, 24
Health Resources and Services Administration
patient education recommendations, 67
Heit, H. A.
urine drug testing, 52, 53
HIPAA. See Health Insurance Portability and 
Accountability Act
HIV/AIDS
pain management issues, 46
serotonin syndrome and, 40
treating patients who have HIV/AIDS 
(exhibit), 47
HRSA. See Health Resources and Services 
Administration
Hyperalgesia. See also Opioid-induced 
hyperalgesia
definition, 3
methadone maintenance therapy and, 45
pain management issues, 45
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I
IAs. See Immunoassays
Immunoassays
benefits and limitations of, 52
POC testing benefits and limitations 
(exhibit), 52
Informed consent
CFR sample consent form, 91
individual identifiers under the privacy 
rule, 92
opioid therapy and, 69–70
patient education and, 65, 69–70
Insomnia
anticonvulsant treatment, 36
antidepressant treatment, 36
L
Lamotrigine
post-traumatic stress disorder treatment, 39
M
Managing addiction risk in patients treated 
with opioids
“do not fill until” option for prescriptions, 50
aberrant drug-related behavior, 54, 56
addiction behaviors checklist (exhibit), 57
collateral information and, 54
Current Opioid Misuse Measure (exhibit), 
56, 58
discontinuation of opioid therapy, 61–63
documentation requirements, 58–59
drug diversion, 60–61, 71
exit strategy (exhibit), 62
issuance of multiple prescriptions for 
Schedule II controlled substances 
(exhibit), 50
key points, 63
managing difficult conversations, 59
medication supply issues, 50–51
nonadherence, 54, 56
patient’s support network and, 50, 54
promoting adherence, 49–51
pseudoaddiction (exhibit), 56
resources for information on drug use 
trends (exhibit), 60
talking with patients about medication 
supply (exhibit), 51
ten steps of universal precautions (exhibit), 49
therapeutic relationship and, 59, 63
tips for clinicians, 49–50, 53, 59
treatment agreements, 50
universal precautions approach, 49
urine drug testing, 51–54, 55
visit intervals, 50
workplace safety issues, 59
Massage therapy
pain management issues, 39
Medication supply issues
“do not fill until” option for prescriptions, 50
“doctor shopping,” 61
addiction specialists and, 51
drug diversion and, 60
issuance of multiple prescriptions for 
Schedule II controlled substances 
(exhibit), 50
pill counts and, 50
talking with patients about medication 
supply (exhibit), 51
using a trusted family member to dispense 
medications, 50
Medication-assisted recovery
buprenorphine and, 43–44
methadone and, 44
naltrexone and, 44
Mental illness. See Psychiatric disorders; specific 
disorders
Methadone
analgesic effects, 44
methadone titration (exhibit), 42
pain management issues, 44
patient education and, 44
referral to treatment programs, 42
Methadone maintenance therapy
hyperalgesia and, 45
opioid treatment programs and, 42
patient education regarding, 71
Mixed nociceptive/neuropathic pain
description, 6
MMT. See Methadone maintenance therapy
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N
Naltrexone
mechanism of action, 44
pain management issues, 44
Narcotic
definition, 3
National Association of State Alcohol and Drug 
Abuse Directors
research findings on Screening, Brief 
Intervention, and Referral to Treatment, 23
National Institute for Health and Clinical 
Excellence
benzodiazepine treatment guidelines, 36
National Institute on Alcohol Abuse and 
Alcoholism
“drink” definitions, 19
National Institute on Drug Abuse
genetic vulnerability to addiction, 8
Neuropathic pain
description, 6
NIAAA. See National Institute on Alcohol 
Abuse and Alcoholism
Nicholson, B.
ongoing patient assessment needs, 31
NIDA. See National Institute on Drug Abuse
Nociceptive pain
description, 6
Non-opioid analgesics
pain management issues, 35
summary of (exhibit), 35–36
Nonpharmacological pain management
benefits of, 37
cognitive-behavioral therapy, 38
complementary and alternative medicine, 
38–39
physical therapy, 38
therapeutic exercise, 37
Nonsteroidal antiinflammatory drugs
pain management issues, 35, 46
NSAIDS. See Nonsteroidal antiinflammatory 
drugs
O
OIH. See Opioid-induced hyperalgesia
Opioid Risk Tool
description, 28
elements of (exhibit), 30
Opioid treatment programs
patient management and, 42
referral to methadone therapy and, 42
Opioid-induced hyperalgesia
compared with tolerance, 44–45
definition, 3
Opioids
adverse effects of, 40
as part of a multidimensional treatment 
approach, 40
considerations before using for pain  
management, 40
discontinuation of opioid therapy, 43, 
61–63
documentation of chronic opioid therapy, 
58–59
dose finding, 41–42
evaluating risk of developing problematic 
opioid use, 28–30
exit strategy (exhibit), 62
informed consent and, 69–70
legal and regulatory issues of therapy, 71
limitations of treatment with, 40
managing addiction risk in patients treated 
with, 49–63
methadone titration (exhibit), 42
monitoring use of, 42
opioid rotation (exhibit), 45
patient education issues, 69–71
reasons for discontinuing, 61, 63
referral to opioid treatment programs, 42
relapse issues, 40, 42–43
replacement of with buprenorphine, 43–44
risk of patient’s developing problematic 
opioid use (exhibit), 28
risk of therapy, 70
route of administration, 41
selection criteria, 41
serotonin syndrome and, 40
short-acting medications, 41
side effects, 70
signs and symptoms of withdrawal, 61
105
Index
steps to take if opioid therapy is indicated 
(exhibit), 41
SUD involving any drug and susceptibility 
to developing a cross-addiction with 
opioids, 22
titration schedules, 41–42
tolerance issues, 44–45
withdrawal and, 8, 43, 61
ORT. See Opioid Risk Tool
Otis, J. D.
chronic noncancer pain and PTSD  
comorbidity, 25
P
Pain. See also Chronic noncancer pain
basics of, 4
categories of, 5
definition, 3
neurobiology of, 4–5
nociceptors and, 4–5
pain pathways (exhibit), 5
subjective nature of, 4
Pain management
acute pain episodes and, 46
addiction specialist role, 34–35
algorithm for managing chronic pain in 
patients with SUDs (exhibit), 34
benzodiazepines, 35–36
buprenorphine issues, 43–44, 46
cannabinoids, 37
cognitive-behavioral therapy, 38
complementary and alternative medicine, 
38–39
key points, 48
managing addiction risk in patients treated 
with opioids, 49–63
methadone issues, 44
multidisciplinary team approach, 33–35
naltrexone issues, 44
non-opioid analgesics, 35
nonpharmacological treatments, 37–39
opioid therapy, 40–43
overview, 33
patient-controlled analgesia, 46
patients in medication-assisted recovery 
and, 43–44
patients in recovery and, 35–37, 46
patients on agonist therapy for addiction 
or pain and, 46
patients who have HIV/AIDS (exhibit), 47
patients who have sickle cell disease 
(exhibit), 47
patients with active addiction and, 45–46
physical therapy, 38
psychiatric comorbidities and, 39–40
summary of non-opioid analgesics  
(exhibit), 35
therapeutic exercise, 37
tolerance and hyperalgesia, 44–45
treatment outcomes and, 46
treatment team components, 33–34
Passik, S. D.
“4 As” of monitoring and documenting 
opioid response, 59
ongoing patient assessment needs, 31
Patient assessment
assessing ability to cope with chronic pain, 27
assessing pain and function, 15–20
assessing substance use and addiction, 18–20
collateral information and, 13
elements of, 13, 14–15, 23
elements of a comprehensive patient 
assessment (exhibit), 14–15
elements of screening, brief intervention, 
and referral to treatment (exhibit), 23
elements to document during patient visits 
(exhibit), 31
evaluating risk of developing problematic 
opioid use, 28
false-positive or false-negative results and, 13
Federal protection of patient health  
information (exhibit), 24
key points, 32
limitations of standardized tools, 13
ongoing assessment needs, 30–31
Opioid Risk Tool, 28, 30
psychiatric comorbidities, 24–27
referrals for further assessment, 23–24
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Screener and Opioid Assessment for 
Patients with Pain—Revised, 28, 29
substance use disorder screening, 20–23
tips for clinicians, 15, 16–17, 19, 23–24, 
30–31
tools for, 13, 15–23, 87–89
tools to assess coping (exhibit), 27
tools to assess emotional distress, anxiety, 
pain-related fear, and depression (exhibit), 
26, 88–89
tools to assess pain interference and 
functional capacities (exhibit), 87
tools to assess pain interference with 
life activities and functional capacities 
(exhibit), 19
tools to assess pain level (exhibit), 17–18, 87
tools to assess several dimensions of pain 
(exhibit), 18, 87
tools to screen for substance use disorders 
(exhibit), 22, 88
treatment setting options, 31–32
Patient education
content areas, 69
cultural sensitivity and, 65–66
effective education strategies, 66–68
family members and caregivers and, 66
health literacy and, 66
Health Resources and Services 
Administration recommendations, 67
informed consent and, 65, 69–70
Internet as a source of, 66, 68
key points, 74
linguistically appropriate materials, 65–66
methadone maintenance therapy, 71
methadone treatment, 44
online sources, 66, 68
opioid information, 69–71
reliable Web sites with information on 
chronic pain and pain treatment  
(exhibit), 68
reliable Web sites with information on 
substance use disorders (exhibit), 69
selected online sources of information on 
health literacy (exhibit), 66
take-home handouts and pamphlets, 68
talking with patients before surgery 
(exhibit), 70
talking with patients following a teach-
back approach (exhibit), 67
teach-back method, 67
time commitment and, 66
urine drug testing, 54
value of, 65
Patient-controlled analgesia
monitoring of, 46
Physical dependence
definition, 2, 3
Physical inactivity
chronic noncancer pain and, 7
Physical therapy
for patients with HIV/AIDS, 47
pain management issues, 38
Post-traumatic stress disorder
chronic noncancer pain and, 25–26
lamotrigine treatment, 39
symptoms, 26
tools to assess emotional distress, anxiety, 
pain-related fear, and depression  
(exhibit), 26
Pregabalin
anxiety treatment, 39
Pseudoaddiction
definition, 3
exhibit describing, 56
Psychiatric disorders. See also specif ic disorders
addiction risk factor, 9
comorbidity with addiction, 9, 24–27, 
39–40
difficulty of differentiating a substance-
induced condition from a primary  
psychiatric disorder, 25
pain management issues, 39–40
PT. See Physical therapy
PTSD. See Post-traumatic stress disorder
R
Recovery
definition, 3
Referring patients for further assessment
clinician-patient relationship and, 24
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confidentiality and, 24
Federal protection of patient health 
information (exhibit), 24
need for pain treatment and, 23
SUD specialists, 23
tips for clinicians, 23–24
Relapse
definition, 4
opioid use and, 40, 42–43
Reward response
cravings and, 8, 61
mechanism of, 7–8
withdrawal and, 8
S
SAMHSA, See Substance Abuse and Mental 
Health Services Administration
SBIRT. See Screening, Brief Intervention, and 
Referral to Treatment
SCD. See Sickle-cell disease
Screener and Opioid Assessment for Patients 
with Pain—Revised
description, 28
questions (exhibit), 29
Screening, Brief Intervention, and Referral to 
Treatment
description, 23
elements of (exhibit), 23
Selective serotonin reuptake inhibitors
anxiety treatment, 39
Serotonin syndrome
description, 40
Sickle-cell disease
description, 46, 47
treating patients who have SCD (exhibit), 
47
SOAPP-R. See Screener and Opioid 
Assessment for Patients with 
Pain—Revised
Somatization
categories of, 27
description, 27
SSRIs. See Selective serotonin reuptake 
inhibitors
States
documentation of chronic opioid therapy, 58
laws, regulations, and policies regarding 
addiction specialists, 35
prescription monitoring programs, 61
Stress response
mechanism of, 8
Substance Abuse and Mental Health Services 
Administration
general, ii, ix, xi, 1, 4, 23, 69, 97, 99  
Screening, Brief Intervention, and Referral to 
Treatment, 23
Substance use disorders. See also Addiction; 
specif ic substances
algorithm for managing chronic pain in 
patients with SUDs (exhibit), 34
anxiety and, 25
assessing pain and function in patients 
with SUDs, 16–20
basics of, 4
cognitive-behavioral therapy and, 38
cross-addiction and, 9, 22
definition, 4
DSM-IV-TR criteria for substance abuse 
and substance dependence (exhibit), 21
items to include in substance use  
assessment (exhibit), 20
pain management issues, 33–48
patients in recovery, 35–37, 46
patients with active addiction, 45
positive and negative reinforcement link 
with chronic noncancer pain, 9
prevalence of chronic noncancer pain and, 1
psychiatric comorbidities, 24–27
referral for addiction treatment, 45
reliable Web sites with information on 
substance use disorders (exhibit), 69
screening for, 20–23
steps following substance abuse assessment 
(exhibit), 22
suicide and, 27
tolerance and, 9–10
tools to screen for (exhibit), 22, 88
SUDs. See Substance use disorders
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Suicide
chronic noncancer pain and, 27
substance use disorders and, 27
withdrawal and, 10
T
Tang, N. K.
suicide risk in patients with chronic 
noncancer pain, 27
Teach-back approach to patient education
description, 67
talking with patients following a teach-
back approach (exhibit), 67
TIPs. See Treatment Improvement Protocols
Therapeutic exercise
pain management issues, 37
Tolerance
analgesic and anxiolytic substances used to 
treat chronic noncancer pain and, 9–10
compared with opioid-induced  
hyperalgesia, 44–45
definition, 2, 4
Transcutaneous electrical nerve stimulation
pain management issues, 38
Trazodone
anxiety treatment, 39
Treatment agreements
addiction specialists and, 50
common elements of, 72
informed decisions about, 72
key points, 74
revising, 72
sample pain treatment agreement  
(exhibit), 73
tips for clinicians, 71–72
uses for, 50, 71
Treatment Improvement Protocols
audience for, 2
definitions, 2–4
purpose of, 2
Treatment settings
local resources, 31–32
pain clinics, 31
primary care physicians and, 32
specialty consultations, 32
Tricyclic antidepressants. See also specif ic drugs
anxiety treatment, 39
withdrawal from opioids and, 61
U
U.S. Department of Defense
VA/DoD Clinical Practice Guideline for the  
Management of Opioid Therapy for Chronic 
Pain, 65
U.S. Department of Veterans Affairs
VA/DoD Clinical Practice Guideline for 
the Management of Opioid Therapy for 
Chronic Pain, 65
UDT. See Urine drug testing
Universal precautions
description, 49
ten steps of universal precautions (exhibit), 49
University of Wisconsin
Pain and Policy Studies Group Web site 
of State regulations regarding opioid 
therapy, 58
Urine drug testing
“no limits” tests, 52
efficacy of, 51
false-positive and false-negative results, 52–53
immunoassays, 52
intervals for, 54
patient education about, 54
POC testing benefits and limitations 
(exhibit), 52
results of, 52–54
specific substance identification tests, 52
talking with patients about aberrant urine 
drug testing results (exhibit), 53
talking with patients who are resistant to 
urine drug testing (exhibit), 55
tips for clinicians, 53
types of, 51–52
unexpected results, 53
V
VA/DoD Clinical Practice Guideline for the 
Management of Opioid Therapy for 
Chronic Pain, 65
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Valproic acid
anxiety treatment, 39
Van Ameringen, M.
anticonvulsant treatment for anxiety, 39
Venlafaxine
anxiety treatment, 39
depression treatment, 39
W
Withdrawal
addiction specialists and, 63
depression and, 10
reward response and, 8
symptoms of, 10, 61
Workplace safety
clinician and patient protection, 59
plans for, 59
World Health Organization
pain ladder, 47
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*Under revision
TIP 1  State Methadone Treatment Guidelines—
Replaced by TIP 43
TIP 2*  Pregnant, Substance-Using Women—
BKD107
TIP 3  Screening and Assessment of Alcohol- and 
Other Drug-Abusing Adolescents—Replaced 
by TIP 31
TIP 4  Guidelines for the Treatment of Alcohol- 
and Other Drug-Abusing Adolescents—
Replaced by TIP 32
TIP 5  Improving Treatment for Drug-Exposed 
Infants—BKD110
TIP 6*  Screening for Infectious Diseases Among 
Substance Abusers—BKD131 
Quick Guide for Clinicians QGCT06 
KAP Keys for Clinicians KAPT06
TIP 7  Screening and Assessment for Alcohol and 
Other Drug Abuse Among Adults in the 
Criminal Justice System—Replaced by TIP 44
TIP 8  Intensive Outpatient Treatment for Alcohol 
and Other Drug Abuse—Replaced by TIPs 46 
and 47
TIP 9  Assessment and Treatment of Patients With 
Coexisting Mental Illness and Alcohol and 
Other Drug Abuse—Replaced by TIP 42 
TIP 10  Assessment and Treatment of Cocaine-
Abusing Methadone-Maintained Patients—
Replaced by TIP 43 
TIP 11*  Simple Screening Instruments for Outreach 
for Alcohol and Other Drug Abuse and 
Infectious Diseases—BKD143 
 Quick Guide for Clinicians QGCT11
 KAP Keys for Clinicians KAPT11
TIP 12  Combining Substance Abuse Treatment 
With Intermediate Sanctions for Adults in 
the Criminal Justice System—Replaced by TIP 
44 
TIP 13  Role and Current Status of Patient 
Placement Criteria in the Treatment of 
Substance Use Disorders—BKD161
 Quick Guide for Clinicians QGCT13 
 Quick Guide for Administrators QGAT13
 KAP Keys for Clinicians KAPT13 
csAT TIps and publications Based on TIps
What Is a TIp?
Treatment Improvement Protocols (TIPs) are the products of a systematic and innovative process that 
brings together clinicians, researchers, program managers, policymakers, and other Federal and non-Fed-
eral experts to reach consensus on state-of-the-art treatment practices. TIPs are developed under CSAT’s 
Knowledge Application Program to improve the treatment capabilities of the Nation’s alcohol and drug 
abuse treatment service system.
What Is a Quick Guide?
A Quick Guide clearly and concisely presents the primary information from a TIP in a pocket-sized 
booklet. Each Quick Guide is divided into sections to help readers quickly locate relevant material. Some 
contain glossaries of terms or lists of resources. Page numbers from the original TIP are referenced so 
providers can refer back to the source document for more information.
What Are KAp Keys?
Also based on TIPs, KAP Keys are handy, durable tools. Keys may include assessment or screening 
instruments, checklists, and summaries of treatment phases. Printed on coated paper, each KAP Keys set 
is fastened together with a key ring and can be kept within a treatment provider’s reach and consulted 
frequently. The Keys allow you—the busy clinician or program administrator—to locate information eas-
ily and to use this information to enhance treatment services.
ordering Information
Publications may be ordered for free at http://store.samhsa.gov. To order over the phone, please call 
1-877-SAMHSA-7 (1-877-726-4727) (English and Español). Most publications can also be down-
loaded at http://www.kap.samhsa.gov.
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Systems for Alcohol and Other Drug Abuse 
Treatment—BKD162 
TIP 15  Treatment for HIV-Infected Alcohol and 
Other Drug Abusers—Replaced by TIP 37 
TIP 16  Alcohol and Other Drug Screening of 
Hospitalized Trauma Patients—BKD164 
 Quick Guide for Clinicians QGCT16
 KAP Keys for Clinicians KAPT16 
TIP 17  Planning for Alcohol and Other Drug Abuse 
Treatment for Adults in the Criminal Justice 
System—Replaced by TIP 44
TIP 18  The Tuberculosis Epidemic: Legal and 
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 Quick Guide for Clinicians QGCT18
 KAP Keys for Clinicians KAPT18
TIP 19  Detoxification From Alcohol and Other 
Drugs—Replaced by TIP 45
TIP 20  Matching Treatment to Patient Needs in 
Opioid Substitution Therapy—Replaced by 
TIP 43
TIP 21  Combining Alcohol and Other Drug Abuse 
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 Quick Guide for Clinicians and 
Administrators QGCA21
TIP 22  LAAM in the Treatment of Opiate 
Addiction—Replaced by TIP 43
TIP 23  Treatment Drug Courts: Integrating 
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Case Processing—(SMA) 08-3917 
Quick Guide for Administrators QGAT23 
TIP 24  A Guide to Substance Abuse Services for 
Primary Care Clinicians—(SMA) 08-4075
 Concise Desk Reference Guide BKD123
 Quick Guide for Clinicians QGCT24
 KAP Keys for Clinicians KAPT24
TIP 25  Substance Abuse Treatment and Domestic 
Violence—(SMA) 08-4076
 Linking Substance Abuse Treatment and 
Domestic Violence Services: A Guide for 
Treatment Providers MS668 
 Linking Substance Abuse Treatment and 
Domestic Violence Services: A Guide for 
Administrators MS667 
 Quick Guide for Clinicians QGCT25 
 KAP Keys for Clinicians KAPT25 
TIP 26  Substance Abuse Among Older Adults—
(SMA) 08-3918
 Substance Abuse Among Older Adults: A 
Guide for Treatment Providers MS669 
 Substance Abuse Among Older Adults: A 
Guide for Social Service Providers MS670 
 Substance Abuse Among Older Adults: 
Physician’s Guide MS671 
 Quick Guide for Clinicians QGCT26
 KAP Keys for Clinicians KAPT26 
TIP 27  Comprehensive Case Management for 
Substance Abuse Treatment—(SMA) 
08-4215
 Case Management for Substance Abuse 
Treatment: A Guide for Treatment Providers 
MS673
 Case Management for Substance Abuse 
Treatment: A Guide for Administrators 
MS672
 Quick Guide for Clinicians QGCT27
 Quick Guide for Administrators QGAT27
TIP 28*  Naltrexone and Alcoholism Treatment—
Replaced by TIP 49
TIP 29  Substance Use Disorder Treatment for 
People With Physical and Cognitive 
Disabilities—(SMA) 08-4078 
 Quick Guide for Clinicians QGCT29 
 Quick Guide for Administrators (SMA) 
08-3592 
 KAP Keys for Clinicians KAPT29 
TIP 30  Continuity of Offender Treatment for 
Substance Use Disorders From Institution to 
Community—(SMA) 08-3920
 Quick Guide for Clinicians QGCT30 
 KAP Keys for Clinicians KAPT30 
TIP 31  Screening and Assessing Adolescents for 
Substance Use Disorders—(SMA) 08-4079
 See companion products for TIP 32. 
TIP 32  Treatment of Adolescents With Substance 
Use Disorders—(SMA) 08-4080
 Quick Guide for Clinicians QGC312 
 KAP Keys for Clinicians KAP312 
TIP 33  Treatment for Stimulant Use Disorders—
(SMA) 06-4209
 Quick Guide for Clinicians QGCT33 
 KAP Keys for Clinicians KAPT33 
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 Quick Guide for Clinicians QGCT36 
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 Available in Spanish: PHD981S 
 Helping Yourself Heal: A Recovering Man’s 
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TIP 41  Substance Abuse Treatment: Group 
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 Quick Guide for Clinicians QGCT41
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 Quick Guide for Clinicians (SMA) 07-4034
 Quick Guide for Administrators QGAT42
 KAP Keys for Clinicians (SMA) 08-4036 
TIP 43  Medication-Assisted Treatment for Opioid 
Addiction in Opioid Treatment Programs—
(SMA) 08-4214
 Quick Guide for Clinicians QGCT43 
 KAP Keys for Clinicians (SMA) 07-4108 
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Criminal Justice System—(SMA) 05-4056 
 Quick Guide for Clinicians QGCT44
 KAP Keys for Clinicians (SMA) 07-4150 
TIP 45  Detoxification and Substance Abuse 
Treatment—(SMA) 08-4131 
 Quick Guide for Clinicians (SMA) 06-4225
 KAP Keys for Clinicians (SMA) 06-4224 
 Quick Guide for Administrators (SMA) 
06-4226 
TIP 46  Substance Abuse: Administrative Issues in 
Outpatient Treatment—(SMA) 06-4157 
 Quick Guide for Administrators (SMA) 
07-4232 
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